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ABSTRACT 
 
A SYNTHETIC HUMAN BRAIN ECM HYDROGEL FOR TIGHT CONTROL OF 
ASTROCYTE ACTIVATION 
SEPTEMBER 2019 
SUALYNETH GALARZA 
B.S., UNIVERSITY OF PUERTO RICO MAYAGUEZ 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Shelly R. Peyton 
 
 
Bioengineers have aimed to design instructive extracellular matrix (ECM) models that can tailor 
the protein composition and biomechanics of the brain in vitro in order to study how astrocytes 
remodel the brain during trauma and inflammation. However, these parameters cannot be 
independently controlled in protein-based models, and although tunable in synthetic systems, 
current astrocyte cultures fail to retain their characteristic stellate morphology without becoming 
activated. To this date there is no biomaterial model that can retain astrocyte quiescence in vitro. 
This dissertation sought to develop such an in vitro model that would enable the study of specific 
ECM factors that control astrocyte activation while retaining quiescent astrocytes in vitro. Here we 
introduce a synthetic hydrogel, that for the first time shows maintenance of astrocyte quiescence, 
and control over activation on demand. We first characterized the human brain ECM via 
proteomics, and the brain biomechanics via needle-induced cavitation rheology and volume-
controlled cavity expansion and incorporated the top ECM components responsible for integrin-
mediated and MMP-mediated degradation alongside matched mechanical properties into a fully 
synthetic hydrogel. Using this hydrogel, composed of just PEG and peptides, we demonstrate 
control over astrocyte activation via tuning of the integrin-binding and MMP-degradable profile or 
via cytokine molecules, in contrast to other protein-based models like collagen where astrocytes 
 ix 
remain in a reactive state. Finally, to aid with the implementation of biomaterials as in vitro platforms 
to predict in vivo physiology, the correlation between current 2D, 3D and in vivo studies of 
glioblastoma motility was explored, and how an effect size can help standardize comparison across 
labs and culture dimensions. An additional study highlighted the importance of adopting growth 
rate in drug metric responses and how these can be implemented in current biomaterial platforms. 
Overall, this work can help integrate biomaterials as models to predict in vivo physiology. This brain 
hydrogel system can be used as a new platform to model the physiological state of quiescent 
astrocytes and their reactivity upon injury, for the first time, in vitro. 
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 1 
CHAPTER 1 
 
1: BIOMATERIALS TO MIMIC THE BRAIN EXTRACELLULAR MATRIX 
 
 
1.1 The Extracellular Matrix (ECM) composes the tissue microenvironment 
 
1.1.1 The brain extracellular matrix (ECM) 
 
The brain is covered by layers of membranes, the meninges, and submerged in cerebrospinal 
fluid1. This organ can be grossly divided into different neuroanatomical functional regions such as 
the frontal, parietal, temporal, occipital lobes and central gray matter structures1. Anatomically and 
histologically, the brain can be further stratified into the cerebral cortex representing the outermost 
gray matter overlying white matter and innermost deep gray matter components (fig. 1.1a). The 
cerebral cortex incorporates neurons and glial cells, whereas the white matters hosts 
oligodendrocytes and axons from cortical and subcortical projection neurons2-4.  
 
 
 
Figure 1.1: The brain extracellular matrix (ECM). a) The brain cerebral cortex accounts for 80% 
of the organ volume and is macroscopically divided into white and gray matter structures. These 
tissues are mainly composed of water, lipids and protein. b) Microscopically, the extracellular space 
accounts for 20% of the total volume of the mature brain and is filled with an organized extracellular 
matrix (ECM). Histology has identified three main ECM structures in the brain: the basement 
membrane near vasculature, interstitial matrix between cells, and perineuronal nets surrounding 
neuron axons. 
 
Immunohistochemical studies that have characterized the brain extracellular space, which 
accounts for 20% of the total volume of the mature brain, have identified three prominent structures 
that compose the brain extracellular matrix compartments: the blood-brain barrier (BBB), the 
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perineuronal nets (ECM structure most prominent around neurons) and the interstitial matrix (figure 
1.1b)5-8. Cells are the main source of these extracellular proteins that compose and give rise to 
differences in tissues. In the brain, astrocytes are the big synthesizers of proteins in the cortex9. 
The components of the extracellular matrix can be divided into core proteins, core associated 
proteins and ECM regulators like small molecules that interact with the ECM10-12. Core ECM 
proteins include collagens, proteoglycans and glycoproteins11. Collagens and glycoproteins, like 
fibronectin and laminin, are mostly found around the vasculature in the basement membrane8. A 
mixture of collagen, glycoproteins and proteoglycans can be found in interstitial ECM giving rise to 
the microenvironment that surrounds the cells10. Matrix affiliated proteins and ECM regulators 
include those proteins and small molecules that are colocalized in the extracellular space but do 
not readily assemble to form the matrix that gives rise to tissue10. The interaction of cell with ECM 
components provide the cues give rise to biological cascades13. 
Integrin molecule pairs, consisting of 𝛂 and 𝛽 heterodimers, are the main surface receptors 
from which cells interact with ECM proteins14-17. These transmembrane receptors can bind to both 
ECM proteins and the cellular cytoskeleton providing mechanical and biochemical signaling that 
regulates cell response17. Additionally, in order to degrade and remodel the ECM, cell release 
enzymes that allow them to spread and migrate in the native microenvironment. Matrix 
metalloproteinases (MMP) are a family of enzymes that cleave various proteins of the ECM18. 
Together these interactions of cells and their ECM microenvironment have been shown to play a 
role in development19, 20, differentiation21 and disease17, 18, 20. 
 
1.1.2 The composition of the brain ECM changes during health and disease 
 
The extracellular matrix has been found to undergo dynamic changes during development, 
health and disease13, 22, 23. For example, ECM molecules are already present in the developing 
embryo where they play important roles in the development of the central nervous system7. The 
composition of the brain ECM has been shown to change during different developmental stages7. 
Similarly, studies have found changes in the ECM composition during disease progression that 
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have been in instances used as biomarkers. As an example, proteins like serpins have been shown 
to be present in brain metastases samples via histology approaches while these proteins are not 
present in the normal brain (figure 1.2a)24. Similarly, during transitioning stages of glioblastoma 
there is an increase in the deposition of tenascin C in the human cortex (figure 1.2b)25.   
 
 
Figure 1.2: Changes of the brain ECM in brain tumors. a) Alterations in ECM protein deposition 
in the brain after brain metastasis progress. Representative brain metastasis tissue microarray 
cores stained with neuroserpin or serpin B2 antibodies. Figure adapted from 24with permission from 
Elsevier. b) The ECM protein tenascin C is highly abundant in the brain of a glioblastoma patient 
in contrast to a healthy donor. Figure adapted from25 with permission from American Association 
of Cancer Research. c) Glioblastoma progression is influenced by the microenvironment of the 
normal brain. Venkatesh et al., showed neuron secretion of neuroligin-3 and cleavage by 
extracellular protease ADAM10 stimulates oncogenic signaling in glioma cells inducing 
transcriptional changes that lead to glioma growth. Figure adapted from26 with permission from 
Springer Nature. 
 
While this is a glycoprotein normally expressed in very low levels in the healthy brain8, an 
increase in the abundance of tenascin c receptors have been shown to increase cell proliferation 
and initiation of brain tumor cells25. Recently, work by Venkatesh et al.,26 illustrated how targeting 
the brain microenvironment could be a potential avenue to eradicate glioblastoma. In their work 
they found that the progression of glioblastoma is influenced by the microenvironment of the normal 
brain where neurons secrete the protein neuroligin-3 which upon cleavage by proteases in the brain 
extracellular space stimulates and oncogenic signaling in glioma cells that induces glioma cell 
growth (figure 1.2c)26, 27. Authors found that by inhibiting the cleavage of this protein by the protease 
a cb Tenascin C 
in Glioblastoma
Glioblastoma Patient
Normal Brain
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Adam10 glioblastoma progression could be inhibited. However, current understanding of the 
interaction between cancer cells and the brain microenvironment is limited. These examples 
highlight the need to consider the unique physiology of the brain microenvironment and how it 
would offer a new approach to treating cancer cells by focusing on the surrounding cells. The idea 
of interrupting the molecular support that cancer cells receive from the brain microenvironment 
raises the possibility of blocking the progression of a diverse range of cancers. 
 
1.1.3 Extracellular matrix remodeling give rise to differences in brain mechanical 
properties 
 
The extracellular matrix changes during health and disease have a critical effect in the 
mechanical properties of the tissue19, 22, 28-32. For example, the ECM is known to stiffen during 
cancer progression 31, 33. Research has shown that the stiffening of the microenvironment in tissues 
like the breast, comes from increases in pressure forces caused from cell increased proliferation 
and due to the increase in collagen deposition at the site of the tumor by local cells like fibroblasts 
and stem cells34-37. In the case of the brain, comparison of the Young’s modulus measured via 
indentation of normal brain and glioma samples showed that glioma samples undergo stiffening as 
the compression is increased (figure 1.3a)31. Similarly, dynamic changes in the stiffness and 
viscoelastic properties of brain tissue have been also correlated with Alzheimer’s disease38, 
traumatic axonal injuries39, cortical contusions40, and brain tumors41. One study showed the elastic 
modulus (Gd) of normal brain tissue was higher in comparison to areas where a tumor or breast 
cancer metastases had formed (figure 1.3b)41. 
These macroscale mechanical properties also matter at the microscale, since central nervous 
system cells have been shown to respond to mechanical cues29, 31 and undergo differentiation 
changes depending on local stiffness22. Both neurons and glia, as major cellular constituents of the 
brain, contribute to mechanical properties of the tissue42. Measurements at the cellular level have 
reported glial cells to be softer than neurons, and both single cells show a frequency dependent 
Young’s modulus similar to bulk brain tissue and elastic moduli magnitude at a macroscopic level22. 
Inspection of cell responses to changes in the substrate shear modulus have shown that neurons 
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reduce their number of branches as substrates reach a higher modulus, while astrocytes increase 
in the surface area in more rigid substrates (figure 1.3c)22. Similarly, protein arrangement within 
this cell types can change dependent on the mechanical properties of the substrate (figure 1.3d)31. 
However, while there have been many studies on the elastic, viscoelastic, and poroelastic 
properties of the brain, there has not been a consensus on the magnitude of several key mechanical 
properties of this tissue. Reports of Young’s elastic modulus of the brain range from 100s of Pa to 
10s of kPa and vary considerably among experimental techniques22, 29, 32, 43. This highlights the 
need for studies that can characterize location dependent mechanical properties of the brain. 
 
 
Figure 1.3: Disease alters brain mechanical properties and cells are sensitive to modulus 
changes. a) Relative Young’s modulus comparison obtained via indentation of normal mouse brain 
and glioma samples show glioma brain follows compression stiffening. Figure adapted from31 with 
permission from IOP Science. b) Jamin et al., showed the elastic modulus (Gd) of normal brain 
parenchyma is higher compared to metastases produced by U-87-MG, RG2 and MDA-MB-231 cell 
lines and as measured by magnetic resonance elastography. Mechanical properties were 
dependent on the cell line. Figure adapted from41 with permission from American Association for 
Cancer Research. c) Neuron and astrocytes show morphological changes in branch length and cell 
area respectively upon increasing substrate shear modulus. Figure adapted from22 with permission 
from annual review of biomedical engineering. d) Pogoda et al., showed substrate stiffness effect 
on glioma cell morphology and cytoskeleton protein arrangement.31 
 
1.1.4 Astrocytes are a key cellular component of the brain microenvironment 
 
Major drivers of the changes in the brain ECM during health and disease are the cellular 
constituents of the tissue. Astrocytes constitute approximately 30% of the cells in the mammalian 
a
b
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brain characterized by their star-shaped morphology and cellular cytoplasmic processes reaching 
both synapses and capillary walls9, 44, 45. These cells populate gray and white matter tissue and the 
spinal cord of the CNS and function as key mediators of the brain ECM homeostasis44.  
During brain trauma and inflammation, astrocytes adopt a reactive phenotype where they are 
termed as reactive astrocytes45, 46. These post-injury astrocytes are identified by upregulation of 
intermediate filament proteins like glial fibrillary acidic protein (GFAP), vimentin and nestin, 
alongside aberrant morphological changes spanning from moderate astrogliosis to severe 
astrogliosis (figure 1.4a)47-49. In contrast to healthy tissue astrocytes, whose processes do not 
overlap, reactive astrocytes are characterized by a high expression or GFAP and overlapping 
processes47, 50. Others have shown, via time-lapse microscopy and immunostaining, that these 
cells are first responders to extravasation of cancer cells in the brain microenvironment (figure 
1.4b)51-53 and remain activated many days post injury (figure 1.4c)50. 
Studies aimed to understand molecular mechanisms driving reactive astrocyte interactions 
have identify ECM components like the protein collagen I induces astrocyte activation mediated by  
integrin-N-cadherin signaling50. Similarly, others have found that reactive astrocytes exhibit pro- or 
anti-inflammatory functions dependent on the type of injury. A1 neuroinflammatory astrocytes 
upregulate many genes destructive to synapses and are suggested to be harmful54-56. Alternatively, 
ischemia-induced A2 astrocytes upregulate many neurotrophic factors that promote survival, 
growth of neurons, and have been suggested to be helpful57-60. As an example of helpful astrocytes, 
during breast cancer metastasis to the brain, reactive astrocytes have been shown to produce the 
plasminogen activators (PA) tPA and uPA to convert plasminogen into plasmin since this creates 
a mechanism to eliminate extravasated cancer cells24. Yet, blocking of plasminogen by cancer cells 
via serpins has been shown to prevent their death. (figure 1.4d)61. However, these helpful 
astrocytes can become harmful as remaining cancer cells induce signaling changes. These cancer 
cells that remain in the brain vasculature induce changes in reactive astrocytes by producing 
calcium and cGAMP signals that result in astrocyte production of inflammation cytokines TNF and 
IFN-alpha that induce cancer cell proliferation (figure 1.4e)51, 61. Together, these examples show  
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 Figure 1.4: Astrocytes are key components of the brain microenvironment. a) Glial fibrillary 
acidic protein (GFAP) staining of astrocytes in wild type mice shows morphology in healthy tissue, 
moderate astrogliosis and severe astrogliosis events. Astrocyte processes do not overlap in healthy 
tissue. Figure adapted from 47 with permission from Elsevier. b) Astrocytes are the first responders 
upon cancer cell invasion in the brain. GFP+ H2030-BrM3(green) are surrounded by GFAP+ 
activated astrocytes (red) in the brain parenchyma at early (day 7) and later (day 21) time points 
after intracardiac inoculation in mice. Blue, collagen IV (ColIV) staining in vessels. Scale bars, 10 
µm. Adapted from 51 with permission from Springer Nature. c) Example images depicting GFAP 
staining (green) of naïve spinal cord and injured spinal cords at day 7 and day 14 post injury (d.p.i.) 
Scale bars 50 𝜇m. Figure adapted from50 with permission from Springer Nature. d) Reactive 
astrocytes defend the brain microenvironment by producing the plasminogen activators (PA) tPA 
and uPA that activate plasminogen to plasmin which eliminates extravasated cancer cells. Cancer 
cells block this response through anti-PA serpins (neuroserpin/serpinB2) that inhibit plasmin 
generation and prevent cancer cell death. e) Surviving cancer cells continue to interact with reactive 
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astrocytes during brain colonization and establishing gap junctions with reactive astrocytes where 
they send calcium and cGAMP to astrocytes via Cx43 junction, and activate a signaling pathway 
in astrocytes leading to secretion of TNF and IFN-alpha that induces cancer cell proliferation. Figure 
adapted from61 with permission from Elsevier. 
 
how astrocytes are a key component of the brain microenvironment and extracellular cues can 
affect their response. However, although some of these molecular mechanisms have been 
identified in physiologically relevant animal models like rodents62, the large number of cell types 
involved in inflammatory responses in CNS injury and disease45, as well as the complex cell-cell 
interactions among these and other neural cell types has hampered mechanistic understanding of 
environment driven astrocyte reactivity. 
1.2 Better models are needed to understand brain cell-ECM interactions in vitro  
 
1.2.1 Limitations in studying astrocytes in vivo  
 
Current in vivo astrocyte studies in rodents face the challenge of isolating single cell-ECM 
interactions that lead to activation due to the poor control on the microenvironmental cues of this 
system45, 52, 63. As such, what relevant extracellular and intracellular signaling pathways induce 
astrocyte activation remain to be understood. Similarly, studies have highlighted major differences 
between human astrocytes to those from different species. For example, Oberheim et al.,44 
highlighted how protoplasmic astrocytes in the human neocortex are 2.6-fold larger in diameter and 
extend 10-fold more GFAP positive primary processes than rodent astrocytes.  Similarly, the 
deposition of calcium by human astrocytes is significantly faster than in rodent counterparts. Lastly, 
the human neocortex contains several subclasses of astrocytes not represented in rodent models44. 
Those astrocytes that are present in both species, like is the case of fibrous astrocytes are larger 
in diameter in the human brain44. Thus, human cortical astrocytes are larger and structurally more 
complex and diverse then those in the rodent brain9, 44. In addition, rodent models are expensive, 
time-consuming, and difficult to control and manipulate64. These examples highlight the need for 
more humanized models in which to study astrocytes in vitro. 
1.2.2 Biomaterials to understand astrocyte activation in vitro 
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Within the context of the brain, cell culture platforms derived from tissue such as tissue 
slices, decellularized scaffolds and organoids have been used as more complex in vitro models of 
the brain65, 66. Astrocytes grown in three-dimensional (3D) organoids pose recent cell culture 
platforms that provide aspects of the brain architecture, but their inherent complexity limits the 
identification of individual drivers of astrocyte activation67-70. Alternatively, protein-based 3D 
hydrogels, mostly composed of collagen71, hyaluronic acid72-74, and mixtures of these proteins75, 76, 
have been popularized as brain in vitro platforms, as they constitute native brain ECM proteins, 
exert biocompatibility, and in certain cases, lower upregulation of GFAP as compared to astrocytes 
grown in a two-dimensional monolayer75 (figure 1.5 a-d). However, previous studies have identified 
certain combinations of proteins, cytokines, and stiffnesses can influence astrocyte activation, and 
these parameters cannot be independently controlled in these materials77. For example, a study 
that explored astrocyte response in a wound assay found different ECM proteins influenced 
astrocyte migration speeds77. Similarly, the simultaneous tuning of mechanical and biochemical 
properties in commercially available protein system impedes identifying what specific parameters 
control for astrocyte activation. As an example, a combination of collagen, hyaluronic acid and 
Matrigel resulted in quiescent astrocyte culture, but it remains poorly understood what particular 
protein composition led to that response as the exact composition of these materials is lot-
dependent and in the case of Matrigel is not completely understood (figure 1.5d)75.  
Synthetic hydrogels, in contrast, provide a tremendous opportunity to design tissue specific 
scaffolds with tight control of parameters, but bioactive moieties need to be incorporated to 
represent the microenvironment of interest (figure 1.5e)78, 79. Yet, currently there is no in vitro model 
that can simultaneously culture quiescent astrocytes with their characteristic star-shape 
morphology and allow for controlled activation in vitro. For example, a recent platform developed 
by Papadimitriou et al.,80 to culture fetal primary astrocytes in a poly-ethylene-glycol (PEG) heparin 
hydrogel, produced cells with high level of GFAP expression similar to that in 2D cultures (figure 
1.5f)81. Other studies have focused on the development of hyaluronic acid (HA) containing PEG 
hydrogels, due to the presence of HA in the brain but cultures take a very long time (around 48-70 
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days) to differentiate from neural stem progenitor cells (NS/PC) to astrocytes (figure 1.5g)82. In work 
by Seidlits et al.,82 NS/PC were differentiated into astrocytes with low levels of GFAP but further 
staining for other astrocyte markers suggest these cells differentiated into oligodendrocytes instead 
(figure 1.5h). Similarly, other work that has looked into the elimination of serum-based cultures 
since these are known to induce activation of astrocytes in vitro and replace it for Heparin-binding 
EGF-like growth factor (HBEGF) cultures have also resulted in reactive astrocytes cultures 
regardless of dimensionality83. Overall most of these studies are also conducted with primary 
murine astrocytes which also impedes direct comparison to the human specific astrocyte 
phenotypes identified by Oberheim et al.44 Lastly, a vast number of astrocytes with low expression 
of GFAP show rounded morphologies in biomaterial platforms82, 84. Taken together these examples 
highlight the need for better models to control for astrocyte activation in vitro. 
1.2.3 Translation of biomaterial models to predict physiological responses & means to 
standardize in vitro models to identify druggable targets 
 
Reactive astrocytes are an integral part of brain cancers as they have been shown to 
become reactive near metastases from lung24, breast24 and melanoma85 origin (figure 1.6a). Yet, 
the percentage of patients with brain metastases that are susceptible to targeted therapy is very 
low61(fig. 1.6b). Similarly, mechanisms that could be targeted in these reactive astrocytes remain 
poorly understood. Perhaps, the current lack of appropriate model systems is a potential limiting 
factor in uncovering molecular mechanisms underlying brain cell-ECM interactions. These 
examples highlight the need for better biomaterials to predict physiological responses that could 
lead to druggable target identification.  
Bioengineers have aimed to develop better models to better translate in vitro responses to 
in vivo physiology (figure 1.6c)66, 86, 87. However, as materials increase in complexity additional 
interpretation challenges arise with them. For example, one of the foreseeable applications for 
biomaterials is as platforms to study cell-drug responses. Currently, a number of studies comparing 
across reported responses have highlighted the heterogeneity of responses to similar compounds88 
that is mostly attributed to differences in experimental design from different groups. Yet, these  
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Figure 1.5: Hydrogels as biomaterials to study astrocytes in vitro: current activation control 
and morphology limitations. a) Protein based hydrogels have been employed as biomaterials for 
in vitro cell culture due to their inherent biochemical signals to cells, but their mechanical and 
biochemical properties cannot be independently tuned. b) Normal astrocyte culture in 2D plastic 
show adherent morphology and high expression of GFAP (red). Hoechst stain labels the nucleus 
blue, whereas rhodamine-GFAP labels cytoskeleton red. Astrocyte culture in 3D collagen hydrogel 
with 0.5wt% Hyaluronic acid (HA) shows rounded morphology of cells with GFP positive (green). 
Figure from84 with permission from American Chemical Society. c) Puschmann et al., show 
astrocyte culture in 2D and a 3D bioactive laminin coated nanofiber-based culture system. Figure 
shows immunocytochemical detection of intermediate filament proteins GFAP (green) and nestin 
(red). Figure adapted from76 with permission from Wiley. d) Examples of inactive and active 
astrocytes in 3D culture in a gel composed of 2 mg/mL collagen, 1mg/mL Hyaluronic acid, and 
1mg/mL Matrigel. Immunofluorescence images of DAPI (blue, and membrane (purple) or GFAP 
(green). Figure from75 with permission from Elsevier. e) Synthetic hydrogels allow for controlled 
modification of mechanical and biochemical properties but, need incorporation of bioactive moieties 
to allow for cell mediated interactions. f) Immunocytochemical images of fetal primary human 
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astrocytes cultured in a starPEG-Heparin 3D hydrogel with neural stem cell markers GFAP (green), 
SOX2 (red) and neural fate determinant NEUROD1 (blue). Heatmap for expression levels of neural 
stem/progenitor cell markers show high levels of astrocyte activation with GFAP similar to 2D. 
Figure from81 with permission from Elsevier. g) GFAP expression by Neural Stem/progenitor cells 
evaluated with RT-PCR in 2D and 3D hydrogels with different integrin binding peptides. Cells 
showed a statistically significant decrease in GFAP expression compared to NS/PCs cultured in 
the same media conditions in 2D after 42 and 70 days of differentiation. Representative images in 
h) show cells present high staining for GFAP (red) while in a 3D with YIGSR, IKVAV, and RGD 
peptides did not differentiate to astrocytes as seen with lack of GFAP. Authors show the cells 
differentiated to oligodendrocyte type astrocytes. Figures from 82 with permission from Wiley. i) 
Astrocytes intermediate filament morphology visualized by immunocytochemical staining for nestin 
(green) and vimentin (red) and nuclei with DAPI (blue) in 2D and 3D cultures in bioactive 3D 
nanofiber cultures with HB-EGF treatment. Figures from 83 with permission from Wiley. 
 
cases were from traditional culture polystyrene (TCPS) which easy to use and hence allows for 
standardization. As these drug screening assays move to more complex biomaterials other 
parameters need to be taken into consideration like, for example, how fast cells grow in these 
systems89, the incorporation of multicellular components90, and cell line responses versus patient 
derived cells91.  
 
 
Figure 1.6: Better models can be used to predict preclinical combination therapies in brain 
cancer. a) Priego et al., showed brain metastases acquired from human donors from lung, breast 
cancer and melanoma had reactive astrocytes surrounding the tumors. Figures adapted from 85 
with permission from Springer Nature. b) Currently, the percentage of patients harboring brain 
metastases that are susceptible to targeted therapy is very low. Figure from 61 with permission from 
Elsevier.  c) As showed by Schwartz et al., the combination of more physiologically relevant 
biomaterial platforms could help identify new targets and ECM-mediated drug resistance. Figure 
from 86 from Biorxiv.  
Work by Jansen et al.,92 show how cell culture media supplement needed to be incorporated in 
order to rescue the viability of different cell lines cultured in 3D. Similarly, a high-profile study 
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illustrated how growth rate needs to be accounted for in drug response metrics89, 93. In order to 
implement biomaterials as platforms to identify druggable targets, standardization94, 95 of 3D 
cultures should be implemented that allow for comparison across studies and better translation 
between models. 
 
1.3 Hypothesis 
 
Current models to recreate the brain extracellular matrix are very limited in their ability to 
mimic human astrocyte reactivity in vitro. Here, I hypothesize the design and implementation of a 
tissue specific hydrogel would provide a tool to control for astrocyte activation in vitro. While current 
brain hydrogels can mimic some of the mechanical properties of the tissue, they are too simplistic 
in the array of bioactive cues they provide for cell interaction. Considering the unique brain 
physiology and protein content will help pinpoint what drivers of the ECM can control for astrocyte 
reactivity. I foresee that the development of such a platform would help advance biomaterial 
applications in hypothesis driven and drug testing methodologies of the brain. 
1.4 Objectives 
 
The following were the objectives for this dissertation: 
1. Mechanical and proteomic characterization of human brain tissue 
2. Design of a brain specific hydrogel to control for astrocyte activation in vitro 
3. Standardization of in vitro biomaterials and their correlation with in vivo physiology in glioma 
motility via effect size 
4. Assessment of biomaterials as platforms for drug screening and growth rate drug response  
1.5 Significance 
 
I have conducted a throughout characterization of human brain tissue providing detail 
information on its ECM composition and biomechanical responses. I have designed a fully synthetic 
brain hydrogel filtering integrin binding and matrix metalloproteinase degradable proteins 
incorporated as peptides in a PEG based hydrogel. This approach resulted in a brain-specific ECM 
microenvironment that provided an optimal niche for quiescent astrocyte culture achieved for the 
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very first time in vitro. I explored external cues to induce astrocyte activation and how the phenotype 
of these cells is changed upon cytokine-induced activation in vitro. I explored possible avenues to 
standardize cell responses obtained from biomaterials to allow for comparison across reports and 
expand drug screening applications. Overall this is the first in vitro system to allow for quiescent 
astrocyte culture that will open avenues in the exploration of astrocyte role in traumatic brain injury, 
cancer and other neurological diseases not possible in current systems. 
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CHAPTER 2 
2: BULK, LOCAL AND IN SITU MECHANICAL PROPERTIES OF BRAIN TISSUE 
 
2.1 Introduction 
 
In order to characterize the extracellular matrix (ECM) properties of brain tissue we start 
first with the biomechanics of the organ. Work by others has shown that the dynamic changes in 
the stiffness and viscoelastic properties of brain tissue correlate with Alzheimer’s disease38, 
traumatic axonal injuries39, cortical contusions40 and brain tumors41, and it is the ECM, which 
occupies an estimated 20% of the brain organ, that is considered to give rise to these mechanical 
changes6. In the brain, during neurulation, mechanical changes at the tissue level can alter 
cytoskeletal contractility28 and the ability of cells to bind to ECM components, leading to an increase 
in cell ECM and enzyme production96 This crosslinking can further alter tissue-level mechanics97. 
Similarly, the changes in ECM composition during brain development give rise to differences in the 
mechanical properties of normal tissue19. Transitions of mature brain from a healthy to a disease 
state during glioblastoma have also shown to result in mechanical property changes due to the 
increase in ECM proteins like Tenascin-C25, 31. Together, these studies highlight the importance of 
understanding brain mechanical properties and their relation to disease progression. To fully 
understand the dysfunctions inherent to brain disorders, it is important to consider the mechanical 
properties of the brain and the signaling changes they induce in cells. Thus, the response of brain 
tissue to deformation would be of interest for tissue engineering, modeling of TBI, and the design 
of brain specific biomaterials like is the motivation of this work.  
However, while there have been many studies on the elastic, and viscoelastic properties 
of brain, there are discrepancies in the reported mechanical properties of the tissue. Reports of the 
Young’s elastic modulus, E, of brain range from 100s of Pa to 10s of kPa,22, 29, 32 and are reported 
to vary significantly among experimental techniques32, 43, 98 (figure. 2.1). Previous studies probing 
different compartments of the brain have identified that brain tissue exhibits location-dependent 
mechanical properties like intraregional anisotropy for white matter in contrast to gray matter98-100, 
intraregional variations in different compartments of the brain101-103, and regional inhomogeneities 
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between corpus callosum, corona radiata, brain stem and gray matter structures99, 104. These elastic 
and viscoelastic properties of brain tissue have been measured most commonly by rheology31, 98, 
103, 105, shear relaxation99, 105-107, and unconfined uniaxial compression or tension100, 105, 108. At the 
microscale, measurements have been conducted via macroscale instrumented indentation101, 103, 
109-111, and atomic force microscopy (AFM)-enabled instrumented indentation104, 112, 113. The macro 
and micrometer length scales of these techniques are limited in their spatial resolution and the 
need for sectioning of the sample limits the capabilities to test intra- and inter regional variations in 
situ. 
To overcome these limitations, we have complemented, alongside shear rheology and 
indentation, two relatively new mechanical techniques: needle-induced cavitation rheology (NICR) 
and volume-controlled cavity expansion (VCCE) as techniques to measure elastic modulus in situ 
at an arbitrary location. This approach allows to explore the continuity among diverse mechanical 
techniques and sample preparations effect on the characterization of porcine and murine brain 
mechanical properties. NICR and VCCE provide the capabilities of testing local deformation, in situ 
at a spatial resolution within 100𝜇m to 10 mm not possible with indentation or rheology114-117. NICR 
has recently been used to explore mechanical properties of polymers and tissues like the eye114, 
bone marrow117, lung118 and skin119. Similarly, VCCE incorporates the same methodology of NICR 
with an incompressible working fluid120, providing additional information about the cavity volume 
which cannot be visually extracted in biological samples due to the inherent opaque nature of most 
tissues. Here the mechanical properties of porcine brain were measured via these four techniques 
to characterize brain mechanical properties at a specific location and to introduce NICR and VCCE 
as an alternative, inexpensive technique to characterize localized modulus of brain tissue. Results 
show brain modulus remains constant after freezing and is dependent on strain rates. Indentation, 
rheology and VCCE find brain modulus is approximately 1kPa while NICR and VCCE show 
modulus stiffens at higher stretches where NICR provides a significantly higher modulus due to its 
relation to a critical pressure. A finite element modeling (FEM) simulation was used to investigate 
this critical pressure event with two constitutive models upon introducing a cavity in brain.  
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2.2 Results 
 
2.2.1 Wide range of variation in brain modulus reports across the literature 
 
Figure 2.1 illustrates the wide range of modulus reported for brain tissue via two of the 
most widely used techniques: shear rheology and indentation. Differences in this set of values 
could be attributed to parameters like technique43, post-mortem time121, 122, location103, 
temperature122, 123, species124 and strain rates125. Figure 2.1 a-c illustrates the elastic (G’) and loss 
(G”) modulus obtained via oscillatory shear rheology for bovine, porcine and human brain. From 
these reports, most of the measurements were conducted within 6 hours post-mortem, however, a 
large range of moduli is reported for porcine brain mostly due to the lack of availability of human 
brain (fig. 2.1a). Given the capability of the rheology set up to control for temperature, this 
parameter has been used and shown to impact the modulus reported. From our search from a pool 
of 10 publications, we found that these reports had a wide range of temperatures to measure brain 
under shear, ranging from 4 to 37 oC (fig. 2.1b). Similarly, the frequency under which shear was 
performed ranged widely across these reports (fig. 2.1c). Although these reports show a somewhat 
similar range for G’ and G” for these range of frequencies, this can be a limitation for the design of 
cell instructive biomaterials as these values range from 0.1 to 10 of kPas and biomaterials, 
particularly hydrogels126, have been shown to induce differences in cell responses out of the 
modulation of this property alone. For this reason, it is difficult to compare brain modulus across 
species or the effect of temperature or post-mortem time in brain tissue and how a single value 
could be used to design a biomaterial. Additionally, the need to section samples in shear rheology 
could also impact the modulus reported110. 
To overcome these challenges, there has been an increasing interest in acquiring the 
localized mechanical properties of brain tissue. This is the case of indentation, where local 
properties can be measured, however, a limited set of publications have focused on the mechanical 
properties of brain with this technique. Figure 2.1 shows a comparison of the Young’s modulus 
reported for bovine, porcine and rat brain for white and gray matter locations via indentation. 
Comparison within the same species does not show significant discrepancies for white and gray 
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modulus (fig. 2.1d-e). However, there seems to be discrepancies between species as rat brain 
reported a lower modulus compared to bovine brain measured in vitro (fig. 2.1d-e). Only one report 
has conducted indentation in the porcine brain in vivo while the animal was alive and under 
anesthesia109. The modulus reported for this work seem higher that that obtained for porcine brain 
in vitro (fig. 2.1d). Among the work compared in figure 2.1d and e, the major difference was the 
post-mortem time of testing, as temperature was not controlled or reported in these  
 
 
Figure 2.1: Wide range of modulus reported for brain tissue. a) Storage (G’) and loss (G”) 
modulus reported in literature for bovine, porcine and human brain data from122 as measured via 
oscillatory shear rheology and presented as a function of post-mortem time, b) temperature and c) 
frequency. In shear rheology most measurements were conducted within 6 hours post mortem but 
wide range of modulus reported could be attributed at differences in temperature (b) during testing 
and frequency tested (c). a) Young’s modulus reported in the literature for bovine (78kHz), porcine 
(20kHz) and rat (20kHz) brain white and b) gray matter as measured via indentation (flat probe 
bovine and rat; spherical probe porcine) presented as a function of post-mortem time at the moment 
of testing. Modulus obtained via indentation for porcine and rat brain was reported converted to 
shear modulus in the publication to allow for comparison to shear rheology reports. Modulus 
remained constant within the time-lapse tested for bovine brain. There are apparent differences 
between species modulus. Limited amount of work for brain tissue measurements via indentation. 
Bovine data from 111 Porcine data from 109(in vivo), 103 and 104. Rat data from 127. 
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publications (fig. 2.1d-e). However, post-mortem time comparison for bovine brain shows the 
modulus follows a constant trend. Other parameters that can vary in this technique include probe 
geometry and dimensions111 and loading rates128. The methodology across these reports was 
similar. Rates were within 20-78 kHz, all work was with flat punch probe outside of in vivo porcine 
brain that used an spherical punch. No indentation reports for human brain were found. 
2.2.2 Four complementary techniques to characterize brain bulk, local, and in situ 
properties 
 
To overcome the large range of values reported in literature (figure 2.1), intact brain tissue 
was harvested, with minimal post mortem time, from 6-month old pigs and 12-weeks old mice. 
Porcine brain was chosen as a model organism because they are anatomically similar to humans129, 
while murine brain was chosen for their widespread use as subjects for in vivo studies of the brain64. 
Figure 2.2 summarizes the four techniques used to measure the localized and bulk mechanical 
properties: shear rheology (fig 2.2a), indentation (fig. 2.2b), needle-induced cavitation rheology 
(NICR) (fig. 2.2c) and volume-controlled cavity expansion (VCCE) (fig.2.2d). Shear rheology and 
indentation are two conventional techniques most commonly used to characterize brain tissue. 
Shear rheology allows for measurements of the bulk elastic or viscoelastic properties of a biopsy 
punched sample by analyzing the material response to an applied frequency deformation (fig. 2.2a). 
Indentation provides the advantage of testing local mechanical properties of a material upon 
applying a load within an indentation depth resulting in a load-unload curve that can be related to 
the effective modulus of the material (fig. 2.2b). Both shear rheology and indentation techniques 
require the sample to be manipulated to fit specific dimensions. Rheology samples were punched 
to an 8mm diameter in the white matter region of cortical slices, while brain slices of 1mm height 
were used for indentation in white and gray matter regions. 
Needle-induced cavitation rheology (NICR) and volume-controlled cavity expansion 
(VCCE), in contrast, do not require sample manipulation as they provide the advantage of testing 
at an arbitrary location (fig. 2.2c-d). Both of these techniques rely on the insertion of a needle at a 
specific location where fluid is pressurized into the system. For NICR, this fluid can be air 
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(compressible) or water (incompressible) and multiple needle radii are used to obtain a critical 
pressure (Pc) (fig. 2.2c). By obtaining a critical pressure as a function of needle radii an effective 
young’s modulus can be obtained following the relation Pc = 5/6E + 2𝜆/r115. VCCE, in contrast, 
monitors the pressure as a function of volume while an incompressible fluid (silicone oil) is 
pressurized in the system120. The volume measurements are transformed into an effective cavity 
radius (𝑎) and the pressure-effective radius results are used to find the elastic properties of the 
material in accordance with a chosen constitutive model (fig 2.2d). 
 
 
 
Figure 2.2: Measurement of brain mechanical properties via four techniques. a) White matter 
was excised from porcine brain slices with a sample punch of diameter of 8 mm. Samples were 
placed between two parallel plates and oscillatory shear was performed to obtain a dynamic 
modulus. Open and closed triangles represent elastic and loss modulus, respectively. b) A custom-
built indentation instrument was used to measure localized properties of brain tissue. A flat 
cylindrical punch with diameter of 1.5 mm came into contact with a cortical sample containing white 
and gray matter regions of height (h). Loading force was tracked as a function of indentation depth 
and a modulus was extracted from the loading curve. Cartoon depicts loading curve histogram (1) 
representative of hysteresis exhibited by brain samples. c) Needle-induced cavitation rheology was 
performed to assess local deformation of brain in situ. Porcine brain coronal slices were tested at 
white or gray matter regions. Cartoon circle depicts location of measurement. Multiple 
measurements are conducted with needles of varying small radius size to account for the role of 
surface tension. Single measurements tracked pressure increase in the system as a working fluid 
(compressible or incompressible) is pressurized in the sample. A critical pressure (Pc) is obtained 
and plotted as a function of 1/needle radius. An effective Young’s modulus (Eeff) can be extracted 
 21 
from the y-intercept of this curve following the relation Pc = 5/6E + 2𝜆/r. d) Volume controlled cavity 
expansion is an extension of needle-induced cavitation rheology in which a needle of larger 
diameter is placed in the location of measurement and an incompressible fluid is pressurized in the 
system. Throughout the experiment the pressure inside a cavity is measured as well as the volume 
of the cavity which is then transformed into an effective cavity radius. The pressure-effective radius 
curve is used to find the elastic properties of a material in accordance with a chosen constitutive 
model. 
 
2.2.3 Conventional techniques show brain tissue has a low Young’s modulus and these 
differ per species  
 
Figure 2.3 shows the modulus comparison for rheology and indentation of porcine and 
murine tissue. We found indentation and rheology values of white matter were similar in the case 
of porcine brain and showed no significant discrepancies in the modulus reported for the same 
brain (fig. 2.3a). In the case of murine individual brains, the brain was too small and did not allow 
for different technique measurements of the same brain. We found that comparison of modulus 
measurements between different animals showed no significant difference between the two 
techniques (fig. 2.3b). Comparison of the bulk modulus of both techniques, average of all brains, 
show no significant difference in the case of porcine brain (fig. 2.3 c).  We found, however, 
indentation gave a higher modulus for murine brain as compared to rheology (fig. 2.3d). Similarly, 
indentation provided a wider range of values in contrast to shear rheology. Together, these results 
show minimal variation in the modulus across individual animals as compared via two conventional 
techniques that measure bulk mechanical properties. For measurements conducted within the 
same brain via two distinct techniques, modulus obtained was very similar. Comparison across 
species via indentation shows murine brain had a larger moduli. 
2.2.4 Young’s modulus of brain tissue remains constant after freezing 
 
Post-mortem tissues can be used for a myriad of applications ranging from cell culture to 
genetic and molecular profiling. Conservation of these samples, if required for RNA and protein 
work, is mostly undergoing freezing at very low temperatures.  For this reason, it would be of 
interest to investigate how mechanical properties of the tissue change overtime after harvest and 
if freezing manipulation would change the mechanical properties of the brain. We found, via 
indentation, that the Young’s modulus of porcine and murine brain remained constant within 6 hours 
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post-harvest (fig. 2.4 a). Similarly, comparison of post-harvest and post-thawed brain tissue showed 
similar modulus via shear rheology measurements (fig. 2.4 b-c). Given that one of the major 
motivators to characterize brain mechanical properties in species such as porcine is due to the 
challenges in obtaining fresh human brain tissue, we decided to test the mechanical properties of 
post-thawed human brain tissue. We acquired three human brains with minimal post mortem time 
as indicated by the NIH neurobiobank report and tested the Young’s modulus via indentation of the 
white and gray matter structures. We found that the Young’s modulus was very similar to that of 
post-harvest porcine brain when probed at white and gray matter structures (fig. 2.4 d). 
 
 
Figure 2.3: Porcine and murine brain Young’s modulus as measured via indentation and 
shear rheology techniques. a) Six porcine brains were tested via shear rheology (black) and 
indentation (blue). White matter samples were extracted from the same porcine brain and prepared 
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for each technique. Indentation measurements illustrate a wider distribution of moduli 
measurements within the same brain. Comparison of average modulus between both techniques 
shows no significant difference between measurements. Each data point represents an 
independent measurement. b) Thirteen murine brains were acquired, and measurements were 
conducted on individual brains due to their small size. Comparison across modulus obtained for all 
murine brain showed no significant difference between independent brains.  c) Comparison of bulk 
measurements obtained via shear rheology and indentation for all porcine brains show no 
significant difference between the modulus reported by each technique. Porcine brain reported a 
modulus of approximately 1 kPa.  d) Comparison of bulk measurements for all murine brains shows 
indentation reported a modulus higher than that obtain via shear rheology. Shear rheology data 
was acquired in collaboration with Dr. Nathan Birch and Dr. Jessica Schiffman. Statistical analyses 
were performed using Prism (GraphPad). Data in a, c and d was analyzed using a t-test. Data in b 
was analyzed using a one-way analysis of variance (ANOVA). * indicates P<0.05; N.S., not 
significant. 
 
We similarly found that modulus had a weak dependence with temperature. Shear rheology 
measurements of porcine brain complex modulus (G*) show a slightly lower modulus obtained at 
37 0C as compared to 25 0C (fig. 2.5 a). This was also the case for viscous properties of brain as 
the viscosity showed very weak dependence with temperature (fig. 2.5 b). Together, these data 
show that the Young’s modulus measured for brain tissue after flash freezing conservation is similar 
to that of post-harvest brain. 
 
 
Figure 2.4: Similar Young’s modulus between post-harvest and post-thaw brain samples. a) 
Young’s modulus measurements for porcine (black) and murine (purple) brains as measured via 
indentation over a period of 6 hours post-harvest shows a constant trend. b) Comparison between 
post-harvest and c) post-thaw Young’s modulus measurements obtained via shear rheology show 
a similar modulus within a period of 3 hours of testing. Shear rheology data gathered in 
collaboration with Dr. Nathan Birch and Dr. Jessica Schiffman. d) Post-thaw human Young’s 
modulus as measured via indentation at white (blue open circles) and gray (blue closed circles) 
matter locations exhibits similar Young’s modulus to that of fresh porcine and murine brain. Data 
depicts data gathered for three human brains in order of testing.  
 
However, we also found that the method of freezing impacts the load-unload curves 
obtained via indentation. Figure 2.6 compares loading cycles across post-harvest samples (fig. 
2.6a), flash frozen-then thawed (fig, 2.6b), and slowly frozen at -80 oC (fig. 2.6c). Post-harvest 
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samples exhibited large hysteresis at every cycle performed (fig. 2.6a). We did observe an increase 
in modulus with increasing cycle at the same location after samples were allowed to recover for 50 
seconds in each cycle. Post-thaw samples tested that were previously flash frozen exhibited a large 
hysteresis in the first cycle that was decreased with subsequent loading (fig. 2.6b). This change 
was more dramatic for post-thaw samples that were previously frozen slowly at -80 oC as the 
hysteresis area was smaller (fig. 2.6c). A significant increase in the loading slope was seen after 
the first cycle, however, subsequent cycles had a very similar slope (fig, 2.6c). Together, these data 
show that the method of freezing impacts the mechanical properties of brain tissue. 
 
 
 
Figure 2.5: Porcine brain complex modulus and viscosity relation with temperature and 
frequency. a) Complex modulus (G*) obtained for six porcine brain samples at 25 0C (black) and 
37 0C (gray) shows slight decrease. Measurements at both temperatures show a weak dependence 
on frequency. Data are mean (solid line) and standard deviation (dashed line for 25 0C and shaded 
area for 37 0C). b) Measurements of viscosity at 25 0C and 37 0C show very weak dependence on 
temperature as measured via shear rheology. Shear rheology data gathered in collaboration with 
Dr. Nathan Birch and Dr. Jessica Schiffman. 
 
2.2.5 Young’s modulus of brain tissue exhibits strain rate dependence and strain 
hardening more dramatic at higher strains 
 
Both shear rheology and indentation techniques apply a frequency dependent strain to the 
material. Work by others has shown that brain tissue exhibits a strain rate dependent response in 
techniques like uniaxial compression (fig. 2.7 a-c) and indentation (fig. 2.7 d-e). This has also been 
observed in different species like porcine (fig 2.7 a, d), bovine (fig 2.7 b,e), and human brain (fig. 
2.7c). We next decided to explore how brain tissue strain rate dependent properties affect the 
modulus obtained from these measurements. To obtain linear elastic properties of brain shear 
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rheology is conducted in the quasistatic regime43. However, moving beyond to faster strain rates 
brain tissue exhibits higher modulus values (fig. 2.7).  
Figure 2.8a shows that the modulus reported in literature for porcine brain, as well as that 
conducted in this work, shows a clear dependence on the strain rate. We found that regardless of 
freezing, post-thaw human brain still exhibited a strain rate dependence in the modulus obtained 
via indentation (fig. 2.8b). Similarly, we found a strong correlation moving beyond the quasistatic 
region to those values reported at very high strain rates (fig. 2.8c). Together, these results highlight 
the strong dependence of modulus on strain rate and how this could be one of the reasons why 
there is a wide variation in brain tissue modulus reports in the literature (fig. 2.1). It is important to 
mention, however, that literature values that reported very high modulus at high strain rates were 
also conducted at high strains (50%, indentation) (fig.2.8c). 
 
 
Figure 2.6: Method of freezing impacts mechanical properties of brain. a) Load-unload curve 
for porcine brain as measured post-harvest. Each cycle exhibits large hysteresis and the loading 
curve increased with each subsequent cycle. b) Load-unload cycles for human brain tissue flash 
frozen after low post-mortem time. Initial cycle exhibits large hysteresis and slope increases with 
each cycle. c) Load-unload curves of human brain re-frozen upon thaw and subsequently tested 
via indentation. Curves show less hysteresis in comparison with flash-frozen sample. Loading curve 
increased with subsequent cycle. All cycles were performed within 50 seconds from each other to 
allow for tissue recovery after each cycle. 
 
2.2.6 NICR and VCCE show brain tissue stiffens at larger stretches and results in 
modulus variation 
 
Because of the large local variation reported by others, we wanted to introduce a technique 
that would allow for location specific measurements. Needle induced cavitation rheology (NICR) 
has recently been used by others to measure mechanical properties of biological samples and has 
been validated as a robust technique to measure mechanical properties alongside more 
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conventional techniques like indentation and rheology114, 115, 130-132. This technique allows us to 
induce a localized increase in pressure in situ that can be related to the Young’s modulus of a 
material by a single measurement if we know the surface tension between the solvent and the 
material following the relation Pc = 1.5E 130. Alternatively, when the surface tension of the material 
is not known, several measurements can be conducted with multiple needle radii and the Young’s 
modulus can be estimated by the intercept of the relation shown in section 2.1.1. The technique, 
which relies on a hyperelastic neo-Hookean material model133, has the capability of measuring local 
elastic properties on the length scale of microns to millimeters not possible with rheology or 
indentation. Similarly, VCCE is a novel technique to measure nonlinear elastic properties of 
compliant materials such as soft PDMS120. Since VCCE is an extension of NICR methodology, it 
has the same capabilities of in situ, localized measurements as NICR; however, since VCCE also 
allows measurement of both pressure and volume of injected incompressible fluid, it allows for 
fitting of any incompressible hyperelastic constitutive equation with a single measurement. Here 
we expanded the use of this technique to characterize the elastic behavior of the brain tissue with 
an incompressible two-term Ogden model, which has been previously shown to capture the strain 
stiffening response of the brain tissue100.  
Figure 2.9a shows representative data gathered for three porcine brains via VCCE where similar 
pressure-stretch curves can be observed for measurements at low stretches (below 1.1) while 
significant differences across brains are observed at larger stretches. Analysis of the localized 
modulus of white and gray matter via VCCE resulted in small Young’s modulus within the smaller 
stretch regime (fig. 2.9b). From this analysis we found white matter had a significantly higher 
Young’s modulus as compared to gray matter in the porcine cortex (fig. 2.9b). In the case of NICR, 
because the surface tension of the material is not known, we most conduct multiple measurements 
with needles of different radii as shown in figure 2.9c. The brain modulus calculated from this 
approach depends on the formation of an instability event that results in a critical pressure (Pc). 
From this Pc-needle relation we can obtain an effective Young’s modulus from the intercept (fig. 
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2.2c and fig.2.8c). For the twelve brains tested via NICR, we found large variation in the modulus 
and very high values (fig. 2.9d). We will discuss these results further in section 2.1.7.  
In the case of indentation, where we can also test white and gray matter structures of the 
cortex, we found no significant difference in the modulus reported for individual white and gray 
matter structures of porcine brain (fig. 2.9 e). This is in contrast to VCCE, were we consistently 
found a higher modulus in white matter (fig. 2.9b). Comparison of the four techniques illustrates 
that VCCE shows a similar modulus as those obtained via rheology and indentation since we 
consider the smaller stretch regime (fig. 2.9 f). 
 
 
Figure 2.7: Literature reports show brain tissue exhibits strain rate dependence. a) Stress-
strain curves for porcine brain b) bovine brain and c) human brain as measured via uniaxial 
compression show strain rate dependence in literature reports. d) Stress-strain curves for porcine 
and e) bovine brain show loading rate dependence as measured via indentation. f) Load and 
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displacement curves for post-harvest murine brain also show loading rate dependence as 
measured via indentation. 
 
NICR reported significantly higher modulus as compared to the other techniques since it 
relies on a critical pressure, but we still observed a higher modulus for white matter as compared 
to gray matter. Hence, we next sought to understand why NICR would provide significant higher 
modulus for the same porcine brain samples in which indentation and rheology were conducted. 
2.2.7 Analytical and finite element modeling predict that cavitation instability is unlikely 
in strain-hardening tissues like brain 
 
We used analytical and finite element (FE) models of cavity growth to simulate the pressure-
stretch relationship in absence of surface tension (fig. 2.10a) and in the presence of surface  
 
 
Figure 2.8: Modulus correlates with strain rate. a) Porcine brain Young’s modulus as measured 
via indentation shows correlation with strain rate with Pearson’s r r=0.75 (p<0.01). Literature 
porcine brain data (black) from 104 and 103 .b) Compression modulus reported from uniaxial 
compression test for human white matter and post-thaw human brain measured in this work shows 
correlation with strain rate with a Pearson’s r r=0.9 (p<0.0001). Literature data from 122 c) Modulus 
correlation at larger strain rates reported in literature shows Pearson’s r=0.59 (p=0.09) and r=0.9 
(p<0.0001), respectively. Modulus of post-thaw human tissue collected in this work (red circles) 
also shows correlation with strain rate. Pearson’s correlation was performed using Prism 
(GraphPad). **, **** indicate P<0.01 and P<0.0001. 
 
tension (Fig. 2.10b) for the Neo-Hookean and Ogden material models. The analytical model of a 
spherical cavity plots pressure vs. hoop stretch at the surface, while the FE model plots pressure 
vs. areal stretch, consistent with the work of Hutchens and Crosby130. FE model uses a geometry 
with the needle retracted from its initial position, as shown in figure 2.10c. From figure 2.10a, we 
see that the FE model gives a similar P/E – stretch relationship to the analytical model, and that 
the retracted needle geometry (of an initially cylindrical cavity (i)) shows a near-spherical geometry, 
at low stretches (ii) and especially at larger stretches (iii).  
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Since cavitation instabilities occur when there is either a plateau or maximum in the pressure-
stretch curve, our FE and analytical models do not predict cavitation in the two-term Ogden model 
used here (same as Hutchens and Crosby) due to appreciable strain stiffening. The Ogden model 
shows a pressure-stretch curve that continues to increase with increasing stretch, unlike the Neo-
Hookean model, where P/E asymptotically approaches 5/6 at increasing stretch (fig. 2.10a). When 
the effect of surface tension between air and tissue is superimposed with elastic resistance to 
deformation, the surface tension provides a larger driving force for cavitation instability because it 
has a decreasing stress-stretch relationship for lambda > 1.5. However, even when surface tension 
is incorporated in the model with conservative values (low E ~ 1 kPa, low needle radius r ~100 um), 
there is no maximum in the pressure-stretch curve, indicating that cavitation is not expected due to 
strain stiffening. Together this data indicate that a cavitation instability is unlikely in brain tissue due 
to its strain hardening properties. 
Because others have shown that the critical pressure obtained via NICR can be associated to 
elastic events or plastic deformations115, 116 we performed pressurization cycles in post-harvest 
murine brain to track the critical pressure in subsequent cycles. Here, we hypothesized based on 
previous work116, that if the critical pressure were to change over time (decrease) another event 
outside of cavitation is occurring in brain tissue, which could be indicative of fracture. Figure 2.11 
shows pressurization cycle results in which we see a decrease in the critical pressure after the first 
NICR cycle. Work by others has illustrated that brain undergoes softening when loaded after a 
certain threshold until material failure is observed100. It is possible this decrease in critical pressure 
in brain tissue via NICR is associated to a fracture event. 
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Figure 2.9: Needle-induced cavitation rheology and cavity expansion show brain tissue 
stiffens at larger stretches. a) Representative data for three porcine brains obtained via cavity 
expansion. Pressure-stretch curves show similar slope at smaller stretches. At higher stretches 
pressure increases significantly and higher variation between brain tissue can be observed. b) 
Localized measurements of porcine brain via cavity expansion at low stretches show white matter 
modulus is significantly higher than gray matter. Each circle represents a single measurement. c) 
Representative cavitation rheology data for white matter. Multiple needles of varying diameter are 
used to obtain a critical pressure (Pc). The y-intercept of a linear regression between the critical 
pressure and 1/needle radius is used to obtain the modulus following the equation Pc = 5/6E + 2𝛄/r. 
d) Young’s modulus obtained via cavitation rheology shows a wider range of moduli for white matter 
(white circles) and gray matter (gray circles). Each data point represents the y-intercept obtained 
from cavitation rheology measurements in a single brain. e) Violin plots of white matter (white 
circles) and gray matter (gray circles) modulus obtained via indentation show no significant 
difference between these two structures. Each circle represents a single measurement. f) Young’s 
modulus obtained for porcine white (white) and gray (gray) matter for rheology, indentation, cavity 
expansion and needle-induced cavitation rheology. Cavitation rheology show significantly higher 
values for brain potentially for measurements conducted at larger stretches. Cavitation rheology 
and cavity expansion data gathered in collaboration with Aleksander Mijailovic, Dr. Krystyn Van 
Vliet, Shabnam Raayai-Ardakani, Dr. Tal Cohen and Dr. Alfred Crosby. Statistical analyses were 
performed using Prism (GraphPad). Data in b and d was analyzed using a T-test. **, *** indicate 
P<0.01 and P<0.0001; NS, not significant. 
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Figure 2.10: Finite element modeling shows the strain stiffening behavior of brain does not 
allow for maximum pressure-stretch values. a) Pressure-stretch curves normalized by Young’s 
modulus (E) for a Neo-Hookean model (gray) and an Ogden model of brain tissue reproduced from 
Hutchens and Crosby, 2014 (black), with 𝛂1=4, 𝛂4=8, 𝛍1=𝛍2. Dotted lines represent analytical 
results for a pressurized sphere, and circles represent finite element models of a needle geometry. 
The Neo-Hookean model approaches the asymptotic value P/E=5/6, indicating expected cavitation, 
whereas the Ogden model shows extensive strain stiffening behavior without an asymptotic 
plateau, suggesting cavitation instabilities cannot occur. b) Pressure-stress curves from part (a) 
with surface tension included, using a needle with radius of 100 𝛍m, a surface tension value of 72 
mN/m, and Young’s modulus of 1 kPa. Under these conditions, a Neo-Hookean material is 
expected to cavitate as shown by a peak in the pressure. However, even in this conservative model 
where the effect of surface tension is most pronounced (i.e., small needle radius, low Young’s 
modulus), the strain stiffening behavior of the Ogden model does not allow for a maximum value in 
the pressure-stretch curve, and thus cavitation should not occur. c) Axisymmetric finite element 
modeling of the needle geometry for the brain shown in figure (a) with areal stretches of i. 𝛌eff = 1, 
ii. 𝛌eff = 1.13, and iii. 𝛌eff = 2.39. The top panel represents the full geometry (with a needle radius R, 
a width of 100R and height of 50R) and the bottom panel represents a zoom of the full geometry. 
In the underformed configuration (i.), the initial unpressurized cylindrical void has a radius R and 
height R. As the void is pressurized, the deformation approaches a spherical geometry as stretch 
increases (ii. and iii.) Data obtained in collaboration with Aleksander Mijailovic and Dr. Krystyn Van 
Vliet. 
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c
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Figure 2.11: Pressurization cycles via NICR in murine brain result in decrease in pressure. 
Air as a working fluid was pressurized into a mouse brain in order to evaluate if the critical pressure 
achieved would remain constant over time which is indicative of an elastic event. In this case we 
observed a decrease in the critical pressure after subsequent cycles. Softening in brain tissue has 
been shown to happen by others after a failure event 100 which could be indicative of fracture in 
NICR. 
 
2.3 Materials and Methods  
 
2.3.1 Sample preparation 
 
Brains from 6-month old pigs were collected from Baystate Medical Center Springfield MA. Brains 
from B6 albino mice, 12 weeks old, were received from the Tremblay lab at the University of 
Massachusetts, Amherst. The six porcine brains were dissected two hours post-mortem as four 
mm-thick horizontal slices and used for indentation, and cavitation rheology. Mice brain were kept 
whole for indentation and cavitation rheology and tested 30 minutes post-mortem. Brain tissue 
punches from both animals were 8 mm wide and 1 mm thick for shear rheology. To prevent tissue 
dehydration, all samples were placed in phosphate-buffered saline (pH 7.4) and kept on ice until 
mechanical testing was performed. To assure tissue integrity, most test were performed within 6 
hours post mortem43, and all tests were performed within 48 hours. To test the effect of freezing 
tissue, some samples were flash frozen overnight and kept at -80C and tested within a period of 4 
hours post-thaw. 
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2.3.2 Shear rheology 
 
Small-amplitude oscillatory-shear tests were performed on murine and porcine brain punches. 
Samples were placed in the lower plate of a Kinexus Pro rheometer (Malvern Instrument, UK) while 
the top plate was lowered into the sample and any excess was removed. The configuration was 
parallel-plate geometry, with a diameter of 8 mm. The temperature was maintained at 250C and the 
oscillatory frequency sweeps were conducted between 0.1 and 1 Hz. Temperature variation was 
captured by heating samples to 350C. Finally, the effective Young’s modulus, Eeff, was calculated 
at a frequency of 0.1 Hz assuming an isotropic material of Poisson’s ratio, v of 0.5. 
  𝐸,-- = 2𝐺 ∗ (1 + 𝜈)                                         
Four mice brain samples were subjected to rheology at 250C and then temperature was raised to 
370C. A total of 6 porcine brains were tested at 250C. Samples were tested after frozen to address 
rheological changes after thaw and rheology was performed at 250C. 
2.3.3 Indentation 
 
For indentation measurements, a cylindrical flat punch (High-Speed M2 Tool Steel Hardened 
Undersized Rod, 1.5-mm diameter) came into contact with brain tissue samples with a fixed 
displacement rate (20 𝛍m/s) and a maximum load (1.5 mN). A force transducer (Honeywell 
Sensotec, Columbus, OH) monitored the loading force, P, while a nanoposition manipulator 
(Burleigh instruments Inchworm Model IW-820) controlled the displacement, δ. A material 
compliance factor, C, calculated as the ratio between change in displacement over change in force 𝐶 = 6768                                   
was recorded by a National Instruments LabVIEW code. For the case of a contact radius, r, much 
smaller than the dimensions of the elastic sample, a, with a correction confinement described by 
0.5 <a/h < 2 where h is the sample height, the effective Young’s modulus (Eeff) can be calculated 
given the relation, 117 𝐸,-- = 9:;{=>=.99@ABC>=.99(AB)D}F    
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Nine mice brains were subjected to testing, a total of 6 porcine brains and 3 individual human 
brains. For the loading cycles, each cycle was performed within 50 seconds of each other to allow 
for tissue recovery as shown by others. 
2.3.4 Needle-induced Cavitation rheology (NICR)  
 
Needle-induced cavitation rheology (NICR) measurements were taken in a custom-built instrument 
consisting of a syringe pump (New Era Syringe Pump NE1000), pressure sensor (Omega 
Engineering PX26-001GV), and a syringe needle connected to a DAQ card that can record the 
pressure overtime. A needle was inserted into the tissue sample (1.8 mm) and air was injected at 
a rate 400 𝛍L/min. The pressure increases steadily balanced by the sample elasticity and surface 
tension until a critical pressure is reached that gives rise to a sudden and abrupt pressure collapse. 
This pressure change was recorded overtime using a custom-developed LabVIEW code for 
different needles with gauges between (22-32 gauge). The critical pressure achieved is a function 
of the needle radius, and an effective Young’s modulus can be calculated with the following 
equation assuming an isotropic material on the size scale of the needle130  𝑃H = 1.05𝐸 + K.=LM              
Were Pc is the critical pressure, 𝜸 is the surface tension, and r is the inner radius of the needle. 
2.3.5 Volume Controlled Cavity expansion (VCCE) 
 
Volume Controlled Cavity Expansion (VCCE) technique has been previously discussed in detail by 
Raayai-Ardakani et al. 120 In summary, using a needle-syringe system connected to an Instron 
Universal Testing Machine, a cavity filled with incompressible liquid (silicone oil) is expanded (in a 
volume controlled manner – rate of  2.7	 𝜇𝐿 𝑠⁄ ) inside the material of interest. Silicone oil was chosen 
to ensure immiscibility with the surrounding material. Throughout the experiment, the pressure inside 
the cavity is measured using a load cell connected to the syringe piston and is calibrated (by 
subtracting the frictional forces in the system and normalizing by the cross-sectional area of the 
piston) as previously discussed120. The volume measurements at every instance of the experiment 
are then transformed into an effective cavity radius (𝑎) and the pressure-effective radius results are 
used to find the elastic properties of the material in accordance with a chosen constitutive model.  
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Since brain has been previously identified as a strain-stiffening material100, here, we employ an 
incompressible, one-term Ogden model with the strain energy density defined as  
𝑊(𝜆=, 𝜆K, 𝜆9) = 2𝐸3𝛼K (𝜆=X + 𝜆KX + 𝜆9X − 3) 
where 𝐸 is the Young’s Modulus of the material and 𝛼 is an exponent capturing the strain-stiffening 
response of the material, and 𝜆Z(𝑖 = 1,2,3) are the principal stretches. In the case of the problem of 
the expansion of a cavity then 𝜆K = 𝜆9 = 𝜆\ and 𝜆= = 𝜆\]K where 𝜆\ is the circumferential stretch in the 
bulk material encapsulating the cavity. Employing the above strain energy density, it can be 
theoretically shown that the pressure inside the cavity (inside a body of material much larger than the 
radius of the cavity) can be found as  
𝑝(𝜆)=	 _`9X ∫ (=]	bcDd)(=]	bcD)=b 6bcbcedfg 
where 𝜆 is the circumferential stretch at the cavity wall which can be written as the ratio of the cavity 
radius at every time instance (𝑎) normalized by the initial cavity radius (𝑎h). 
From the experimental measurements, values of 𝑎 and 𝑝 are known for the duration of the expansion 
process, while the initial radius of the cavity is an unknown that cannot be measured using the 
conventional techniques available. Therefore, to be able to use this theoretical model against the 
experimental results to identify the elastic properties (𝐸, 𝛼) of the material120, one can consider 𝑎h as 
an additional unknown in the problem and fit the result for the three unknowns.  
Under three circumstances the test results were considered as physically un-acceptable (not 
successful) and have been removed from the analysis: (1) the pressure measurement captures 
negative or zero values, or (2) the measurements captures a pressure of more than 200 Pa at 𝜆 = 1 
(pre-stress), or (3) if the measured 𝑎his larger than the average radius of the needle (average of the 
inner and outer radii; a gauge 22 needle has been used for these experiments). Under the third 
condition, the measurements are believed to be dominated by damages incurred on the brain tissue 
rather than by elastic processes.  
2.4 Discussion 
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Changes in the elastic properties of brain tissue have been correlated with progression of 
neurodegenerative disorders134, traumatic brain injury39, 40 and brain cancers41. Previous studies 
probing different compartments of the brain have identified that brain tissue exhibits location-
dependent mechanical properties like  intraregional anisotropy98, 100, 135, intraregional variations136-
138, and regional inhomogeneities between different compartments104, 135. Yet, although most of the 
investigations carried in brain tissue explore bulk mechanical properties at distinct locations via 
rheology99, 139, 140 and indentation111, 138, 141 the macro and micrometer length scales of these 
techniques are limited in their spatial resolution and the need for sectioning of the sample limits the 
capabilities to test intra- and inter regional variations in situ. 
Needle-induced cavitation rheology (NICR)133 and volume-controlled cavity expansion 
(VCCE)120 are two relatively novel techniques that provide the capabilities to test local deformation, 
in situ at a spatial resolution within 100𝜇m to 10 mm not possible with indentation or rheology. NICR 
has recently been used to explore mechanical properties of polymers and tissues like the eye116, 
bone marrow117, lung118 and skin142, highlighting its capabilities of testing local mechanical 
properties in situ. Similarly, VCCE incorporates the same methodology of NICR with an 
incompressible working fluid120, providing additional information about the cavity volume which 
cannot be visually extracted in biological samples due to the inherent opaque nature of most 
tissues. Here we measured mechanical properties of porcine brain via NICR and VCCE alongside 
rheology and indentation to validate their applicability in obtaining modulus at a specific location. 
From our modulus comparison with conventional techniques shown in figure 2.3, we found 
rheology and indentation values of 0.9 + 0.1kPa and 1.0 + 0.2kPa, respectively for porcine brain, 
which show agreement with those reported in work by others111, 143. Indentation allows for localized 
measurements at the surface of the sample at a micrometer length scale and we observed a wide 
range of stiffness for porcine (0.1-10 kPa) and murine (0.4 – 11 kPa) tested at different locations. 
Comparison of the average of these measurements, in contrast, showed no significant difference 
among individual brains, but murine cortex resulted in a higher modulus compared to porcine cortex 
via indentation (fig 2.2). This result would agree with recent work from MacManus et al.,144 where 
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indentation of murine and porcine brain in the same cortex location yielded different moduli. 
Similarly, others have used more localized techniques to investigate the mechanical properties of 
white and gray matter. In our case, white matter was found to be slightly stiffer then gray matter (fig. 
2.9) similar to studies from99, 111, 138, 145 and in contrast to studies from139, 146. However, NICR reported 
values of 4.75±0.9 kPa and 3.65± 0.7 kPa for white and gray matter respectively which are 
significantly higher compared to conventional techniques. VCCE, in contrast, obtained an average 
modulus of 1 kPa similar to that found via indentation and rheology. Previous NICR modulus values 
for synthetic soft materials, like hydrogels, have shown agreement with shear rheology and contact 
mechanics techniques115, 133. In the case of biological tissues, like in this work, some have reported 
a slightly higher value via NICR in contrast to other techniques117, 118 while others have shown good 
agreement116. Hence, we next sought to understand why NICR of brain tissue would yield a 
significantly higher modulus in comparison to other techniques. 
We begin with the assumptions in VCCE and NICR analysis. In both techniques, we 
assume hyperelastic material behavior and a spherical cavity forms with increasing pressure; the 
main difference is that, in NICR, the maximum pressure value is used to measure E, whereas in 
VCCE, the pressure-volume relationship before the maximum pressure is fit to measure E. In NICR, 
we specifically assume that the material behaves in a Neo-Hookean manner, which leads to an 
elastic cavitation instability at a high enough pressure133. Assuming the effect of surface tension is 
modelled from equation shown in section 2.1.1, we find the modulus by extrapolating the critical 
pressure to an infinite needle radius (where surface tension contribution is zero) (fig. 2.2). In VCCE, 
we assume that a cavity of initially unknown volume and shape is expanded spherically. With a 
large enough needle such that surface tension is negligible, we can fit a hyperelastic constitutive 
model to the measured pressure vs inserted incompressible fluid volume. In both techniques, we 
assume that the material does not fracture in the modelled part of the deformation (but can fracture 
after, for example after the cavitation pressure Pc is reached in NICR), that the deformation rate is 
sufficiently slow such that viscoelastic effects are negligible, and that the tissue behaves 
hyperelastically.  We emphasize that, while the deformation mechanism is essentially the same in 
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both techniques (except for the pressurizing fluid, which must be incompressible in VCCE and can 
be either incompressible or compressible in NICR), the main difference is the assumption of elastic 
cavitation in NICR, which is not necessary in VCCE because a pressure-stretch curve may be fit. 
The discrepancy in the measurement of Young’s modulus by NICR vs. that of rheology, 
indentation and VCCE is likely due to the inadequate assumption of a Neo-Hookean material. While 
we cannot confirm this experimentally by imaging due to brain tissue’s opacity, theoretical evidence 
suggests that cavitation is unlikely in brain due to its strain stiffening behavior as seen in figure 2.8. 
From figure 2.9a, we see that an Ogden model of brain tissue reported by Franceschini et al.,100 
has appreciable strain stiffening and will not have a maximum or plateau in the pressure-stretch 
curve, unlike the Neo-Hookean model which becomes increasingly compliant at higher stretch. 
Figure 2.9b suggests that, even with the conservative assumptions of low surface tension/E ratio 
and low needle radius (i.e., conditions that increase the driving force for cavitation due to a 
decreasing –pressure stretch relationship), the Ogden model of brain tissue does not predict 
cavitation. Thus, brain tissue’s appreciable strain stiffening makes the assumption of cavitation 
unsatisfactory. Hence, the modulus cannot be accurately measured from the critical pressure Pc 
from equation (Pc = 5/6E + 2𝜆/r), and Pc may instead be correlated to fracture events. In the case 
of VCCE, we note that the surface tension effect should be negligible in these experiments due to 
the large needle radius, so figure 2.9a is governed by only the brain tissue’s elastic response, and 
we hypothesize that damage or fracture govern the response at higher stretches. While the 
cavitation assumption is likely invalid in NICR for strain stiffening materials, we sought to evaluate 
validity of the assumption of spherical deformation in VCCE, which is critical in the technique’s 
analysis. 
To verify the assumption of nearly spherical cavity geometry in VCCE, we performed finite 
element modelling of the VCCE experiment, and we compared the pressure-stretch curve from our 
analytic model to that of the FE model. In our experiments, needles are typically retracted after 
insertion into the material, leaving a cavity in the original volume pierced by the needle, so in our 
modelling, we replicate this setup with an initially cylindrically shaped cavity. During pressurization, 
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the cavity approaches spherical at relatively low surface hoop stretch (lambda = 1.1) (fig. 2.9c), 
and the pressure-stretch behavior is similar in magnitude and trend to the analytical solution (fig. 
2.9a). However, given that NICR like VCCE is a needle-based technique that relies on the 
pressurization of the system and we see larger variations in the modulus at larger stretches in 
VCCE (fig. 2.8a) it is possible NICR measurements are occurring at a larger stretch regime. Hence 
it would be of great interest to understand the event that leads to a critical pressure in NICR. 
From pressurization cycles performed by others via NICR, the shape of the cavity formed 
can be indicative if the event occurring is an elastic instability or fracture115, 116. This is also related 
to the critical pressure obtained in subsequent cycles. From the pressurization cycles performed in 
murine brain in figure 2.11 we see a decrease in the critical pressure after the first pressurization 
cycle event. Work by others have associated the brain softening event to take place after the 
material has reached failure at large stretches. Loading cycles performed by Franceschini et al.,100 
identified brain underwent softening beyond the failure point. It is possible the event leading to a 
critical pressure in NICR for brain is associated with fracture in this case, but additional studies 
should be conducted to confirm this. However, fracture events have been shown to happen at very 
large stretches and strain rate events100, 147. Given that brain exhibits strain rate dependent 
responses and strain hardening behavior, NICR would be an effective technique to study local 
deformation of brain in situ and what parameters induce fracture in brain. This could be beneficial 
for studies related to traumatic brain injury or blast induce cavitation which rely in similar 
mechanisms as NICR to induce the formation of an instability event. 
As for NICR for brain tissue explored here, constitutive relation assumptions can verge 
advantages or limitations dependent on the technique. For example, assumptions in rheology in 
which brain exhibits linear elastic deformations at low strains and more viscoelastic deformation at 
higher strains are very good. However, the assumption of a homogeneous deformation can pose 
as a limitation since other work as shown the heterogeneity present in brain tissue99. In the case of 
indentation which also assumes homogenous deformation, this is dependent on the technique 
parameters like probe size or distance to different areas of the tissue. In contrast to rheology, 
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however, indentation assumptions of linear elastic deformations at low strains are dependent on 
strain rates. This pose limitations in frequency dependent materials like the brain (fig. 2.6). In our 
VCCE (and NICR) analysis, we assume that the deformation length-scales and deformation rates 
are in a sufficient range such that brain behaves as an incompressible, hyper-elastic solid, and 
does not have significant viscoelastic, poro-elastic, or fracture behavior.   
Similarly, we aimed to conduct our measurements within the first six hours of acquiring the tissue 
samples due to previous work highlighting the effect of post-mortem time in measured modulus43, 
106, 121, 148. We observed no significant change in brain modulus when tested within the 6 hours post-
mortem via indentation and shear rheology (fig. 2.4). Similarly, to address contradicting literature 
on the effect of freezing of brain tissue149-151 we performed shear rheology in post-thaw samples. 
Although we observed an increase in the spread of the moduli range obtained via shear rheology, 
no major moduli differences were found under post-thaw measurements conducted via these two 
techniques (fig 2.4). This result agrees with observations from149 with moduli remaining constant 
during a large period of time. This also extended to post-thaw human brain tissue which we saw 
exhibited similar modulus to post-harvest brain and values remained constant within the time 
window tested. Similarly, others have recently shown the importance of controlled storage 
conditions of brain for mechanical property tests123, 152. We saw that for the case of measurements 
conducted with 25 0C and 37 0C modulus did not change significantly and exhibited similar viscous 
responses (fig. 2.5). 
Together we present two techniques to probe local measurements in situ: NICR and VCCE 
that not only provide mechanical information but also response to deformation events at length 
scales beyond traditional techniques like rheology and contact mechanics. We foresee the use of 
this technique in additional biological materials and the expansion of constitutive models beyond 
Neo-Hookean to better describe materials following strain hardening and viscoelastic responses 
like brain tissue. Future work could help expand brain deformation with incompressible fluids in 
NICR. Similarly, future work evaluating the fracture events within NICR and how these can translate 
to other brain related diseases like TBI and blast wave induced cavitation. We think this would help 
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expand the range of biological tissues that can be probed in situ given the inherent advantage of 
both cavitation rheology and cavity expansion techniques. 
2.5 Conclusion  
 
In this study we complemented four distinct techniques to characterize local and in situ 
modulus of brain tissue and to compare continuity among mechanical techniques. We find that 
brain tissue has a low Young’s modulus as measured via bulk, localized and in situ mechanical 
techniques and white matter tissue reported a higher modulus via VCCE. Brain tissue was found 
to exhibit similar Young’s modulus after freezing and modulus remained constant within a window 
of 6 hours of testing. Modulus was found to correlate with strain rate and percent of strain applied. 
Additionally, loading cycles showed that brain tissue exhibits strain hardening. While VCCE can be 
used to understand the material response via a constitute relation applied to a pressure-stretch 
curve, NICR can help explore events associated with higher stretches where we expect fracture 
can occur as our FE experiments indicate cavitation is unlikely in strain hardening tissues like the 
brain. We foresee the use of this technique in additional biological materials and the expansion of 
constitutive models beyond Neo-Hookean to better describe materials following strain hardening 
and viscoelastic responses like brain tissue. Future work could help expand brain deformation with 
incompressible fluids in NICR. Similarly, future work evaluating the fracture events within NICR and 
how these can translate to other brain related diseases like TBI and blast wave induced cavitation. 
We think this would help expand the range of biological tissues that can be probed in situ given the 
inherent advantage of both cavitation rheology and cavity expansion technique. 
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CHAPTER 3 
3: PROTEOMICS OF HUMAN BRAIN AND THYMUS ECM PROTEINS 
 
3.1 Introduction 
 
The brain extracellular space, accounts for 20% of the total volume of the mature brain, and 
consists of three prominent structures that compose the brain extracellular matrix compartments: 
the blood-brain barrier (BBB), the perineuronal nets (ECM structure most prominent around 
neurons) and the interstitial matrix5-8. Cells are the main source of these ECM proteins that 
compose and give rise to differences in tissues. In the brain, astrocytes are the big synthesizers of 
proteins in the cortex9. 
Others have shown that the components of the ECM can be divided into core proteins, core 
associated proteins and ECM regulators like small molecules that interact with the ECM10-12. Core 
ECM proteins include collagens, proteoglycans and glycoproteins11. Collagens and glycoproteins, 
like fibronectin and laminin, are mostly found around the vasculature in the basement membrane8. 
A mixture of collagen, glycoproteins and proteoglycans can be found in interstitial ECM giving rise 
to the microenvironment that surrounds the cells10. Matrix affiliated proteins and ECM regulators 
include those proteins and small molecules that are colocalized in the extracellular space but do 
not readily assemble to form the matrix that gives rise to tissue10. The interaction of cell with ECM 
components provide the cues give rise to biological cascades13. 
Integrin molecule pairs, consisting of 𝛂 and 𝛽 heterodimers, are the main surface receptors 
from which cells interact with ECM proteins14-17. These transmembrane receptors can bind to both 
ECM proteins and the cellular cytoskeleton providing mechanical and biochemical signaling that 
regulates cell response17. Additionally, in order to degrade and remodel the ECM, cell release 
enzymes that allow them to spread and migrate in the native microenvironment. Matrix 
metalloproteinases (MMP) are a family of enzymes that cleave various proteins of the ECM18. 
Together these interactions of cells and their ECM microenvironment have been shown to play a 
role in development19, 20, differentiation153 and disease17, 18, 20.  
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In order to understand the ECM dynamic changes during development, health and 
disease13, 22, 23, as for example, ECM molecules are already present in the developing embryo 
where they play important roles in the development of the central nervous system7 and the 
composition of these brain ECM proteins has been shown to change during different developmental 
stages7, others have aimed to characterize the ECM composition of tissues via proteomics. 
Proteomic work by others has illustrated the ECM diversity in tissues10, 154, as for example, 
comparisons between lung and colon tissues ECM highlighted there are a subset of proteins unique 
to each tissue and could give rise to the macroscopic differences that are observed in different 
organs. However, proteomic work has been limited to a subset of tissues as it has become a new 
approach and although there is a vast range of work with histological approaches, like the publicly 
accessible Protein atlas, these are not focused on the ECM composition. A limited number of 
existing reports, however, focused on the deposition of ECM proteins has been limited to those 
produced from in vitro cell culture or have been performed in tissue from origin other than human 
and hence are limited in the information they can provide from the native human microenvironment. 
These are examples that illustrate how additional work in needed in order to characterize the ECM 
profile of human brain tissue. Hence, to expand on this set of proteomic characterization, this work 
aimed to characterize the ECM composition of tissues of human origin, particularly brain, at a 
defined age and healthy state and complemented with histology to assess protein location. The 
proteomics performed in this work could be used for the design of tissue specific instructive 
materials of the ECM in vitro.   
 
3.2 Results and Discussion 
 
3.2.1 Characterization of the Human Brain ECM  
 
We acquired four healthy human frontal cortex samples (fig. 3.1a) given that the cerebral cortex 
accounts for 77% of the brain volume in order to characterize the unique brain ECM-profile.155 
These samples were decellularized and enriched for ECM proteins following an ECM enrichment 
protocol recently introduced by Naba et al,154 which resulted in an insoluble pellet of 1-2 (w/w) % 
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analyzed via Liquid-Chromatography Mass-spectrometry (LC-MS/MS) (fig. 3.1a).154 Protein hits 
were compared to the Human Matrisome Database and classified into ECM core or related proteins  
 
 
 
Figure 3.1: Characterization of the Human Brain Cortex Extracellular Matrix. a) Right frontal 
cortex samples from four healthy human donors were decellularized and enriched for extracellular 
matrix (ECM) proteins resulting in an insoluble pellet that was solubilized, reduced, and digested 
into peptides identified via Liquid Chromatography-Mass Spectrometry (LC-MS). b) Protein hits 
were compared to the Human Matrisome Database and classified into ECM core or related 
proteins. Data shown is average number of proteins found in four donors + s.d.  c) Distribution of 
Brain ECM signature proteins among donors d) Proteins present in at least two donors were 
screened for affinity to integrin binding and e) enzymatic degradation via matrix metalloproteinases 
(MMP). Heat map depicts protein abundance based on peptide spectrum match (PSM) normalized 
to protein molecular weight (MW) for Integrin binding- and MMP-degradable proteins. f) The Human 
Protein Atlas was screened for ECM proteins in the human brain cortex as identified via histology 
images. Heat map depicts protein abundance via histology expression of integrin binding and g) 
MMP-degradable proteins in the human brain cortex. Degree of expression denoted as ND (not 
detected), low, medium or high. 
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(fig. 3.1b). Glycoproteins, collagens and proteoglycans, which are known to interact with integrin 
heterodimers, compose the core ECM proteins (fig. 3.1b).12 From this list, and including hits found 
in at least two donors, proteins  were further stratified by affinity to integrin binding and enzymatic 
degradation via matrix metalloproteinases (fig. 3.1c-e, Table A.1, A.3, and A.4 ). Peptide spectrum 
match (PSM) and the protein molecular weight were used to quantify a relative abundance of 
selected proteins (fig. 3.1d-e). In sum, we found 116 ECM proteins, 18 with known integrin 
interactions and 21 known to be degraded by matrix metalloproteinases (fig. 3.1d-e, Table A.1, A.3, 
A.4).  
 To address protein localization, we complemented our LC-MS/MS findings with a published 
histological screen of brain proteins by the Human Protein Atlas156,  where we found 147 brain ECM 
proteins in the cortex (Table A.2). These were similarly screened by core proteins known from the 
Matrisome database, resulting in 17 proteins with known integrin binding and 24 that undergo MMP 
degradation (fig. 3.1f-g, Table A.2). Spatial location of proteins within the brain cortex was assessed 
via the protein atlas histology to differentiate proteins located at the basement membrane 
(endothelial cells) or at the intercellular space (astrocytes, neurons, neuropil) (fig. 3.1f-g).7 The 
grade of histology reported by the Protein Atlas (ND, high, medium, or low) was used to assess 
abundance of proteins alongside location (Table A.5, A.6). Tables A.1, A.2, A.5 and A.6 show the 
complete list of human brain ECM proteins as categorized for Core or matrisome related proteins. 
These are further stratified into integrin-binding and MMP-degradable proteins in tables A.3, A.4 
and A.7 
3.2.2 Proteomics of pediatric and fetal thymus 
 
In order to expand this proteomic characterization to other tissues, we explored the ECM 
composition of fetal and pediatric thymus with the aim to understand what set of ECM proteins help 
in T-cell maturation in collaboration with the Maehr group at UMass Medical School. The use of 
proteomics could help characterize the unique features of the thymus ECM and could also help us 
validate how sensitive is this technique to the protein composition of the same tissue at different 
stages of development. Figure 3.2 shows differences in the thymus ECM composition between 
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fetal to pediatric stages of development. We found that the fetal thymus is rich in ECM proteins that 
are usually present in the vasculature like fibronectins, fibrillins, and thrombospondins, while these 
proteins were not present in the pediatric thymus (fig. 3.2a). This composition was very conserved 
across the two fetal thymus samples tested (fig. 3.2b). We also found that regardless of the 
developmental stage, the ECM was rich in glycoproteins and a low number of proteoglycans was 
detected although more where present at the fetal stage (fig. 3.2a, and b). Comparison of the set 
of samples identified 11 unique proteins for the fetal thymus that were not present at the pediatric 
stage, however, both share a set of 19 proteins that compose the thymus tissue (fig.3.2c). 
 
 
 
Figure 3.2: Proteomics to identify ECM changes in development. a) ECM proteins identified 
via proteomics workflow in fetal and pediatric thymus. Heat map depicts percent of protein as 
normalized via peptide spectrum match and molecular weight of protein. b) Distribution of core 
ECM proteins across two samples for pediatric thymus and one fetal thymus sample. All samples 
contain three technical replicates. Data shown is mean with s.e.m. for collagens (orange), 
glycoproteins (green) and proteoglycans (blue). c) Venn diagram depicts ECM proteins found in 
both samples and proteins found in individual thymus. 
 
3.2.3 Screening of integrin-binding and MMP-degradable proteins of tissue specific 
proteomes 
The proteomic information acquired with this approach allows for the design of tissue specific 
instructive materials that could be used to understand ECM signals that regulate cell behavior in 
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vitro. In order to accomplish this, literature mining was performed to identify ECM proteins that have 
been shown by others to interact with cells via integrin-heterodimers. By further identifying amino 
acid sequences present in these proteins with literature mining, these specific sequences of 
interactions are known and can be synthesized at small scales via solid phase peptide synthesis. 
Together, the combination of these approaches illustrates a simple way to extract the ECM 
composition of tissues via proteomics in order to design tissue specific instructive biomaterials (fig 
3.3). We foresee the information presented here being used by others aiming to understand the 
proteomic composition of human brain and thymus tissue. 
 
 
Figure 3.3: Proteomics and histology complemented workflow. a) Healthy human brain was 
acquired and b) decellularized and enriched for ECM proteins prepared for mass spectrometry via 
digestion. c) Publicly accessible histology data on the same organ of interest (e.g. brain) was used 
to assess protein localization in the extracellular space. d) Both approaches used were screened 
against the human MATRISOME database to identify proteins that belong to the human Core of 
Matrisome associated ECM. e) For the design of tissue specific ECM instructive biomaterials, the 
list of ECM proteins can be further stratified into integrin-binding and MMP-degradable proteins that 
would allow for cell-ECM interaction in vitro. 
 
3.3 Materials and Methods  
 
3.3.1 Acquisition of human brain tissue 
Human tissues were obtained from the NIH NeuroBioBank at Harvard Medical School. Frozen post-
mortem tissues from four neurologically normal individuals from the ages of 30-68 where obtained 
flash frozen.  
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3.3.2 Decellularization and Enrichment of tissue 
The CNMCS Compartment Protein Extraction Kit (Millipore, Sigma) was used to decellularize all 
human brain tissue samples. Briefly, intracellular soluble proteins were extracted with sequential 
incubation in the appropriate buffers according to manufacturer’s instructions. This resulted in an 
insoluble ECM-rich pellet. 
 
3.3.3 In-solution digestion of proteins for LC-MS/MS 
The ECM-rich pellet of four brain tissue samples was solubilized and reduced in 8 M Urea, 100 mM 
ammonium bicarbonate, and 10 mM dithiothreitol (DTT) (Thermo) for 30 minutes at pH 8 and 37C. 
Samples were then alkylated with 25mM iodoacetamide (Sigma-Aldrich) in the dark at RT for 30 
minutes. Samples were subsequently quenched with 5mM DTT and the solution was diluted to 2 
M urea with 100 mM ammonium bicarbonate (pH 8). Proteins were digested via trypsin (Thermo) 
and Lys-C endoproteinase (Promega, Madison, WI) at a ratio of 1:50 enzyme to protein overnight 
(12-16 hours) at 37 C. Finally, samples were cleaned and concentrated using a C18 column 
(Thermo). 
 
3.3.4 LC-MS/MS protein analysis 
Digested peptides were separated by reverse phase LC gradient prior to mass analysis. Mass 
spectrometry analysis was performed in an Orbitrap Fusion Tribid (Thermo). Identified peptides 
were aligned against the Matrisome using the Thermo Proteome Discoverer 1.41.x. Parameters for 
analysis used trypsin as a protease, with 4 missed cleavages per peptide, a precursor mass 
tolerance of 10 ppm, and fragment tolerance of 0.6 Da. 
 
3.3.5 Identification of integrin-binding and MMP-degradable proteins in brain 
Using a top-down approach, we screened the human cerebral cortex for ECM tissue features that 
could be incorporated into a synthetic poly(ethylene)glycol (PEG)-based hydrogel to capture 
biochemical properties of the brain. The cerebral cortex accounts for 77% of the brain volume155, 
and we assessed the brain cortex ECM composition via histology-based bioinformatics and 
proteomics. Histology data from the Human Protein Atlas156 was used to identify cortex enriched 
proteins, their expression, and local distribution. Human brain samples analyzed by LC-MS 
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identified relative protein abundance. From the list of ECM proteins, those with integrin-binding 
capabilities and susceptibility to matrix metalloproteinase (MMP) cleavage were chosen to allow 
for cell adhesion and hydrogel degradation. Bioactive motifs of the selected proteins previously 
identified in literature were synthesized and incorporated in the hydrogel as 9 cell-adhesive ligand 
peptides and 5 MMP-degradable sequences representative of the brain ECM.  
 
3.3.6 Thymus ECM protein enrichment 
 
Three tissue samples from healthy patients were obtained from the UMass Medical School 
(Worcester, MA). ECM proteins were extracted from 300mg, 600mg, and 90mg samples using the 
CNMCS compartmental protein extraction kit according to the manufacturer’s instructions 
(Millipore, Billerica, MA). This resulted in an insoluble ECM pellet. 
 
3.3.7 Thymus Mass Spectrometry LC/MS 
 
Three biological replicates were analyzed for two individual pediatric thymus and one fetal 
thymus tissue. The ECM-rich pellet prepared from the CNMCS kit was solubilized and reduced in 
8M urea 100mM of ammonium bicarbonate, and 10mM dithiothreitol (DTT) (Thermo) for 30 minutes 
at pH 8 and 37C. Samples were alkylated with 25mM iodoacetamide (Sigma-Aldrich) in the dark at 
RT for 30minutes and subsequently quenched with 5mM DTT. This solution was then diluted to 2 
M urea with 100 mM ammonium bicarbonate at pH 8 and cleaved via trypsin (Thermo) and Lys-C 
endoproteinase (Promega Madison, WI), at a ratio of 1:50 enzyme to substrate overnight (12-18hrs) 
at 37C. Samples were desalted and concentrated using a C18 column (Thermo). A reverse phase 
LC gradient was used to separate peptides prior to mass analysis. Mass spectrometry analysis was 
performed in an Orbitrap Fusion Tribid (Thermo). Resulting peptides were aligned against the 
Matrisome using the Thermo Proteome Discoverer 1.41.14. Parameters used trypsin as a protease, 
with 4 missed cleavage per peptides, a precursor mass tolerance of 10 ppm, and fragment 
tolerance of 0.6 Da 
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3.3.8 Identifying integrin-binding and MMP-degradable proteins in Pediatric and Fetal 
Thymus 
 
Manual data mining was used to identify 14 integrin-binding and 20 MMP-degradable 
proteins in pediatric thymus. For the fetal thymus 21 proteins were integrin-binding and 27 were 
MMP-degradable. This list was used to identify which proteins would be represented by integrin-
binding or degradable peptide sequences. The proteins were relatively quantified with the peptide-
spectrum match (PSM) from the mass spectrometry data and normalized to the molecular weight 
of the protein. The ratio was annotated for each protein and a relative percent abundance was 
obtained from the ratio of each protein over a sum of the total ratio identified per sample. This value 
was averaged across all the patient scores and was used to determine the percentage of each 
integrin-binding peptide and MMP-degradable crosslinker to use for proteins in the thymus ECM 
cocktail represented in supplementary tables 1 and 2, respectively. 
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CHAPTER 4 
 
4: TIGHT CONTROL OF ASTROCYTE ACTIVATION IN A SYNTHETIC BRAIN HYDROGEL 
 
4.1 Introduction 
 
In order to understand how ECM signals are instructive to cells, we aimed to design a 
tissue specific brain hydrogel based on the proteomic information gathered from Chapter 3. To test 
this design, we focused on a particular cell type that has been known to remodel and produce the 
brain ECM, astrocytes. Astrocytes constitute approximately 30% of the cells in the mammalian 
brain and function as key mediators of the brain ECM homeostasis.9, 44, 45 During brain trauma157 
and inflammation45, 46, astrocytes adopt a reactive phenotype characterized by upregulation of the 
intermediate filament proteins glial fibrillary acidic protein (GFAP)9, 44, 45, vimentin158, and nestin158, 
alongside morphological changes48. It is these reactive astrocytes  that have been shown to help 
mediate brain metastasis24, 51, 159, 160, and form glial scarring following an injury that impedes 
recovery50, 157. Yet, mechanisms that control for astrocyte activation remain poorly understood. A 
potential limitation to address this question is that current in vivo studies of astrocyte activation 
cannot isolate how single cell-ECM events lead to astrocyte reactivity. As such, what relevant 
extracellular signaling pathways control astrocyte activation remain to be understood. There is an 
imminent need for in vitro models in which to complete mechanistic investigations of astrocyte 
activation. 
In order to pinpoint what single cell-ECM interactions regulate the activation of these cells 
we need better controlled environments. For this reason, bioengineers have aimed to develop more 
tunable systems in which to study astrocytes in vitro. Astrocytes grown as three-dimensional (3D) 
organoids67, 68, 70 provide aspects of the brain architecture, like stellate morphology, and astrocyte 
heterogeneity, yet their use of Matrigel and the culture of astrocytes in close proximity limit the 
isolation of cell-cell and cell-ECM interactions. This is of particular importance since astrocyte 
processes only overlap in vivo when they are reactive.9, 47 Similarly, protein-based 3D hydrogels, 
typically Type I collagen71, 75, hyaluronic acid73, or mixtures of these proteins71, 75, have been 
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popularized as brain in vitro platforms, as they are ECM proteins that exert biocompatibility, and in 
certain cases, lower upregulation of GFAP75 as compared to astrocytes grown in a 2D monolayer. 
Yet, the combination of proteins50, 75, 77, 161, cytokines55, and mechanical77 cues that have been 
shown to influence astrocyte activation, cannot be independently controlled in these materials.  
Synthetic hydrogels, in contrast, provide a tremendous opportunity to design tissue-specific 
scaffolds with tight control over parameters, like stiffness and ligand density, but bioactive moieties 
need to be incorporated to represent the microenvironment of interest.76, 80, 81 Yet, these models 
are characterized by astrocytes that adopt a rounded morphology or express high levels of GFAP 
when in an stellate form. Currently there is no cell culture environment that can retain inactive or 
quiescent astrocytes in vitro. 
We sought to develop such an in vitro model that would enable us and others to study the 
specific extracellular factors that control astrocyte activation while starting from a quiescent state.  
To accomplish this, we first characterized the human brain ECM via mass spectrometry and Protein 
Atlas histology156 as shown in Chapter 3, and incorporated the top ECM components responsible 
for  integrin-mediated adhesion and MMP-mediated degradation of the brain into a fully synthetic 
hydrogel, like will be discussed further in this chapter. Using this biomaterial, composed of solely 
of poly(ethylene)glycol (PEG) and peptides, we overcome the current challenge of retaining primary 
human astrocyte quiescence in vitro and we can control and induce activation. Here we 
demonstrate control over astrocyte activation via tuning of the integrin-binding and MMP-
degradable profile or via cytokine molecules, in contrast to other protein-based models like collagen 
where astrocytes remain in a state of activation.  
4.2 Results and discussion 
 
4.2.1 Design of a synthetic Brain ECM hydrogel 
 
Astrocytes have been shown to be responsive to ECM proteins in vitro. For example, work by 
Johnson et al,77 demonstrated that the ECM composition determined astrocyte responses to the 
substrate stiffness and inflammatory stimuli. In this work, astrocyte migration was arrested when 
cultured on fibronectin while fast migration was observed when cultured on tenascin or laminin.  
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Others have shown, astrocyte attachment to fibronectin, laminin and fibrillin-1 regulates IL-1 
induced activation in an integrin-dependent manner.162 We thus hypothesized that a brain-specific 
ECM would allow for control of astrocyte activation in vitro. Integrin heterodimers are the 
transmembrane receptors that mediate tissue-specific cell binding to the ECM. We therefore 
narrowed our ECM Matrisome screening, from Chapter 3, to proteins with known interactions with 
integrin heterodimers.163, 164  From the pool of proteins present in both Figs. 3.1d and f, (both 
approaches were used to determine the relative amounts of proteins present in the brain cortex) 
(fig. 4.1a; Table A.7) integrin-binding sequences were matched via literature mining to their integrin 
pairs (Table A.3, A.5, A.7). Proteins identified were screened to those present in at least two donors, 
not present only near endothelial cells, and with known amino acid sequences (fig. 4.1a and 4.2b). 
This resulted in 15 proteins that were further grouped based on the adhesive sequence. Seven 
proteins had the RGD interactive site while eight proteins had a unique site of interaction, these 
are represented by a total of 9-integrin binding peptides that compose the adhesive landscape of 
the synthetic brain ECM (fig. 4.1a and 4.1b).  
Matrix metalloproteinases (MMP) are a family of enzymes that cleave ECM proteins.18 Since 
synthetic hydrogels are characterized by their small mesh size, cells need to be able to degrade 
the biomaterial in order to migrate165. Thus, to allow for hydrogel degradation, we screened ECM 
proteins with the same parameters used for integrins as described above (fig. 4.1a) and we further 
screened ECM proteins with susceptibility to MMP degradation. These were grouped based on the 
MMP of interaction as found via literature mining (Table A.3 and A.6, fig. 4.1a and 4.1c) and resulted 
in nineteen proteins. From this group, sequences known to be degraded by the MMPs of interest 
166(fig. 4.1c) were used to represent the degradable profile of each group of proteins. (fig. 4.1a and 
4.1c). This screen resulted in 5-degradable peptides that compose the degradable landscape of 
the synthetic brain ECM. Both integrin-binding and MMP-degradable peptides can be easily 
incorporated in the hydrogel following a Michael addition reaction.167 Integrin-binding peptides are 
incorporated via a single cysteine functionalization while MMP-degradable peptides have a double- 
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Figure 4.1: Design of a Synthetic Brain Extracellular Matrix Hydrogel. a) Proteins identified via 
in-house proteomics (present in >2 donors) and histology from the protein atlas (not only expressed 
by endothelial cells) were screened by integrin-binding (ITG) and matrix metalloproteinase (MMP) 
degradable sequences, later synthesized into peptides. b) ITG peptides represent the adhesive 
landscape of brain via fifteen proteins, incorporated into the hydrogel via single cysteine 
functionality. Heat map depicts peptide molar distribution in the cocktail. c) MMP peptides represent 
the proteolytic landscape of brain as filtered by a group of 19 degradable proteins and incorporated 
into the hydrogel by two cysteines one at each end. Heat map depicts peptide molar distribution in 
the cocktail. d) Michael addition reaction for the hydrogel formulation and schematic of the hydrogel 
network. Hydrogel is formed by mixing two solutions, solution A with integrin-binding functionality 
and solution B with MMP-degradable functionality with non-degradable crosslinker. e) Young’s 
modulus of post-thawed human brain f) fresh and post-thawed porcine brain n=6 and g) hydrogel 
tuned to the same Young’s modulus as brain tissue as measured via indentation. Modulus is 
maintained after incorporation of integrin-binding (green) or MMP-degradable (red) peptides.  n=8. 
h) Percent of unreacted thiols after hydrogel reduction with NaBH4. High polymerization efficiency 
is maintained. n=8. All data are mean with s.d. Statistical analyses were performed using Prism 
(GraphPad). Data in e-g was analyzed using a one-way analysis of variance followed by a Tukey’s 
multiple comparison test with 95% confidence interval. N.S. is not significant. 
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Figure 4.2: Identification of Synthetic Peptides via MALDI-TOF. a) Spectra of adhesive and b) 
degradable peptides as identified via MALDI-TOF analysis. c) Peaks corresponding to the different 
amino acid sequences in the mixture. d) Analysis of brain hydrogel supernatant after polymerization 
was performed for 10 minutes shows no peaks. 
 
 
 
Figure 4.3: 2D Adhesion and 3D degradation of integrin-binding and MMP-degradable 
peptides. a) Schematic depicting coverslip functionalization with integrin-binding peptides and cell 
seeding. b) Area fold change after incubation. Cells can adhere to surfaces functionalized with 
integrin-binding peptides better than PEG and similar to RGD. N=2, n=3. c) Schematic depicting a 
competitive binding assay of individual integrin-binding peptides. d) Change in cell area after 
incubation in surfaces. Cell area is significantly decreased in previously treated conditions 
compared to cells allowed to adhere to cocktail of integrin-binding peptides without previous 
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treatment. N=2, n=3. e) Schematic depicting encapsulation of cells in 3D hydrogels functionalized 
with MMP-degradable peptides. f) Distance of process length originating from the cell center. 
Astrocytes elongate processes at each MMP-degradable peptide condition better than PEG alone 
after 24 hours of encapsulation. N=2, n=4. g) Distance of process length originating from cell center 
at different timepoints. Cells elongate processes overtime and can be encapsulated in the brain 
hydrogel for a period of 14 days. N=2, n=4. h) Representative human primary astrocyte morphology 
in the different hydrogel conditions. i. Images of astrocytes in hydrogel without interactive sites, with 
integrin-binding only, MMP-degradable only and both integrin-binding and MMP- degradable 
peptides over 24 hours; After 12 days astrocytes show elongated processes. All data are mean + 
s.d. Statistical analyses were performed using Prism (GraphPad). Data in b, d, and f was analyzed 
using a one-way analysis of variance followed by a Dunnett’s multiple comparison test with 95% 
confidence interval. *, **, ***, and **** indicate P<0.05, P<0.01, P<0.001 and P<0.0001. 
 
end cysteine modification to allow for crosslinking of the hydrogel with degradable backbone (fig. 
4.1d). The formation of the hydrogel consists of two solutions that contain adhesive and degradable 
components, respectively, and which polymerize under a minute (fig. 4.1d). The speed of the 
reaction can be tuned with the strength of the buffer as shown previously.92  
Given the current advances in recombinant protein production and engineering, one 
attractive avenue is the recombinant production168 of ECM proteins used to design this hydrogel 
system. Since proteins also have cysteine sites, they would be able to undergo incorporation into 
the brain hydrogel chemistry. Yet, although it sounds very appealing at first, one important limitation 
from this approach is that this would not limit the interaction between the cells and the protein site 
to be exclusively at integrin binding and MMP degradable sequence domains, as proteins have 
many other sites of interaction. However, if the interest is still to have the whole protein sequence, 
there are multiple challenges that would need to be overcome in order to produce all of these 
proteins successfully. First, posttranslational modifications which are very important for protein 
production, as a most common example glycosylation169, can lead to differences in protein 
stability170, solubility171, antigenicity172, folding173, localization174 and biological activity175 if it is not 
modified properly. This is a challenge since glycosylation169 is a very complex posttranslational 
modification that requires several consecutive steps and involves tens of enzymes and substrates, 
and this process is protein-176, tissue-177 and animal-specific178. Other posttranslational 
modifications such as phosphorylation179, methylation180, C-terminal amination181, etc., although 
less common that glycosylation, may also be important to other recombinant proteins and these 
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depend on the host182 utilized since they are only available in higher eukaryotic cells. Finally, 
overcoming the protein localization production is challenging since recombinant proteins may be 
directed to different cellular compartments by signal peptides183, 184 or through fusion proteins184 
and it is difficult to predict if these would be intracellular184 or secreted184. These different sites of 
protein localization can have advantages or disadvantages, as for example, intracellular185 
accumulation often leads to high protein amounts and allows for an easy recovery but purification 
of the product from the protein-rich cell extract may be difficult. On the other hand, secreted 
proteins184 facilitate its purification and allow for easy recovery but are often highly diluted. 
Additionally, challenges in the secretion pathway184 can further reduce their accumulation in the 
culture medium. Protein localization is particularly important when producing proteins with a specific 
native sequence168, as for example, if they are produced in the cytoplasm, they are highly 
susceptible to proteolysis and would hence lose the desired sequence. Together these are 
examples of the time-consuming, expensive and complex process of producing all ECM proteins 
in the brain hydrogel recombinantly instead of just synthesizing the peptides of interest, which is a 
cheap, fast-turnaround controllable alternative adopted in this work. 
 Next, since microenvironment biomechanical forces can dictate cell behavior, we aimed to 
replicate the modulus of brain tissue in vitro.29 However, reported Young’s modulus of the brain 
ranged from 100s of Pa to 10s of kPa and were found to vary considerably among experimental 
techniques.43 In order to narrow the modulus within the cortex, as discussed in Chapter 2 in more 
detail, we characterized the mechanical properties of human brain, via an indentation technique 
previously published by our group117, and we found the Young’s modulus to be approximately 1kPa  
(fig. 4.1e).117  
Due to limitations in the ability to find fresh human brain tissue, and to confirm there was no 
difference in modulus of fresh tissue, we also characterized the bulk modulus of fresh and post-
thawed porcine brain cortex given the anatomy and gray to white matter ratio is similar to that of 
human brain.111 Via indentation, we found a surprisingly similar Young’s modulus to that of post-
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thaw human brain and a slightly lower post-thaw modulus that was not significantly different (fig. 
4.1e and 4.1f). 
To match these mechanical properties into our brain hydrogel, and taking a similar approach to 
work by others186 that have modulated the biomaterial’s Young’s modulus due to the elastic 
properties of hydrogels, we adjusted the macromer concentration until reaching a similar Young’s 
modulus to that of brain (fig. 4.1g). Given that at very low strains, the brain behaves as an elastic 
material, as shown in work from chapter 2, we find the Young’s modulus is sufficient to modulate 
the mechanical properties of the hydrogel as cells will apply forces at very low strains in the 
biomaterial as well. Similarly, at these low strains, brain tissue does not exhibit strain rate 
dependence has illustrated by shear rheology results in chapter 2 and hence we do not foresee 
these properties as critical in the brain hydrogel design. We also found the Young’s modulus was 
not affected with the incorporation of adhesive or degradable motifs and these peptides can be 
incorporated efficiently into the PEG-maleimide system (fig. 4.1g and 4.1h, fig. 4.2). 
 
 
Figure 4.4: Adhesion of integrin-binding peptides to human cell lines. Cell lines a) SK-N-AS 
and b) MDA-MB-231-BrM2a were seeded in surfaces functionalized with poly(ethylene)glycol 
(PEG) (gray), brain synthetic adhesive peptides (maroon), or previously treated with adhesive 
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cocktail (green) and then seeded into a coverslip functionalized with the integrin-specific peptide 
mixture. Cell area was traced every five minutes for a period of 120- and 100-minutes respectively. 
Cell area increased significantly in the non-treated (maroon) cells that were seeded directly onto 
coverslips with the adhesive peptide mixture, while the cell area remained small in the PEG 
condition. Cells treated with the adhesive peptide mixture for five minutes prior to seeding onto 
coverslips took longer to increase the cell area. Data shown is mean (solid line) + s.d. (shade 
region). N=2, n=30.  c) SK-N-AS and d) MDA-MB-231-BrM2a cells were seeded into coverslips 
functionalized with each integrin-binding peptide for a period of 2 hours. Cells were washed, fixed 
and stained with Dapi and counted with ImageJ software. Data shown is the number of cells 
attached normalized to PEG as mean + s.d. N=2, n=3. e) Representative images of SK-N-AS and 
f) MDA-MB-231-BrM2a cells adhering overtime to coverslips functionalized with the integrin-binding 
peptide mixture or PEG. Cells show a larger area when cultured on coverslips functionalized with 
the adhesive peptide mixture in contrast to PEG alone. 
 
4.2.2 Design and validation of brain-specific integrin-binding peptides 
 
In order to validate that cells can adhere to the integrin-binding peptides we intended to include in 
the brain-specific hydrogel, we performed a 2D adhesion assay with a human neuroblastoma cell 
line SK-N-AS. We found that cell area increased significantly for cells seeded on surfaces 
functionalized with integrin-binding peptides compared to negative control surfaces (fig. 4.3a-b, fig. 
 
 
Figure 4.5: Peptides are specific to human cell adhesion. a) Quantification of cell area traces 
overtime for the murine cell lines Neuro2A and b) mHippoE18. Cells were seeded into coverslips 
functionalized with poly(ethylene)glycol (PEG) (gray), adhesive brain synthetic ECM (maroon) or 
 60 
incubated for five minutes in adhesive brain synthetic ECM mixture followed by seeding into 
coverslip functionalized with adhesive brain synthetic ECM (green). Data shown is mean (solid line) 
+ s.d. (shaded area). N=2, n=30. c) Cells lines Neuro2A and d) mHippoE18 were seeded into 
coverslips functionalized with each integrin-binding peptide and allowed to adhere for 2 hours. 
Change in cell area from time=zero to time=2 hours are shown for each integrin-binding peptide, 
PEG and the adhesive brain synthetic ECM mixture. e) Neuro2A and f) mHippoE18 representative 
images of cell spreading in coverslips functionalized with PEG or the adhesive brain synthetic ECM 
mixture for a period of 120 minutes. g) Competitive binding of the human cell line SK-N-AS and h) 
murine cell line Neuro2A. Cells were previously incubated for five minutes in the peptide of interest 
in soluble form and subsequently seeded into a coverslip functionalized with the integrin-binding 
peptide mixture. Data shown is mean + s.e.m. N=2, n=30. i) Sequences that did not inhibit cell 
adhesion of the Neuro2A cell line to the adhesive peptide mixture functionalized coverslip are not 
found in the protein sequence of the mouse.  
 
4.4).16 Experiments with the commonly used breast cancer cell line MDA-MB-231 in adhesion 
assays showed similar results (fig. 4.4, Tables A.3, A.5).187, 188  
We conversely performed a competitive binding assay where cells were pre-incubated with integrin-
binding peptides in solution before being exposed to a surface with the full cocktail of brain-specific 
integrin-binding peptides (fig. 4.3c). Compared to those cells incubated with peptide, non-treated 
cells fully spread and adhered to the brain peptide cocktail surfaces (fig. 4.3d, fig. 4.5). We also 
found that sequence homology mattered. Exposing a murine cell line to peptides sequences whose 
sequence differed from that of human resulted in non-attachment to the full cocktail surface 
(collagen type IV, periostin, and collagen type XVIII, fig. 4.5).  
We encapsulated human primary astrocytes in hydrogels containing a single integrin-binding 
peptide for a period of 5 minutes prior to fixing and staining for the integrin heterodimers receptors 
expected to bind the peptide ligand, based on an assay developed by Li et al. (Table A.5)189. We 
positively identified integrin heterodimers via immunofluorescence for the predicted integrin ligand-
receptor pairs in contrast to culture in PEG alone (fig. 4.6). Together this data illustrates the human 
specific design of this brain hydrogel and the specificity of the integrin-binding peptides. 
4.2.3 Human Astrocytes cleave MMP-degradable peptides to extend processes 
 
We encapsulated human primary astrocytes in hydrogels containing a single integrin-binding 
peptide for a period of 5 minutes prior to fixing and staining for the integrin heterodimers receptors 
expected to bind the peptide ligand, based on an assay developed by Li et al. (Tables A.3, A.5)189.  
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Astrocytes have a morphology characterized by their ramification and long processes, and we 
expected that gels that do not contain MMP-degradable peptides would yield rounded astrocytes 
or small processes.9, 44 Human primary astrocytes were encapsulated in 3D hydrogels with 
conditions testing blank and functionalized hydrogel with integrin-binding peptides only or with both 
integrin- and MMP-degradable group of peptides (fig. 4.3e). We optimized astrocyte cell density in 
the brain hydrogel to prevent cell clustering over long culture periods (fig. 4.7). We found that 
astrocytes were able to extend processes in conditions that incorporated both integrin-binding and 
MMP-degradable moieties and remained viable in the brain hydrogel for a period of 12 days (fig. 
4.3e, fig. 4.8). In order to verify that each degradable peptide was in fact susceptible to degradation  
 
 
 
Figure 4.6: Adhesive peptides elicit integrin expression via immunofluorescence. a) Human 
primary astrocytes were encapsulated for five minutes in collagen or hydrogels modified with a 
single integrin-binding peptide at the same concentration as in the brain adhesive peptide mixture. 
b) Or non-functionalized poly(ethylene)glycol hydrogels. Hydrogels were fixed and stained for the 
Collagen RGDVTCG YIGSRIVRRADRAVPIKVAV DGEA FYFDLR EIDGIEL ALMKYHILN
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expected integrin-heterodimers known to bind the amino acid sequences selected (Table A3-A5). 
Membrane stain (red) and Dapi (blue) were used for cell co-localization. 
 
by astrocytes, as shown by others166 for other cell types, cells were encapsulated in hydrogels 
containing integrin-binding peptides and individual MMP-degradable crosslinks. Further 
quantification of astrocyte process length from the cell center over time, shows that cells were able 
to extend their processes, over a period of 14 days, better than in PEG alone (fig. 4.3e-i, fig. 4.9). 
Together these results demonstrate that the hydrogel can be degraded and retain cell viability for 
2 weeks.  
4.2.4 Astrocyte activation can be controlled with hydrogel composition 
 
Recent work by Placone et al.,75 illustrated that modifying the concentration of components in a 
protein-based hydrogel composed of Type I Collagen, hyaluronic acid, and Matrigel reduced the 
expression of GFAP, an astrocyte specific marker correlated with activation, in primary fetal human 
 
 
 
Figure 4.7: Optimization of human primary astrocytes seeding density in the brain hydrogel. 
a) Human primary astrocytes were encapsulated at a density of 1,000-, 3,000-, 5,000-, and 8,000 
cells/gel in the brain hydrogel and cultured for a period of 7 days. b) Cells can also be encapsulated 
at greater densities (e.g. 500,000 cell/gel) and form networks over time. 
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Figure 4.8: Human Astrocytes spreading increases with integrin-binding peptide 
concentration. a) Human astrocytes were encapsulated in brain hydrogel with 0.5mM, 1mM, 
1.5mM and 2mM integrin-specific binding mixture and a constant 25mol% MMP-peptide mixture 
for a period of 12 days. b) Cells elongated their processes significantly after 24 hours of 
encapsulation in the 2mM integrin-binding hydrogel. c) Quantification of the distance from the cell 
center for astrocytes culture over a period of 12 days in the hydrogel at the specified condition. 
Data shown is mean + s.d. N=2, n=4. 
 
astrocytes as compared to culture in 3D collagen alone. Similarly, work by Hara et al.,50 
demonstrated that astrocytes become reactive when cultured in a collagen coated substrate as 
mediated by the integrin-n-cadherin pathway. We thus hypothesized that tuning the composition of 
the brain hydrogel would have an impact in astrocyte GFAP expression and this could be compared 
to culture in a collagen gel. 
To test the brain hydrogel effect on astrocyte reactivity, we explored integrin-binding 
peptide concentrations around the range that allowed for cell spreading in a 3D geometry (fig. 4.10). 
We found that increasing the concentration of adhesive peptides beyond a concentration of 2mM 
resulted in astrocytes with long processes similar to those in a collagen-based gel, but beyond a 
3mM concentration yielded astrocytes with high levels of GFAP fluorescence similar to that in 
collagen (fig. 4.11a-c).75 We thus decided to test if modifying the concentration of MMP-degradable 
peptides would also have an effect in activation. We found that combining a 4mM concentration of 
integrin-binding peptides with a 13mol% concentration of MMP-degradable peptides yielded 
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significantly low activation in astrocytes cultured in vitro compared to collagen (fig. 4.11d-f, fig. 
4.10). This result agrees with the astrocyte activation observed by others upon ECM deposition in 
vivo, where, for example, increase in the production of protein has correlated with observed 
astrocyte activation.24, 50 
Figure 4.11g shows representative morphologies and levels of GFAP fluorescence in primary 
astrocytes encapsulated in the different conditions. We found a particular brain hydrogel 
formulation that resulted in low levels of GFAP and stellate morphology. Together these data show 
that astrocyte activation can be controlled in a fully synthetic brain hydrogel by tuning of integrin-
binding and degradable motifs. 
4.2.5 Quiescence is not achievable in protein-based hydrogels 
 
Recent work by Liddelow et al.55 described astrocyte activation via three cytokines 
produced by microglia: interleukin 1 alpha (IL-1alpha), tumor necrosis factor alpha (TNF-alpha) and 
complement component 1, subcomponent q (C1q) were activation was defined by high expression 
of GFAP.55 Similarly, work by Hara et al.,50 identified gfap and vimentin as genes highly expressed 
by spinal cord injured activated astrocytes. To confirm quiescent astrocytes can undergo activation 
in the brain hydrogel, we triggered activation by dosing with the three cytokines identified by 
Liddelow55 after 24 hours of culture in the brain hydrogel (fig. 4.12a). We found that under standard 
culture medium conditions, astrocytes express low levels of activation markers GFAP and Vimentin 
compared to collagen-cultured astrocytes (fig. 4.12b-c).50 
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Figure 4.9: Human primary astrocytes can remodel the synthetic brain hydrogel. 
Representative images of human astrocytes encapsulated in a functionalized brain hydrogel, 
hydrogels with a single MMP-specific peptide and an adhesive peptide concentration of 2mM, or a 
non-degradable PEG hydrogel for a period of 14 days.  
 
 
24 hours 72 hours 7 days 14 days
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Figure 4.10: Optimization of MMP-peptide concentration in the Brain Hydrogel. a) Human 
astrocytes were encapsulated in collagen and brain hydrogels functionalized with 6mol%, 13mol%, 
and 25mol% MMP-specific peptide mixture at a constant 2mM integrin-specific peptide 
concentration. Representative images of cell morphology and dynamic remodeling of the hydrogel 
for a period of 7 days. b) Representative images of astrocyte cell morphology after 72 hours of 
encapsulation. c) Quantification of the distance from the cell center over time for hydrogels at 
different conditions as compared to a non-degradable poly(ethylene)dithiol (PDT) hydrogel. 
Astrocytes encapsulated in a brain hydrogel with 13mol% and 25mol% MMP-specific peptide 
mixture achieve a longer extension similar to collagen cultured astrocytes. d) Cell diameter of 
astrocytes cultured in brain hydrogels at different conditions and collagen for 72 hours. There was 
no significant difference in the cell diameter. Data shown is mean + s.d. N=3, n=4. 
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Figure 4.11: Human Primary Astrocytes Activation can be Controlled via Integrin-binding 
and MMP-degradable Peptides in the Brain Hydrogel. a) Box and whisker plot show distance of 
process length from the cell center increases with integrin-specific peptide concentration. N=2, n=3. 
b) Normalized fluorescence intensity of glial fibrillary acidic protein (GFAP) as a function of integrin-
specific peptide concentration. Low concentrations of integrin-specific peptides retain low activation 
of astrocytes and short process length. c) Box and whisker plot illustrating length of astrocyte 
process originating from cell center at different hydrogel conditions and time points. Astrocyte 
process length varies with hydrogel degradability which can be tuned with MMP-degradable peptide 
concentration. N=2, n=4. d) Normalized GFAP fluorescence as a function of hydrogel integrin-
binding and MMP-degradable peptide concentration after 72 hours of encapsulation. N=2, n=4. e) 
Representative images of astrocytes encapsulated in different hydrogel conditions at 72 hours. 
GFAP expression is lowest at the 4mM integrin-binding and 13mol% MMP-degradable hydrogel 
condition. Data in b,c and e are mean + s.d. Data in f is mean + s.e.m. Statistical analyses were 
performed using Prism (GraphPad). Data in b, c, e and f were analyzed using a one-way analysis 
of variance followed by a Dunnett’s multiple comparison test with 95% confidence interval. *, **, ***, 
and **** indicate P<0.05, P<0.01, P<0.001 and P<0.0001. N.S. is not significant. 
 
 
Similarly, using a serum-free media with the trophic support of Heparin-Binding EGF-like growth 
factor (HBEGF) denoted as quiescent medium in the publication by Liddelow et al.,55 we obtained 
a quiescent astrocyte population low on activation markers, while in collagen, the population 
remained highly activated with positive expression of GFAP and Vimentin (fig. 4.12b-c, fig. 4.13). 
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Additional dosing with cytokines resulted in astrocyte population changes that became significantly 
activated with increasing dosages after 24 hours of culture (fig. 4.12b-c). In contrast, astrocytes 
cultured in collagen, with or without serum, retained a similar population of activation markers 
across conditions. These results illustrate that activation can be observed in the brain hydrogel, but 
collagen cultured astrocytes are already in an activated state. 
To further confirm a reactive phenotype, we quantified changes in astrocyte morphology. Work by 
others have demonstrated that activated astrocytes become significantly smaller compared to non-
activated astrocytes in vivo.55  In the case of astrocytes expressing high levels of gfap marker during 
activation, cells exhibit aberrant different morphologies resulting in a heterogenous population.48 
We found that astrocytes retain predominantly a stellate morphology when cultured in the brain 
hydrogel in standard and quiescent conditions while the population changes to that of rounded, 
polarized and stellate cells in cytokine induced conditions (fig. 4.12d-e). In collagen, we found 
astrocytes exhibited a heterogeneous range of morphologies as expected in activated populations 
(fig. 4.12d-e).48  Similar to A1 activated astrocytes in the work by Liddelow et al., we found 
astrocytes process length, volume and surface area was decreased significantly in the highest 
treated cytokine concentration in the brain hydrogel while there was no significant difference across 
collagen cultured conditions (fig. 4.12f-h).55 Together these results confirm a reactive astrocyte 
phenotype of rounded and smaller sized astrocytes compared to quiescent populations that could 
only be captured in a synthetic hydrogel with additional integrin-binding and MMP-degradable sites, 
and not in collagen culture alone.  
4.2.6 Reactive astrocytes are highly migratory in vitro 
 
Astrocytes have been shown to become highly migratory upon activation in vivo46, 190. To confirm 
their reactive phenotype we explored astrocyte migration speeds upon dosing with cytokines in the 
fully synthetic brain hydrogel. As compared to highly migratory astrocytes on 2D TCPS, we found 
that cells migrated significantly more in cytokine dose brain hydrogel conditions as compared to 
the standard culture in the control brain hydrogel (fig. 4.12i).191  Together these data demonstrate 
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Figure 4.12: Dynamic astrocyte activation can be recapitulated in the brain hydrogel. a) 
Human primary astrocytes were encapsulated in biomaterials for 24 hours and dosed with 
cytokines IL-1alpha, TNF and C1q after 24 hours. b) Representative images of astrocytes after 48 
hours in biomaterials and incubated with standard culture medium (control), defined quiescent 
medium, and dosed with cytokines. Scale bar 20 microns. c) Cell population distribution across 
conditions stained for gfap, vimentin activation markers and dapi for nuclear stain. N=2, n=250 cells 
per condition. d) Distribution of cell morphology and e) representative cell morphologies in the 
different populations identified as round (gray), stellate (blue) or polarized (light blue). N=3, n = 100 
cells per condition. f) Quantification of distance from cell center of astrocytes N=6, n=3. g) Single 
cell volume and h. Single cell surface area for astrocytes encapsulated for 48 hours at different 
conditions. Process length, cell volume and area decreased significantly in cytokine dosed 
astrocytes, indicative of activated phenotype. N=3, n=3). i) Comparison of migration speed 
astrocytes seeded in 2D TCPS, 3D brain hydrogel with and without cytokines shows astrocytes 
migrate significantly more in activated conditions. N = 2. All plots represent mean + s.e.m. Statistical 
analyses were performed using Prism (GraphPad). Data in c was analyzed using a one-way 
analysis of variance (ANOVA). Data in f-h were analyzed using a two-way ANOVA followed by a 
Tukey’s multiple comparison test with 95% confidence interval. Data in i was analyzed using a one-
way ANOVA followed by a Dunnett’s multiple comparison test with 95% confidence interval. *, ** 
and **** indicate P<0.05, P<0.01 and P<0.0001; NS, not significant. 
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Figure 4.13: Astrocytes undergo cytokine mediated activation in the brain hydrogel. 
Representative images of astrocytes encapsulated in collagen or brain hydrogel at control (c), 
quiescent medium (Q), or cytokine dosed conditions with increasing concentrations (+) and (++). 
 
that astrocytes cultured in the brain hydrogel remain quiescent in vitro and can undergo cytokine 
mediated activation as shown by changes in morphology, activation markers and a migratory 
phenotype. Similarly, together this data illustrates the heterogeneity in the cell population of reactive 
astrocytes as expected from work by others in vivo48. However, it would be of interest to understand 
why there is a clustering to three major group of cells based on their morphology and if there is a 
genetic predisposition that allows certain cells to become reactive as stellate or as rounded cells. 
For example, given that this group of cells is of primary origin from a human brain, it is possible 
there are different genetic profiles when looking at each individual cell type. Future work could help 
pinpoint what are the major differences in these three different groups of activated astrocytes by 
resorting to tools like single cell sequencing techniques. As discussed by Liddelow et al.,45 only two 
types of reactive astrocytes have been identified so far (e.g. A1 and A2) however, it is possible that 
astrocytes are reactive in more than just two states. Single cell genomics could be applied to the 
population of astrocytes in the brain hydrogel and these profiles could be compared to results 
published by Zamanian et al.,54 on the genetic profile of reactive astrocytes immunopanned in 2D. 
Another alternative to control for this population, however, could be sorting of cells via 
flowcytometry to then culture a pure astrocyte population and completely divide them based on 
their genetic profile.  
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4.2.7 Incorporation of Hyaluronic acid (HA) in the brain gel induces activation 
 
Because HA is a polysaccharide present in brain tissue that has been commonly incorporated in in 
vitro ECM models of the brain and, correlation between concentrations and disease have been 
shown by others,72, 73, 192, 193 we decided to test how HA would affect astrocyte activation in the brain 
hydrogel.  We incorporated thiolated HA in the brain hydrogel system and stained for GFAP after 
48 hours of encapsulation (fig. 4.14). We found that astrocytes GFAP expression increased in a 
dose dependent manner, with 0.1mM HA being the lowest dose at which astrocytes remained 
quiescent (fig. 4.14). This finding agrees with that shown by others in which low and high molecular 
weight HA induce activation of glial cells.193 Others have also shown increase in malignant 
phenotype of glioma cells in a dose dependent manner.192  
To further test if astrocyte activation could be induced with cytokine dosage like shown previously, 
astrocytes encapsulated in HA-modified brain hydrogels were dosed with cytokines and stained for 
gfap markers (fig. 4.15).  
 
 
Figure 4.14: Human primary astrocytes become activated to hyaluronic acid in a dose 
dependent manner. a) Normalized GFAP fluorescence increases with increasing concentration of 
hyaluronate thiol in the brain hydrogel. Data shown are mean and s.e.m. N=2, n=3. b) Distance 
from the cell center for astrocytes encapsulated in hyaluronate thiol modified brain hydrogels for 
48 hours. Process length decreases with increasing concentration of HA. Data shown are mean 
and s.e.m. N=2, n=3. c) Representative bright field images of astrocytes encapsulated in 
hyaluronate thiol modified brain hydrogels for a period of 48 hours. 
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Figure 4.15: Hyaluronate thiol (HA) in the brain hydrogel masks effect of cytokine induced 
activation. a) Representative images of primary astrocytes in HA modified brain hydrogels with 
standard culture medium (control), defined quiescent medium, or dosed with cytokine medium. 
Cells were stained for gfap (green), membrane (red) and dapi (blue). b) Distance from the cell 
center for astrocytes encapsulated in collagen and HA modified brain hydrogels. Morphology did 
not change based on culture medium. Data shown mean and s.e.m. N=2, n=3. c) Normalized GFAP 
expression for astrocytes in HA modified brain hydrogel after 48 hours of encapsulation with 
standard culture medium or defined quiescent medium. Gfap increased significantly in HA 
concentrations beyond 0.5mM. Data shown are mean + s.e.m. N=2, n=3.  d) Distance from cell 
center for cytokine dosed conditions including the best HA dosed conditions. There was no change 
in cell morphology for collagen or HA containing brain hydrogel after cytokine dosing. Data shown 
is mean + s.e.m. N=1, n=3. e) Normalized gfap fluorescence for cytokine dosed conditions. There 
was no significant change in gfap after cytokine dosing. Data are mean + s.e.m. N=2, n=3.  f) 
Representative cell morphology for astrocytes cultured in brain hydrogel modified with HA. Cell 
morphology becomes rounded with the presence of HA. 
 
We found that astrocyte activation was inhibited in the presence of HA in the brain hydrogel and 
cells exhibited predominantly a rounded morphology. Together these results show that astrocytes 
become reactive in a HA dose dependent manner and at high concentrations of HA cells do not 
undergo cytokine activation in vitro. 
4.3 Materials and methods 
 
4.3.1 Cell Culture 
Normal human astrocytes of cortical origin were purchased from ScienCell Research Laboratories 
(San Diego, CA USA) and maintained in Astrocyte medium (ScienCell, San Diego, CA USA). 
Primary cells were used at passage 1 to 5. MDA-MB-231-BrM2a and MDA-MB-231 cell lines (from 
where) were cultured on 10% serum DMEM while neuronal cells N2A and SK-N-AS were culture 
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on 10% serum DMEM supplemented with 0.1mM NEAA, 1% L-glutamine and 1mM sodium 
pyruvate. 
 
4.3.2 Identification of integrin-binding and MMP-degradable proteins in brain 
Using a top-down approach, we screened the human cerebral cortex for ECM tissue features that 
could be incorporated into a synthetic poly(ethylene)glycol (PEG)-based hydrogel to capture 
biochemical properties of the brain. The cerebral cortex accounts for 77% of the brain volume155, 
and we assessed the brain cortex ECM composition via histology-based bioinformatics and 
proteomics. Histology data from the Human Protein Atlas156 was used to identify cortex enriched 
proteins, their expression, and local distribution. Human brain samples analyzed by LC-MS 
identified relative protein abundance. From the list of ECM proteins, those with integrin-binding 
capabilities and susceptibility to matrix metalloproteinase (MMP) cleavage were chosen to allow 
for cell adhesion and hydrogel degradation. Bioactive motifs of the selected proteins previously 
identified in literature were synthesized and incorporated in the hydrogel as 9 cell-adhesive ligand 
peptides and 5 MMP-degradable sequences representative of the brain ECM.  
 
4.3.3 PEG-Maleimide hydrogel bulk modulus optimization 
To modulate the physical properties of the brain hydrogel, we characterized porcine and murine 
brain tissue and tuned the hydrogel to the same modulus. To assess the hydrogel modulus, PEG-
Maleimide hydrogels were formed and swollen in PBS buffer overnight. The effective Young’s 
modulus was measured using an indentation custom built instrument used as previously 
described.92 Briefly, a flat cylindrical punch was brought into contact with the hydrogel at a fixed 
displacement rate of 15 um/s, for a maximum load of 1.5mN. The linear curve of the low regime 
section was analyzed using a Hertzian model accounting for dimensional confinement between the 
contact radius (a) and the sample height (h) (0.5 < a/h <2) as described previously117. 
 
4.3.4 Solid-phase peptide synthesis 
All the peptides were synthesized on a CEM’s Liberty Blue automated solid phase peptide 
synthesizer (CEM, Mathews, NC) using Fmoc protected amino acids (Iris Biotech GMBH, 
Germany). The peptide was cleaved from the resin by sparging-nitrogen gas through a solution of 
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trifluoroacetic acid (TFA), triisopropylsilane (TIPS), 2,2’(Ethylenedioxy)diethanethiol (DODT) and 
water at a ratio of 92.5:2.5:2.5:2.5 % by volume, respectively (Sigma-Aldrich, St. Louis, MO) for 2-
3 hours at room temperature in a reactor vessel (ChemGlass, Vineland, NJ). After reaction, the 
solution was filtered, and the peptide was precipitated using ethyl ether at -80C (Thermo). The 
molecular weight of the peptide was validated using a MicroFlex MALDI-TOF (Bruker, Billerica, 
MA) using alpha-cyano-4-hydroxycinnamic acid as the matrix (Sigma-Aldrich). Peptides were 
analyzed and purified to >95% on a VYDAC reversed-phase C18 column attached to a Waters 
2487 dual (lambda) adsorbable detector and 1525 binary HPLC pump (Waters, Milford, MA). 
The following sequences were synthesized: GRGDSPCG, GCALMKYHILNTLQCSE, 
GCDPGIVRRADRAAVP, GCDPGIKVAV, GCDPGYISGR, GCGDGEA, GCGFYFDLR, CSVTCG, 
CGGAEIDGIEL, GCRDIPVSLRSGDRCG, GCRDRPFSMIMGDRCG, GCRDVPLSLTMGDRCG, 
GCRDVPLSLYSGDRCG, GCRDIPESLRAGDRCG 
 
4.3.5 Collagen Hydrogel Preparation 
Type I collagen extracted from rat tails was used to construct an in vitro 3D hydrogel. Collagen gels 
were formed by neutralizing collagen I with NaOH, according to the manufacturer’s instructions. 
10X DMEM (Sigma) and cells in cold, serum-free media were then added to the neutralized 
collagen and allowed to polymerize at 37C for 30 minutes. 
 
4.3.6 3D Brain-customized Hydrogel Preparation 
A 20K 4-arm PEG-maleimide (Jenkem Technology, Plano, TX) was reacted with 2mM of the brain-
ECM integrin-binding peptide cocktail for 10 minutes in serum free medium at pH 7.4. This solution 
was crosslinked at a 1:1 molar ratio of thiol to Maleimide in TEA at pH 7.4, and the crosslinker 
solution was composed of 75 molar % of 1K linear PEG-dithiol (Jenkem) and 25 molar % of the 
MMP-degradable peptide cocktail. Gels were allowed to polymerize in 10uL volumes with 5,000 
cells/ul and cell culture media was added after 10 minutes to swell the hydrogel. Other hydrogel 
combinations to optimize the system for brain astrocytes were made with 3mM, 4mM integrin-
binding peptides and crosslinked at a 1:1 molar ratio of thiol to Maleimide with 45mM, 22mM, 12mM 
and 6mM MMP-degradable peptide cocktail. 
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4.3.7 Immobilization of integrin-binding peptides on glass surfaces 
Peptides were immobilized into glass coverslips as previously described. 194 Briefly, 15mm 
coverslips were oxygen plasma treated (Harrick Plasma, Ithaca, NY, USA), and silanized through 
vapor phase deposition of (3-aminopropyl)triethoxysilane (Sigma-Aldrich, St. Louis, MO, USA) at 
900C for a minimum of 18 hours. The coverslips were sequentially rinsed in toluene (Fischer 
Scientific), 95% ethanol (Pharmco-AAPER, Brookfield, CT, USA), and water, and dried at 90 C for 
one hour. These were subsequently functionalized with 10 g/L N,N,-disuccinimidyl carbonate 
(Sigma-Aldrich) and 5% v/v diisopropylethylamine (Sigma-Aldrich) in acetone (Fischer Scientific) 
for two hours. Finally, coverslips were rinse three times in acetone and air-dried. Peptides were 
then covalently bound to the glass coverslips via the reactive amines using the same molar 
concentrations as in the integrin-binding cocktail of fig. 5.2b. 
 
4.3.8 Brain hydrogel platform 
Glass surfaces were UV/ozone treated for 10 minutes and functionalized with 2 % volume solution 
of 3-mercaptopropyl-trimethoxysilane (MPT, Thermo) in 95% ethanol (adjusted to pH 5.0 with 
glacial acetic acid) for 1 hour. The wells were rinsed 3 times with 100% ethanol and let to air dry 
for 10 minutes before functionalized brain customized hydrogels on the respective surfaces. 
 
4.3.9 Cell adhesion assay 
Cells were seeded at 10,000 cells per cm2 to functionalized glass coverslip surfaces in serum free 
DMEM and imaged by a controlled Zeiss Axio Observer Z1 microscope (Carl Zeiss, Oberkochen, 
Germany) using an AxioCam MRm camera and an EC Plan-Neofluar 20X 04 NA air objective. 
Images were taken every five-minutes for an incubation period of 1-, 2- and 12-hours. Cell area 
was assessed over time and traced in ImageJ (NIH, Bethesda, MD). 
 
4.3.10 Competitive binding assay 
Cells were seeded at 10,000 cells per cm2 in their normal cell culture media after 30 minutes of 
pretreatment with individual peptides or the complete brain-ECM cocktail. Cells were imaged 
beginning at 5 minutes after seeding in an environment-controlled Zeiss Axio Observer Z1 
microscope (Carl Zeiss, Oberkochen, Germany) using an AxioCam MRm camera and an EC Plan-
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Neofluar 20X 04 NA air objective. Images were taken using Zeiss Axio Observer Z1 (Carl Zeiss) at 
five-minute intervals for 2 hours or every fifteen-minutes for 12 hours and cell areas were traced in 
ImageJ (NIH, Bethesda, MD). 
 
4.3.11 Validation of peptide incorporation 
The Measure-iT thiol kit was used to quantify unreacted thiols (Thermo) as previously described. 
(use lenny’s paper citation). Buffers were prepared according to manufacturing instructions. Single-
cysteine peptides were incorporated at the same concentration they are found in the brain hydrogel 
in a 100 uL volume of PEG-maleimide for 10 minutes before reacting with 100uL of the kit working 
solution. Bi-cysteine peptides were reacted with the PEG-maleimide in 10ul aliquots for 10 minutes 
before reacting with 100uL of the kit working solution. To assess reduction, the hydrogel was 
incubated in sodium borohydrige (NaBH4, Sigma-Aldrich) in water at a molat ratio of 4:1 NaBH4 to 
thiol for 4 hours before adding the thiol kit working solution. Hydrogel supernatant and solutions 
were acquired and read at an excitation of 494nm and emission of 517nm within 5 minutes of the 
reaction taking place. To assess peptides that did not react, hydrogel supernatants were acquired 
and diluted to a theoretical concentration of 100pmole/ul. This solution was analyzed using 
MicroFlex MALDI-TOF (Buker) with alpha-cyano-4-hydroxy cinnamic acid (Sigma-Aldrich) as the 
matrix.  
 
4.3.12 HA spreading and variation of integrin-binding peptide concentration 
Human astrocytes were encapsulated into the brain customized hydrogel with integrin-binding 
peptide concentrations varying from 0 to 4 mM. After 24 hours, hydrogels were fixed in 4% 
formaldehyde for 10 minutes and stained with GFAP, CellMask Membrane stain and Dapi. Cell 
were imaged on a Zeiss Spinning Disc Observer Z1 microscope (Carl Zeiss) using an HRm 
AxioCam and an (specifications of objectives here 10X. Images were taken using Zen (Carl Zeiss) 
and cell areas were traced in ImageJ (NIH). 
 
4.3.13 Immunohistochemistry 
Hydrogels were fixed in 4% paraformaldehyde solution for 10 minutes at room temperature then 
washed 3X with ice-cold PBS. To assess morphology cells were blocked with 5% Bovine Serum 
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albumin (BSA) for 30 minutes followed by incubation with the CellMask membrane stain (Thermo-
Fischer Scientifc) for 1 hour in the dark at room temperature. Gels were then washed 3X with PBS. 
To assess GFAP expression, gels were permeabilized with 0.25% Triton X-100 solutions for 10 
minutes. Hydrogels were then washed with PBS 3X for 5 minutes and blocked with 5% BSA at 
room temperature for 30 minutes. Finally, gels were incubated with primary antibody solutions 
overnight at 4C, washed and incubated in secondary antibody solutions for 1 hour at room 
temperature. Cells were imaged on a Zeiss Spinning Disc Observer Z1 microscope (Carl Zeiss) 
using an HRm AxioCam and an (insert detail of objectives) 20x, 25xW, and 40xW objectives. 
Images were taken using Zen (Carl Zeiss) and cell morphology was analyzed in ImageJ (NIH) and 
Imaris (BitPlane). 
 
4.3.14 Imaging and image processing 
Three dimensional reconstructions of the astrocyte cell morphology were generated from confocal 
Z-stacks using Imaris (Bitplane) to obtain quantitative morphological data. Filament tracing was 
done from the CellMask membrane stain channel to obtain information about the morphology of 
the whole cell. Sholl analysis was performed to access the amount of astrocyte process and length 
(citation of Sholl). Total additive process length, degree of branching (# process ends / # primary 
processes, and cell diameter were calculated for each cell analyzed.  
 
4.3.15 FAK phosphorylation by integrin-binding peptides 
Cells were seeded in the brain customized hydrogel and collagen gel at 10,000 cells in 10uL volume 
gel. Cells were culture for 5, 15, 30, 60 minutes and 24 hours then washed once with ice cold PBS 
and lysed in RIPA buffer (Triton X-100, NaCl, Tris-HCl base, Deoxycholic acid, SDS and water) 
supplemented with protease (EDTA-free protease inhibitor cocktail tablets, 1 tablet in 10 mL, 
Roche, Indianapolis, IN) and phosphatase (1x phosphatase inhibitors cocktail-II, Boston 
Bioproducts, Boston, MA) inhibitors, 1mM phenylmethylsulfonyl fluoride (Thermo Fisher Scientic), 
5 ug/ml pepstatin A (Thermo Fisher Scientic), 10 ug/ml of leupeptin (Thermo Fischer Scientific), 1 
mM sodium pyrophosphate (Thermo Fisher Scientific), 25 mM beta-glycerophosphate (Santa Cruz, 
Dallas, TX). Protein concentrations were determined with a BCA assay (Sigma-Aldrich). PEG-
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maleimide gels were manually dissociated with a pipet tip for 30 seconds after addition of lysis 
buffer and lysate concentrations were adjusted to 1000 ug/ml. Each sample was prepared with 8X 
loading buffer and 40 ug of total protein was loaded into a graduated 8% acrylamide gel (Biorad). 
After western, the protein was transferred onto a xx membrane (Thermo Scientific). Blots were 
blocked in 5% BSA and then incubated overnight in primary antibody. Primary antibodies included: 
pFAK (1:1000, Abcam), FAK (1:500, Abcam), beta-actin (1:1000). Secondary antibodies were 
LiCor anti-rabbit and anti-mouse. Films were developed, imaged and quantified relative to beta-
actin loading for each sample. 
 
4.3.16 Statistical Analysis 
Statistical analysis was performed with GraphPad Prism (7.0d) (GraphPad Software, Inc., La Jolla, 
CA). Statistical significance was evaluated using a one-way analysis of variance (ANOVA) followed 
by a Tukey’s post-test for pairwise comparisons. For the analysis, p-values <0.05 are considered 
significant, where p < 0.05 is denoted with *, < 0.01 with **, < 0.001 with ***, and < 0.0001 with ****. 
 
4.4 Conclusions 
 
Reactive astrocytes play a key role in brain injury and inflammation, yet molecular mechanisms 
that induce activation remain poorly understood.45 Bioengineers have aimed to design brain in vitro 
models that can recapitulate the brain ECM since components like protein composition, cytokines 
and biomechanics have been shown to affect astrocyte activation. 50, 55, 75, 77, 161 However, to date 
there is no in vitro model that can control astrocyte activation.  Our work shows the first hydrogel 
to control astrocyte reactivity as demonstrated by the maintained physiological cell morphology and 
quiescence. Activation can be controlled via tuning of the hydrogel integrin-binding and MMP-
degradable profile or induced via cytokine molecules in vitro in contrast to other protein-based 
models like collagen and hyaluronic acid where they remain reactive. We foresee the use of this 
biomaterial to understand extracellular mechanisms of astrocyte induction, as well as to allow to 
probe interactions of reactive astrocyte with other central nervous system cells.  
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CHAPTER 5 
 
5: CAN BIOMATERIALS PREDICT IN VIVO INVASION OUTCOMES IN 2D OR 3D MODELS? 
CORRELATION BETWEEN 2D, 3D AND IN VIVO MOTILITY 
 
5.1 Introduction 
 
Outside of understanding mechanistic interactions of cells with the ECM, engineers have also 
aimed to identify and understand drivers from the microenvironment that regulate cell migration. 
Cell migration is one of the hallmarks of cancer that mediates cell invasion and metastasis.195 
Metastasis, the spread of cancer cells from the primary tumor to secondary sites, accounts for 90% 
of cancer related deaths since increased invasion of tumor cells is correlated with poor patient 
prognosis.196, 197 In cancers characterized by dramatic tissue invasion, like glioblastoma (GBM) the 
deadliest form of brain cancer198, identifying therapeutic targets that address cancer invasion would 
have dramatic effects in patient survival199. To this end, intrinsic efforts have focused on predicting 
cell invasion in vivo in order to discover druggable targets that could halt malignant cells from 
invading and metastasizing by controlling for cell-extracellular matrix (ECM) interactions200, 
substrate rigidity201 and physical influences of the ECM202, in 2D and 3D tissue model systems in 
which to study cell motility in vitro.165, 203-207  
Mechanistic invasion and motility assays aim to determine the response to particular stimuli or 
inhibitors and determine if that difference is statistically significant from some internal control. 
Currently, motility studies performed in vivo are limited by imaging tools that make it difficult to track 
single cell migration. Although some have adopted the use of intravital imaging and fluorescently 
label of cells208, 209, the use of in vitro systems is still highly preferred due to their tunable control, 
ease of implementation, and reduced cost.  
Across the literature, cellular motility is examined not only via different metrics and assays, but 
also with varying experimental setups as reviewed most recently by Decaestecker et al.210 and 
Ridley et al.211 This diverse set of assays, metrics, and analyses of motility in different biomaterial-
based systems makes it difficult to correlate results across platforms, stimuli, and publish reports. 
Most of the metrics used to analyze cellular invasion and motility have been developed in 2D and 
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translated to 3D studies210. Yet, to date, there has been no systematic study to explicitly relate and 
compare cell motility measurements between these geometries and systems.  
To address this, we performed a study to understand if there is correlation between 2D, 3D 
and in vivo cell motility metrics focused on glioblastoma cell lines as a case study. In this analysis, 
we found that the diversity of invasion and motility assay measurements, approaches, reporting 
tools, and responses all vary across published lab reports. For in house studies of glioblastoma cell 
lines, we found 2D motility correlation with 3D motility, however, there was no obvious relationship 
between assay duration, cell density and cell migration outcome from literature data. Interestingly, 
in vivo invasion in glioma negatively correlated with 3D chemotactic index.  
From this data we identify that standardized metrics are needed to allow for direct comparison 
between 2D, 3D, and in vivo models. Effect size can allow us to better compare the effects of 
different stimuli on motility metrics and perhaps draw conclusions independent of dimension and 
environment94. Given the rise of more physiological in vitro models that result in more complicated 
responses, this could be a first step to implement comparison of metrics across the field. 
Standardizing motility metric outcomes could help bridge the gap between 2D, 3D in vitro systems 
and their translation to in vivo physiology. We foresee this study would highlight the need to move 
towards standardization of motility metrics that will allow for direct comparison across biomaterial 
experiments within different research groups.  
5.2 Results 
In order to understand how cellular motility metrics may interrelate, we analyzed the 
correlations between outcomes for multiple glioma cell lines. These are summarized in Table B.1, 
which include percent invading cells, percent migrating cells, chemotactic index, speed, total, and 
net displacement. Excluding percent invasion, which is a chamber-based endpoint assay, all other 
metrics mentioned are obtained from live, continuous microscopy. The correlations with percent 
invasion are particularly interesting as the invasion of cells in vitro is often assumed to be predictive 
of invasiveness in vivo. Overall, these correlations indicate that it may be possible to infer some 
 81 
cellular motility behaviors from a single assay/measurement. This may be important when making 
decisions regarding experimental design and analysis of data.  
 
5.2.1 No obvious relationship between measurement time or cell density and cell 
migration quantification in literature 
 
Across the literature, cellular motility is examined not only via different metrics and assays, but 
also with varying experimental setup. Thus, we aimed to examine the variability in assay set up 
and its potential effects on outcomes through a careful literature search focused on several of the 
most widely examined cell lines in motility assays. We compiled data from a list of publications 
measuring motility in 2D and 3D platforms (fig. 5.1, and Tables B.1-B.7) among widely used cell 
lines to extrapolate our findings to that beyond our own labs. We focused on studies of cell motility 
in 3D that reported % invasion (fig. 5.1a, b) and % migrating (fig. 5.1c, d), and studies that reported 
% wound closure in 2D (fig. 5.1e). We saw no significant correlation for the 3D motility outcomes 
with the two consistent experimental conditions reported (assay duration and cell density).  In the 
case of wound healing assays, however, there was an unsurprising correlation between assay 
duration and percent of wound closure (r=0.87, p<0.01) (fig. 5.1c).   
We found that biomaterial properties like pore size and composition were similar across 
studies, although concentrations of basement membrane extract (i.e. MatrigelR) used were often 
not reported (Tables B.2-3). Cell invasion outcomes from tissue culture insert assays were reported 
differently across publications and included total cell number, self-defined “invasion value”, fold 
change, percent invasion, or images without quantitative metrics (Table B.4). Assay readouts 
varied significantly between crystal violet, H&E staining, trypsinization prior to counting, or simply 
imaging counting, all at different time points (Tables B.4-5). In the case of invasion, attractants used 
in invasion assays were unique to each study (Table B.7). Thus, we could not determine a 
correlation between the assay experimental setup and the cell migration-related outcomes. We 
were also unable to quantitatively evaluate all experimental design components (such as matrix 
concentration) within this small sample size of publications.   
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5.2.2 In vivo invasion in glioma negatively correlates with 3D chemotactic index 
 
The ultimate goal of in vitro assays is to predict the behavior of cells in a host organism. For 
glioblastoma (GBM), the deadliest form of brain cancer, invasion is a hallmark of its behavior and 
is responsible for recurrence after treatment. Unlike other cancers, in GBM, invasive cells remain 
 
 
Figure 5.1: Motility metrics compared in 2D and 3D environments for glioma cells. Averaged 
motility outcomes determined from live imaging and tracking are shown for individual experimental 
runs and correlated by glioma cell line. a) Percent of cells migrating greater than two cell lengths. 
b) Speed of cells c) Chemotactic index d) Net displacement and e) Total displacement as 
determined from individual tracks.  Pearson r correlation with p values listed on each graph. Data 
gathered in collaboration with Dr. Jennifer Munson, Naciye Atay and Hyuna Kim. 
 
within the primary organ, which allows for straightforward quantification of invasion at an 
endpoint using immunohistochemistry. We hypothesized that this invasion would positively 
correlate with outcomes of cellular motility in vitro. Using data from five models of GBM (our four 
glioma stem cell lines and the rat glioma line RT2) implanted into mouse cortex, we quantified cells 
that had invaded beyond the tumor border and correlated these numbers to our assays in vitro (fig. 
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5.2a). Results from at least five mice were averaged (data from 212) and plotted against averaged 
values from at least four in vitro experiments. For cells in 3D, we did not see a statistically significant 
correlation between any motility metric in vitro and our in vivo results. However, we did see large 
negative effects when correlating 3D chemotactic index and net displacement with in vivo invasion. 
Interestingly, the opposite was true with 2D chemotactic index (fig. 5.3). In 2D, we saw large 
negative relationships of speed and displacement with the invasion metric in vivo (fig. 5.4). Due to 
our low number of cell lines to compare in vitro and in vivo, it is difficult to conclude anything 
concrete between invasion in vitro and in vivo, though we see interesting negative trends that are 
contrary to our current assumptions about translating in vitro invasion outcomes to in vivo results.  
5.2.3 Effect size as a statistical tool to measure motility changes across dimensions 
 
Mechanistic invasion and motility assays aim to determine the response to particular stimuli or 
inhibitor (and determine if that difference is statistically significant from some internal control). It is 
often assumed, though not directly tested, that if a stimulus increases 2D motility it will do the same 
in 3D. To directly test this assumption, we revisited our data and calculated effect sizes (Cohen’s 
d) in 2D and 3D to determine if 1) dimensionality altered the effect of stimuli and 2) we can use 
effect size to better analyze and compare cell motility in response to stimuli across dimensions. 
Effect size is a statistical concept that defines the strength of a relationship between two variables 
or conditions on the same numeric scale94. Thus, one can easily compare the effect of one 
treatment to another regardless of laboratory, experimental setup, or outcome measure to 
determine how universal findings are. 
5.2.3.1 Glioma motility in response to CXCL12.  
 
We examined motility of multiple patient-derived glioma stem cell lines in the presence of 
100nM of CXCL12 in 2D and 3D (fig. 5.6b) by reanalyzing our previously published data 212. 
CXCL12 is a pro-migratory chemokine that has been implicated in glioma motility and invasion213.  
We quantified multiple outcomes with live cell tracking and found that the effect size varied based 
on the dimensionality. For some cell lines (G62) the effect size was nearly equal for percent motile 
cells when cells were stimulated in 2D or 3D and indicated that there was low effect (<0.2) of the 
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stimulation. For G2 and G528, the effect size varied but remained large (>0.8) for both cell lines in 
both dimensions. Interestingly though, for G34, the effect in 2D was medium, but large in 3D, 
indicating that dimensionality may affect this cell line-specific response to CXCL12. 
  
 
Figure 5.2: Correlation of experimental set up and outcomes from literature for tumor cells. 
Compiled data outcomes from existing experiments in the literature that examine tumor cell motility 
as compared to assay parameters. a) Percent invasion in a tissue culture insert-Matrigel assay vs. 
duration of the experiment and b) initial cell seeding density. c) Percent of cells migrating through 
tissue culture inserts (without Matrigel) vs. the duration of the experiment and d) initial cell seeding 
density. e) Percent of wound closure in traditional 2D scratch assay vs the duration of the 
experiment. Pearson r correlation with p values listed on each graph.  
 
5.2.3.2 Breast cancer motility in response to EGF and integrin inhibitors.  
 
To broaden the utility of effect size beyond glioma to breast cancer cell behavior, figure 5.6c 
shows SkBr3 cells that were seeded on a bone-ECM functionalized surface and stimulated with 
EGF or inhibitors for integrin subunits 𝛽1 and 𝛼2214. Comparison of effect sizes, as we saw for 
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glioma, the effect size for 2D and 3D for all types of stimulation had roughly the same effect. EGF 
stimulation had a small effect, 𝛽1 integrin inhibition had a medium effect, and 𝛼2 integrin inhibition 
had a large effect regardless of geometry. Our analysis highlights the utility of using the statistical 
tool effect size to determine its importance given its ability to span dimensionality and cell sources. 
 
 
 
Figure 5.3: Motility metrics for glioma cells in 3D in vitro compared to in vivo invasion. a) 
From left to right the images represent the in vitro invasion assay, live imaging micrograph from 
cells in a 3D hyaluronan matrix in vitro and glioma cells implanted in mouse brain with border 
(dotted line) and invasion beyond the border (arrowhead). b) In vitro percent invasion c) Percent 
cells migrating, d) Speed, e) Chemotactic Index, f) Total Displacement, and g) Net displacement 
graphed by glioma cell line vs. the number of invaded cells beyond the tumor border in vivo per 
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mm2 of tissue. Pearson r correlation with p values listed on each graph. Data gathered in 
collaboration with Dr. Jennifer Munson and Naciye Atay. 
 
 
 
 
Figure 5.4: Motility metrics for glioma cells in 2D in vitro compared to in vivo invasion. a) 
Percent of cells migrating, b) chemotactic index, c) speed, d) total displacement, and e) net 
displacement graphed by glioma cell line vs. the number of invaded cells beyond the tumor border 
in vivo per mm2 of tissue. Pearson r correlation with p values listed on each graph. Data gathered 
in collaboration with Dr. Jennifer Munson and Naciye Atay.  
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Figure 5.5: Invasion of MDA-MB-231 cell line correlates with metastasis. In vivo effect sizes 
compared to tissue culture polystyrene (TCPS) for cells cultured in soft (1kPa) or stiff (41kPa) 
hydrogels prior to implantation. Data gathered in collaboration with Dr. Alyssa Schwartz. 
 
 
 
Figure 5.6: Motility effect sizes for tumor cells in 2D or 3D. a) Cohen’s d (effect size) 
delineations for small, medium and large effect sizes. b) Cohen’s d calculated for percent migrating 
cells when stimulated with CXCL12 vs. vehicle control of patient-derived glioma stem cell lines in 
2D and 3D. c) Cohen’s d for SkBr3 breast cancer cells when stimulated with epidermal growth 
factor or treated with inhibitors of Integrinβ1 or Integrinα2 in 2D (for speed of cell migration) or 3D 
(for invasion into collagen gels). d) Cohen’s d calculated for distance migrated and speed of 
astrocytes cultured in 3D and dosed with cytokines in contrast to astrocytes in a quiescent state. 
Data gathered in collaboration with Dr. Jennifer Munson, Naciye Atay and Hyuna Kim. 
 
5.3 Materials and Methods 
 
5.3.1 Cell culture 
 
All cell culture supplies were purchased from Thermo Fisher Scientific (Waltham, MA) unless 
otherwise noted. The SkBr3 cell line was purchased from ATCC (Manassas, VA), and cells were 
grown in DMEM, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(pen/strep). The G2, G34, G62, and G528 glioblastoma stem cells (GSCs) were originally gifted to 
Dr. Benjamin Purow by Dr. Jakub Godlewski. These cells are primary derived and have been 
reported and characterized previously by Lee et al215. The cells were cultured in Neurobasal media 
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with human recombinant EGF and bFGF (50 ng/mL), N2 and B27 without vitamin A supplements, 
pen/strep in low-adhesion tissue culture flasks (Grenier), and Glutamax.  
 
5.3.2 Preparation of ECMs for SkBr3 migration experiments 
Glass coverslips (15 mm and 18 mm diameter, Fisher Scientific, Agawam, MA, USA) were 
functionalized with 10 g/L N,N-disuccinimidyl carbonate (Sigma-Aldrich) and 5% v/v 
diisopropylethylamine (Sigma-Aldrich), and ECM protein cocktails were then covalently bound to 
the glass coverslips through reactive amines: 5 μg/cm2 of 99% collagen I and 1% osteopontin214. 
Coverslips were incubated with proteins at room temperature for three hours, rinsed three times 
with PBS, and then incubated with 10 μg/cm2 MA(PEG)24 (Thermo Scientific, Rockford, IL, USA) 
for two hours. Coverslips were rinsed three times with PBS, epoxied to the plate (Devcon 5 minute 
epoxy) and UV-sterilized prior to cell seeding. For invasion studies from coverslips, cells were 
seeded on coverslips and then overlaid with a collagen gel as previous described214. 
 
5.3.3 3D Invasion Assays 
Invasion assay data for glioma cells was acquired from our previous publications where it was 
conducted as described212, 216. Briefly, cells were seeded in a 1.2 mg/ml thiolated hyaluronan 
(ESI)/0.8 mg/ml rat tail collagen I (Corning) matrix at a concentration of 1E6 cells/ml. 100µl of this 
gel was applied to a 8-µm pore tissue culture insert (Millipore). Serum free media was applied to 
the top and bottom of the well and the system was incubated for 18h after which gels were removed 
and membranes fixed and stained with DAPI. Membranes were imaged at five non-overlapping 
locations and %invasion was calculated as an extrapolated cell count divided by the seeded cell 
count x 100.  
 
5.3.4 Live Imaging and Analysis  
 
Glioma Motility: The motility metrics were determined via live imaging and single-cell tracking of 
glioma cells in either the hydrogel system (above) or on tissue culture plastic. The EVOS FL Auto 
(ThermoFisher) microscope and the EVOS Onstage Incubator (ThermoFisher) were used for 
imaging in 15 minute intervals for 14-18 hours. The incubator was set to the following conditions: 
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5% CO2, 20% air, and 80% humidity. Images were taken in 20 minute intervals for 18-24 hours. 
The manual tracking feature on Celleste 4.1 was used to record the location of the visually identified 
center of the cell of interest in each image of the sequence. An average of 15 cells were tracked 
per image. The recorded X and Y coordinates were analyzed in Matlab 2018b with the following 
outcomes: average speed, net and total displacements, and chemotactic index of each cell. Two 
to nine image sequences were analyzed per cell type (G528, G62, G34, and G2) and experimental 
condition (2D, 3D) combination per experiment. The averaged values per experiment are reported 
here.  
SkBr3 Motility: Cells were seeded at 4000 cells/cm2 on ECM protein treated surfaces. They were 
then treated with a live-cell fluorescent dye (CMFDA, Life Technologies), and fresh medium or 
medium supplemented with EGF and/or integrin antibodies were provided 4 hours prior to 
microscopy. Brightfield and fluorescent images were taken at 15-minute intervals for 12 hours using 
an EC Plan-Neofluar 10x 0.3 NA air objective (Carl Zeiss). Cells were tracked using Imaris 
(Bitplane, St. Paul, MN, USA) to generate individual cell paths, and individual cell speeds were 
determined by calculating a speed at every 15-minute time interval, then averaging these over the 
entire 12 hours. 
5.3.5 Tumor Inoculation 
 
Eight to ten week old male non-obese diabetic severe combined immunodeficiency (NOD SCID) 
mice were stereotactically injected with 15,000 G2 (n = 3), G34 (n = 5), G62 (n = 4), or 400,000 
G528 (n = 4). The cells were injected 2.7 mm within the tissue at a 2 mm distance lateral and 
posterior to bregma, which is the anatomical site at which the coronal and sagittal sutures of the 
skull intersect. The University of Virginia Institutional Animal Care and Use committee approved all 
animal experiments as stated in protocol 4021.  
 
5.3.6 Tissue post-processing 
 
Evans blue dye injections were administered intravenously to the animals ten to eleven days after 
tumor inoculation. Intracardial saline perfusion was performed the following day to euthanize the 
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animals. The brains were harvested, cryoembedded, and sectioned at 12 µm. Immunostaining for 
4’,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, Sigma) and mouse anti-human nuclei 
(clone 235-1, Millipore) was performed on sections at differing depths of the tumor. EVOS FL Auto 
2.0 was used to scan whole sections. After importing raw images into ImageJ, integrated density 
was used to quantify Evans blue intensity in four to five 0.49 mm2 regions of the image. Integrated 
density of each region was normalized to tumor maximum. 
 
5.3.7 Invasion calculations from published data 
 
Percent of invasion, and migration data were extracted with the WebPlotDigitizer v4.1 from the 
published work cited in figure 4.3 and Tables B1-4. Re-plotted data was used to calculate the 
percent of invasion based on the initial number of seeded cells. 
 
5.3.8 Effect size calculations 
 
Effect size measures were performed between two independent groups following Cohen’s d 
calculation.  𝒅 = 𝑴𝟏 −𝑴𝟐/𝒔𝒑𝒐𝒐𝒍𝒆𝒅 
𝒔𝒑𝒐𝒐𝒍𝒆𝒅 = s(𝒔𝟏𝟐 + 𝒔𝟐𝟐)/𝟐 
Using the online calculator from Dr. Lee A. Becker at the University of Colorado, Colorado Springs 
at https://www.uccs.edu/lbecker/  
 
5.4 Discussion 
 
In this analysis, we found that the diversity of invasion and motility assay measurement 
approaches, reporting tools, and responses all vary across labs (fig. 5.1 and Tables B2-7). Though 
motility metrics have been studied in multiple contexts for decades, there is still not a consensus 
nor clarity in terms of the importance of each and the impact of each on outcomes in vivo. In cancer, 
this is particularly striking as there is already a high level of heterogeneity in the disease itself, 
which is amplified as we move into complex in vitro models. One major impediment to the field’s 
progress is the variability from lab to lab in the implementation and analysis of these experiments. 
 91 
First, we identified high variability in the assay setup. As illustrated in Tables B1-5, concentrations 
of Matrigel used for invasion assays differed, and in some publications, were not reported. We 
know that the source and lot of basement membrane extracts (like Matrigel) can influence 
experiments alone, let alone the concentration217. Similarly, assay durations and cell densities 
differed across most publications using breast cancer cell lines. Unsurprisingly, the assay duration 
correlated positively with degree of wound closure (fig. 5.1c). When we looked through how 
different publications quantified their assay outcomes, we noticed variable methods to count 
invasive cells from the bottoms of tissue culture inserts, including selection of immunocytological 
stain and/or fixation vs. cellular detachment and counting. Regardless, publications generally 
reported some final number, though this could be a percent, fold change, or total number of cells 
that prevented us from directly comparing their results as were able to do for our own experiments. 
A standardized metric that best conveys the raw data would allow to compare outcomes in a 
meaningful way across labs.  
We propose effect size as a useful metric to understand how and if stimuli and inhibitors affect 
cell motility across geometries and labs. For example, as seen on figure 5.6b and 5.6c, comparing 
each Cohen's d value illustrates the effect of each ECM substrate or each stimulus for two different 
cell types. Within each cell line, we can see the significant effect of the stimulus on cell response, 
across geometries, and independent of the cell’s genetic background. Additionally, comparing the 
value of the effect size (>0.2, >0.5, or >0.8) allows us to better understand how large an effect is, 
without the need for a p-value (which has been recently put into question95).  
The desire to understand how 2D cell migration relates to that in 3D is not unique to our study. 
Meyer et al. quantified breast cancer cell line motility and showed that the degree of initial cell 
protrusion in 2D was predictive of 3D invasion across many different stimuli218.  In agreement with 
or analysis of glioma cells, Meyer et al. found no other obvious correlations between 2D and 3D 
cell migration measurements. Similarly, when studying the role of focal adhesion proteins in cellular 
motility, Fraley et al. compared speed, persistence, protrusion length/number/time, etc. in 2D and 
3D and found no correlation between any of the metrics in the two environments.219 Next generation 
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biomaterials are being developed that provide possible explanations of the key differences between 
3D and 2D environments that drive the unique motility phenotypes, such as confinement 220, 221 and 
porosity222. 
Ultimately, we are attempting to predict cell invasion in vivo so that we can potentially discover 
druggable targets to halt malignant cells from invading and metastasizing. In our limited dataset we 
show that there is a negative correlation between migration in 3D collagen gels with invasion in 
vivo. Live imaging data may reveal more information, but with at least our endpoint assay, we 
cannot predict in vivo “invasiveness” with in vitro invasion in glioma. It’s possible that our in vitro 
systems, even when 3D, do not hold enough complexity to capture true in vivo behavior.   
Taken together, standardized metrics are needed that allow for direct comparison between 2D, 
3D, and in vivo models. Effect size can allow us to better compare the effects of different stimuli on 
motility metrics and perhaps draw conclusions independent of dimension and environment. Given 
the rise of more physiological in vitro models that result in more complicated responses, this could 
be a first step to implement comparison of metrics across the field. Finally, standardizing motility 
metric outcomes could help bridge the gap between 2D, 3D in vitro systems and their translation 
to in vivo physiology. 
 
5.5 Conclusions 
 
Current challenges in the field of cellular motility and invasion within biomaterial-based 
systems, including diversity of assays, metrics, and analyses, limit the translation of results across 
platforms and impede correlation between 2D, 3D and in vivo. Here, we summarize the most 
commonly used metrics to quantify cell motility, and describe the interrelation between these 
different motility measurements, the important differences in assays and reporting techniques used 
across the literature and describe the potential contribution of in vitro predictions to in vivo 
outcomes. To our surprise, we found cell invasion in 3D is negatively correlated with invasion in a 
glioblastoma model in vivo.  Given the variability we saw in reporting in the literature, and the 
inability to predict 3D or in vivo invasion from simpler 2D assays, we suggest that standardized 
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metrics are needed. We recommend the use of effect size as a possible avenue that allows direct 
comparison between two different groups independent on dimensionality or stimulus. Given the 
rise of more physiological in vitro models that result in more complicated responses, this could be 
a first step to implement comparison of metrics across the field. Finally, standardizing motility metric 
outcomes could help bridge the gap between 2D, 3D in vitro systems and their translation to in vivo 
physiology. 
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CHAPTER 6 
 
6: APPLICABILITY OF DRUG RESPONSE METRICS FOR CANCER STUDIES USING 
BIOMATERIALS 
 
6.1 Introduction 
 
Bioengineers have also built more complex models of the tumor microenvironment (TME) in 
which to study cell-cell interactions, mechanisms of cancer growth and metastasis, and to test new 
therapies by modulating additional parameters in biomaterials. These models allow researchers to 
culture cells in conditions that include features of the in vivo TME implicated in regulating cancer 
progression, such as the extracellular matrix (ECM) stiffness30, 223, 224, integrin binding to the ECM, 
immune and stromal cells225, growth factor and cytokine deposits226, and a 3D geometry more 
representative of the TME than traditional tissue culture polystyrene (TCPS)227. These biomaterials 
could be particularly useful for drug screening applications to make better predictions of efficacy, 
offering better translation to preclinical models and clinical trials. However, it can be challenging to 
compare drug response reports across different platforms in the current literature in part as a result 
of inconsistent reporting and use of drug response metrics88, and vast differences in cell growth 
rates89 across biomaterial designs. 
As an attempt to address the large differences between cell growth rates across cell lines, 
Harner et al, 89 defined the GR50 (the concentration of a drug that reduces cell growth rate by half) 
as a new metric to account for cell line growth rate differences across drug response studies, with 
the aim to standardize current reports. However, additional parameters have also led to 
inconsistencies in results between studies, for example misinterpretation of drug response metrics 
or incorrect application of metrics in certain cases. As one high profile example, Haibe-Kains et 
al.,88 reported inconsistencies between two large pharmacogenomic studies: the Cancer Genome 
Project (CGP) and the Cancer Cell line Encyclopedia (CCLE) where they compared the IC50 (the 
inhibition concentration of a drug where the response is reduced by half) and the area under the 
dose-response curve (AUC) for 15 drugs across 471 cell lines, and found very little correlation 
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between the two studies (Spearman’s rank correlation of 0.28 and 0.35 for IC50 and AUC, 
respectively).  
To assess how these inconsistencies, translate to the implementation of biomaterials as drug 
screening platforms, we conducted a literature search to investigate how bioengineers have 
quantified drug response metrics in biomaterials. We found that often multiple drug response 
metrics are used, however, it was not clear in every study why certain reporting tools were used, 
and whether or not they were applied correctly. For instance, we found cases where an IC50 was 
reported, but the drug was not effective enough to inhibit growth of half the cell population. Thus, 
when analyzing the literature, we then wondered whether the implementation of a global, consistent 
analysis would reduce the disagreement of values reported. Would methods used to analyze drug 
responses in 2D culture also apply for 3D systems? In the case of co-culture systems, should a 
different approach be used to separate the responses from cancer cells and healthy cells in the 
TME? With this in mind, this study compares select cases in the literature, our own data for cell 
responses to drugs in and on biomaterials, metrics reported, and inconsistencies between studies. 
We attempt to clarify the definitions of drug response measurements used in the field and presents 
examples in which these measurements can and cannot be applied. We conclude with a “decision 
tree” that could help guide what metrics to use when working with biomaterial systems. 
6.2 Results and Discussion 
 
6.2.1 Definitions of Drug Response Metrics 
 
Drug response assays evaluate the impact of a drug on a population of cells over a range 
of concentrations. For simplicity, we will define the number of cells at the start of the assay readout, 
or the ‘initial value’ of the cells as y0 (fig. 6.1a). Unfortunately, many studies do not report y0, which 
prevents some metrics from being reported, as we discussed later in this section. The cells are 
then incubated with drug for a defined period of time (typically 24-72 hours), and cell viability is 
measured (yfinal). Cells are also incubated with a small amount of the vehicle in which the drug was 
dissolved (often DMSO or water), serving as a control (yctrl).  
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Figure 6.1: Definitions and examples of drug response metrics. a) Definitions of drug response 
metrics. The IC50 represents the drug concentration where the response is reduced by half. The 
EC50 represents the concentration of a drug that gives half-maximal response. The GI50 represents 
the concentration of a drug that reduces total cell growth by 50%. The GR50 represents the 
concentration of a drug that reduces cell growth rate by 50%. The Emax represents the fraction of 
viable cells at the highest drug concentration (maximal response), and the AUC represents the 
area under the dose–response curve. b) and e) The y-axis shows the cell count (top plots) and 
normalized growth rate (bottom plots). Drugs are considered “cytotoxic” if viability is reduced below 
the initial value (y0), and “cytostatic” if viability is above the initial value, but below the control value 
(yctrl). Left curves (“Less potent”) show a drug which reduces viability by 50% at maximum dose, 
(IC50 is the maximum dose). c) and f) Middle curves (“Moderately potent”) show a drug which 
completely inhibits growth, but is not cytotoxic (Emax = initial viability). d) and g) Right curves 
(“Potent”) show a drug which is 100% cytotoxic (Emax = 0). Note that in these special cases some 
of the other metrics are also equal to each other, which are labeled on the plot. 
A drug is considered cytostatic if it slows or completely prevents growth of cells228. In other words, 
if the measured cell viability is between y0 and yctrl, that drug is said to be cytostatic at that 
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concentration. Cytotoxic means that the drug reduces the cell number below the initial cell count 
(yfinal<y0). Note that when y0 is not measured, a true drug cytotoxicity cannot be reported. 
There are six typical metrics used to report the effect of a drug on a cell culture: IC50, EC50, 
GI50, GR50, Emax, and AUC (fig. 6.1a). Figure 6.1 gives definitions of these metrics, with three 
hypothetical drug response curves with varying degrees of “potency.” A “potent” drug is 100% 
cytotoxic, a “moderately potent” drug achieves 100% growth inhibition but no net cell death, and a 
“less potent” drug reduces cell growth by 50% (fig. 6.1b-g). Drug potency can also be evaluated by 
the curve response class classifier (CRC), as described by Inglese et al.229 The CRC metric helps 
group the efficacy of cell and drug combinations to reveal if a particular combination is fully cytotoxic 
or cytostatic, and can be valuable in cases where a full dose response curve is not obtained. 
Furthermore, these classifications aid in determining promising cases to select for future screening 
studies.  
The IC50 and Emax metrics do not consider the initial population (y0), nor the number of cell 
divisions during the length of the assay, which was a motivating factor for Hafner et al.,89 to define 
the GR50. Only the GI50 and GR50 take y0 into consideration. GI50 is the dose that inhibits the growth 
of cells by 50%, and GR50 represents inhibition of the growth rate, not total growth, of the cell 
culture. The initial cell population, y0, can vary between type of assay, cell type, or length of assay. 
To account for this variation, GI50 and GR50 are represented as data normalized with respect to the 
initial values (fig. 6.1e-g).  
Although the ‘50’ in IC50, EC50, GI50, and GR50 metrics signifies a 50% inhibition, they can 
be used with values other than 50 to indicate different effects, e.g. IC90230, 231. Negative values can 
be used for the cytotoxic regime (yfinal<y0), although these do not come from the formal definitions 
of GI or GR. In this case, GI-10 would be the concentration where the cells are reduced 10% from 
the initial value (yfinal = 0.9×y0), and GI-100 would be the concentration which kills all the cells. In the 
Figure 5.1 example, 0-100 is defined over the range of 20k£y£100k, while -100-0 is defined over 
the range of 0£y£20k. IC-n or EC-n values are not possible since these metrics do not consider initial 
values. 
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The Emax and AUC metrics represent the maximum and cumulative effects of the drug, 
respectively. Emax is the fraction of viable cells at the highest drug concentration tested in the 
experiment, and AUC is the area under the viability curve for a cell population over the tested drug 
concentration range. Although neither of these metrics make any explicit assumption about growth 
kinetics, they still depend on the concentration range, experiment duration, and cell growth rate, 
which means that their reported values cannot be compared with other studies in most cases. For 
example, work by Fallahi-Sichani et al. 232 found AUC to be a robust response metric when the goal 
was to compare a single drug across identical cell lines. However, these need to be exposed to 
identical dose ranges, and preferentially at an intermediate concentration. Emax can be used with 
multiple drugs and concentration ranges but is more informative at high doses232. Particularly in the 
case of Emax, Fallahi-Sichani and colleagues’ work highlighted it as a parameter that yielded high 
variation independent of cell proliferation rate. Yet, this study was unable to conclude what drug 
metric parameter best describes a drug response without considering drug concentration. 
The IC50 is the most commonly reported drug response metric233, and therefore it is important to 
highlight cases in which it is used with an incorrect definition. For instance, the IC50 should not be 
considered a measure of cell death228. As one example, in a case when the control value is more 
than 200% of the initial value (yctrl > 2×y0, as can be seen in the examples given in fig. 6.1b-d), the 
IC50 will result in a “cytostatic” dose, but the cells are still growing, be it at a reduced rate. Second, 
in a case where a reduction in half the population is not reached, (such as In 234-236) the IC50 cannot 
be appropriately calculated, and instead the EC50 is the more appropriate metric to report. In other 
instances, in the literature, the EC50 and GI50 are confused with the IC50 89. However, the GI50 metric 
is a correction of the IC50, since it takes into consideration the initial cell count (y0) 237.  
Through our analysis, we also found examples where authors report a GI50, when it is 
actually an IC50 (they did not measure y0)238. For example, the cell population could grow over the 
course of an experiment, while the measured population values could still be lower than the control. 
Therefore, the initial cell populations must be measured to know whether a drug is killing cells or  
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Figure 6.2: Application of drug response metrics to data from biomaterial drug screening. 
a) Schematic of typical experimental work flow for a drug response assay. Cells are seeded on a 
2D tissue culture plastic surface, on a 2D biomaterial, or within a 3D biomaterial for drug dosing. 
Wells in a second plate are seeded with the same conditions as the drug dosing plate to measure 
GI50 or GR50 values. After 24 hours, drugs are added to the drug dosing plate and the second plate 
for initial values is assayed simultaneously for initial cell counts. The drug dosed plate is incubated 
for a period of time (e.g. 48 hours) and then assayed for the final cell response. The collected data 
is used to calculate drug response metrics. b) Cells grown on tissue culture plastic achieve 
sufficient growth to generate a traditional dose response curve, as well as a GR values curve to 
calculate a GR50. c) An example of patient cells grown on tissue culture plastic that do not grow 
exponentially over the course of the dosing assay. This results in a curve for traditional drug 
response metrics, but a GR curve cannot be calculated. d) This is a case where cells grow over 
the course of the assay, but sufficient growth for calculating a GR50 measurement is not achieved 
because the resulting GR values are less than 0.5, which is the point where the GR50 is calculated. 
e) Cell line MCTS encapsulated in a degradable 3D hydrogel demonstrate enough growth to 
calculate a GR50 and other drug response metrics. f) Curve response classification descriptions 
for the data shown here. The cases presented here do not exactly correspond with the criteria 
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described by Inglese et al. (particularly r2 values), but we categorized them to their nearest 
classification.  Data gathered in collaboration with Dr. Elizabeth Brooks and Dr. Maria Gencoglu. 
 
only slowing their growth. In addition, the IC50 is sometimes discussed in the context of growth 
inhibition239, although it is not capable of measuring this. This highlights the importance of reporting 
the metric that is most appropriate for observed responses and experimental conditions, given the 
explanations stated above. Similarly measuring the initial cell population values (y0) is 
indispensable as it would allow for GI50 and GR50 calculations (if cell growth of the control is 
achieved over the course of the assay). This is of particular importance when multiple cell lines or 
growth conditions are being tested, as these metrics will account for differences in growth rates.  
The GR50 is very similar to GI50, but is defined by reduction of the growth rate, not cell growth 
as the GI50. Growth rate inhibition is calculated from initial and control values, and the fitting for the 
GR50 relies on the assumption that the cells are in exponential growth before application of the 
drug. GR50 is thus reported to be more robust than GI50 against variations in experimental protocols 
and conditions89.   
 
6.2.2 Applying drug response metrics to data obtained from biomaterial drug screening 
assays 
 
Drug screening cells in biomaterials rather than on TCPS is increasingly popular due to the 
fact that more physiologically relevant features can be captured in biomaterials that may impact 
drug response. 2D223, 240, 241 and 3D91, 234, 242 biomaterial platforms have been developed to study 
cell behavior in vitro. Since it is widely accepted that cells grow at different rates in 2D and 3D 
biomaterial platforms227, it is difficult to compare drug responses across these different 
environments without a GI50 or GR50. Experiments to obtain these metrics require only minor 
adjustments to traditional drug screening protocols performed by seeding cells in an additional plate 
to measure initial population values (y0) (fig. 6.2a). In particular, the GR50 has worked very well for 
over 4,000 combinations of breast cancer cell lines and drugs on TCPS93, but work in 3D 
biomaterials systems has limited the use of the GR50.243   
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Our own lab uses both 2D and 3D biomaterials in addition to TCPS for drug screening 
studies86, 90, and we have adapted our experimental procedures to collect data for calculating GR 
metrics in addition to the other metrics depicted in figure 6.1. However, we have found that the 
GR50 cannot always be applied. As it has been previously reported89, 93, it is necessary for the cells 
to achieve exponential growth over the course of the assay to use the GR50. On TCPS, this is not 
an issue, as demonstrated by our data in figure 5.2b with SKOV-3 ovarian cancer cells dosed with 
Paclitaxel. In this case, the GR values span a -1 to 1 range, which results in a good curve fit to 
calculate a GR50.  
However, another important factor to consider in preclinical drug screening assays is the increasing 
use of patient-derived primary cells. This has become a hurdle as many primary cells grow more 
slowly or in some cases, not at all, making it impossible to calculate a GR50 value. In these cases, 
the calculated GR values remain well below 0.5, even at a control dose. Therefore, the formula for 
calculating GR values can be applied, but with growth rates that are too low they do not provide 
meaningful information. As illustrated by our own data of patient-derived cells, ovarian cancer cells 
from ascites dosed with Cisplatin on TCPS (fig. 6.2c), IC50 and EC50 values could be calculated, 
but growth was too low for a GR50 value, and could not be calculated. This serves as an example 
in which additional drug response metric parameters are necessary to understand the effect of drug 
dosing, given that these primary cells proliferated very slowly when grown in a 3D environment. 
For example, work by Longati et al.234 highlights how pluripotent stem cell (PSC) drug 
response differs on 2D vs. in 3D biomaterials. Although IC50 values were not reported in this work, 
we calculated the IC50 and EC50 from their published data and observed higher resistance in their 
PSC cells in 3D compared to 2D (Table C.1). Work from Ivanov et al. 91 performed drug response 
studies with neural stem cells (NSCs) and the UW228-3 glioblastoma cell line in 3D. They found 
that the NSC drug response was biphasic, but not for the human glioblastoma cell line (which 
showed more resistance in 3D). Here, two IC50 values were reported for the same curve in the case 
of primary cells, representing a situation where an IC50 (or GI/GR/EC50) is inappropriate. In these 
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cases, calculations of AUC or Emax would be more appropriate since they are not dependent on 
curve fitting (fig. 6.1b-d). 
As demonstrated by our own experimental data (fig. 6.2d), culture of 3D patient-derived 
spheroids from ascites in a non-degradable 3D hydrogel exhibited a low growth rate over the course 
of the assay. Although a dose-response curve with Mafosfamide was generated from the data (fig. 
6.2d), this does not mean that a valid GR50 value can be obtained. GR value curves need to pass 
through GR = 0.5 or they cannot have a reliable GR50 value, even if certain curve fitting software 
gives a value for these circumstances, as we demonstrate in figure 6.2d. Therefore, it would be 
good practice to only use the online GR calculator89 to calculate GR metrics from raw data since 
this would ensure that true GR metrics are reported. There are cases of drug screening in 3D 
environments243 where the GR metrics could be applied, but since growth is often slower in 3D than 
in 2D, the application of the GR calculations should be done carefully. In contrast to our dosing of 
ovarian cancer cells above, we demonstrate in figure 6.2e an example where we encapsulated 
SKOV-3 cells grown in multicellular tumor spheroids (MCTS) in a 3D hydrogel and dosed with 
Mafosfamide. In this case, the cell growth was high enough to calculate a GR50. From our own 
work, we recommend reporting the GR50 when possible to best account for differences in growth 
rates between different cell sources. We also encourage others to provide all the raw data and drug 
response curves with their publications to allow others to compare published results with their own 
(Table C.2).  
To further characterize the drug response in different material environments, we applied CRC 
metrics described by Inglese et al. 229 to our own data (fig. 6.2f). We found that the r2 values that 
we obtained for the non-linear curve fits to the data were <0.9, which meant it was not possible to 
fit our results into these exactly defined classes according to the criteria set by Inglese et al. 
However, some of these drugs had >80% efficacy, and displayed drug response curve with one 
(‘Partial’), two (‘Complete’), or no asymptotes (‘Incomplete’). We found that the 3D models, OCAS 
in a 3D non-degradable hydrogel and SKOV-3 MCTS in a degradable 3D hydrogel were in the 
same curve response class: ‘Partial’ even though their GR metrics were very different. Additionally, 
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patient cells on TCPS had a ‘Complete’ response (class 1a), but it was not possible to calculate 
biologically meaningful GR metrics. Interestingly, at the range of concentrations that were tested 
the case of SKOV-3 cells on TCPS was classified with an ‘Incomplete’ response (class 2a), but all 
the traditional dose response and GR metrics could be calculated. These additional metrics could 
be helpful for eliminating cases for further study in biomaterials when there are no responses (class 
4), but we do not show any examples of that in here. Characterization with CRC could be used as 
another method for grouping drug curves responses on biomaterials.   
6.2.3 Evaluation of drug responses in biomaterials reported in literature 
 
To compare IC50 values across studies, we mined data from 25 reports that performed drug 
screening with biomaterial systems, and that provided raw data that could be extracted and 
analyzed independently. We calculated the IC50, EC50, Emax, and AUC values and organized them 
by drug in Table C.1. We were not able to calculate GI50 and GR50, because the initial population 
(y0) and control (yctrl) values were not provided in these studies. Table C.1 shows a summary of the 
reported IC50 values from the literature and the drug response metrics calculated by us from their 
reported data. Table C.2 summarizes cases where the drug response curve did not reach 50% 
inhibition, meaning the IC50 was not reached. Table C.3 summarizes cases where the IC50 values 
reported in the literature did not agree with the values we calculated from reported data. We also 
applied the CRC metrics described by Inglese et al. to the data we extracted from the literature 
(Table C.1-3).  
First, we found that for highly potent drug-cell line combinations, such as MCF7 with 
Paclitaxel or MDA-MB-231 with Epirubicin, IC50 values reported were on the same order of 
magnitude (Table C.1). In contrast, when a cell line was not particularly sensitive to the drug, like 
in the case of the MDA-MB-231 cell line to Paclitaxel or Docetaxel, and MCF7 treatment with 
Doxorubicin or Tamoxifen, IC50 values reported from different studies varied much more strongly. 
This variance appears to be more dependent on the potency of the drug than the platform in which 
the cells were treated. When drug sensitivity was moderate or low, wide ranges in IC50 values 
tended to be even more drastic in the 3D models compared to 2D.  
 104 
Another finding in Table C.1 is that highly efficacious drugs had ‘Complete’ response 
curves, while less efficacious drugs had ‘Partial’ or ‘Incomplete’ curves. This is unsurprising, though 
there are some interesting observations: 1) all the drugs that failed to reach IC50 values had 
‘Incomplete’ curves; 2) ‘Incomplete’ or ‘Partial’ response curves were mostly obtained in 2D models, 
while drugs tested in 3D models tended to display a ‘Complete’ response curve. Paclitaxel results 
with MDA-MB-231 are a good example of this. These results also illustrate the inadequacy of r2. In 
Table C.2 we present 5 cases (out of 28 cases in Table C.1) where r2>0.9, while the drug response 
curve had no asymptotes. So, it is unclear if Inglese et al’s criteria applies here.  
One of the major challenges we encountered during our literature search was that a limited 
number of studies published their drug response curves. Some publications did not report IC50 
values for cases where the drug concentration did not kill half of the cell population (Table C.2). 
Unsurprisingly, these drug response curves were all ‘Incomplete’, with one exception. In most 
cases, there were too few points to even calculate an r2 value from the nonlinear fit. In these cases, 
r2 was reported as ‘N.D.’ (Non-determined). 
Table C.3 illustrates cases in which the IC50 we independently calculated did not agree with 
the one reported. This was mostly the case for cell lines that were fairly drug insensitive, as 
evidenced by the ‘Partial’ response curves of these drugs. Despite the ‘Partial’ response curve, 
Emax, IC50, and other metrics could be calculated for these drugs. This finding is significant, because 
it shows a pitfall of assessing drugs based on metrics without accounting for the drug response 
curve. The drugs in Table C.3 would seem efficacious based on their drug response metrics, 
although the drug response curve shows them to be insensitive to drugs. Finally, similarly to Table 
C.1, the drug response curves in Table C.3 have r2 values of >0.9, but only one asymptote 
(‘Partial’). This again shows that r2 alone is not an adequate criterion for CRC classification.  
The drug response metric values reported in Tables C.1-3 vary by study and may depend 
on the type/length of assay, biomaterial used, and/or analysis conducted. The most commonly used 
cell viability assays in our search included MTT assay, AlamarBlue (i.e. resazurin), Live/Dead 
staining, and CellTiter-Glo. These types of assays indirectly measure the cytostatic or cytotoxic 
 105 
effect of a drug, via metabolic activity, counting of dead cells, cell death, or ATP activity. There are 
additional complications with data reported in the literature. Many publications did not present 
enough data points for us to calculate IC50 and could not be included in the comparison. There 
were other published reports where no metrics were reported, which makes it impossible to relate 
them to other published data. Clearly, better standard practices should be adopted. We recommend 
that future publications explicitly define the metrics they use, for two reasons. First, clearly 
explaining the metrics used in an article would help others learn about drug response metrics, and 
it would also prevent them from misinterpreting results. Second, definitions of the metrics are 
dependent on the context. For example, in the articles we summarized, ‘inhibition’ in IC50 refers to 
the inhibition of cell viability. In other works, however, it may refer to the inhibition of cell growth, 
which should be called a GI50 and calculated accordingly.  
Among the 30 studies we examined, 25 presented drug response curves from which IC50 
values could be obtained. We used the WebPlotDigitizer Tool 
(https://automeris.io/WebPlotDigitizer) 244 to extract drug concentrations and cell viabilities from 
these curves. This data was analyzed in GraphPad Prism to calculate an IC50 using nonlinear 
regression with variable slope (4 parameter) and least squares fit method. From the data 
summarized in Tables C.1-3, we made comparisons between the 51 drug response curves and 
IC50 values reported in these studies. We found our results in agreement with 35 of these (69%), 
including 5 cases where neither we nor the original authors could obtain an IC50 value due to drug 
potencies being too low. In 16 cases (31%) IC50 values were significantly different between the 
value reported and our own calculation. These differences are possible because 1) we extracted 
the numerical data from plots in article figures, which may introduce error; 2) different researchers 
may have used different forms of nonlinear regression (e.g. least squares or robust fit methods for 
curve fitting, fixing the hill slope to the standard -1, or using variable slope); 3) other researchers 
may have chosen different methods (appropriate or not) to handle problems such as outliers and 
negative inhibition, including setting constraints on the maximum and minimum values, manually 
determining outliers, using software algorithms for automatic outlier detection, etc.; and 4) there 
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could be cases where the IC50 could not be calculated due to the shape of the fitted curve, yet some 
data analysis software will attempt to calculate an IC50 that results in an unrealistic value. 
 
6.2.4 Assessing drug response in multicellular culture systems 
 
Coculturing cancer cells with stromal cells (e.g., cancer-associated fibroblasts, pericytes, 
or adipocytes) has been shown to drastically alter drug response, ranging from promoting drug 
resistance to increasing drug sensitivity245-249. Furthermore, multicellular cocultures may be more 
physiologically relevant than monocultures, either in 2D or 3D, as they can account for tissue level 
interactions. In fact, it was recently shown that basal-like and mesenchymal-like subclasses of 
breast cancer could be distinguished based on their expected drug sensitivities, but only when co-
cultured with fibroblasts246. It is unclear how much complexity is required to accurately predict in 
vivo drug efficacy, but recreating aspects of the cellular TME is emerging as an important 
consideration due to the in vivo spatial heterogeneity243. Logsdon et al., found that MDA-MB-231 
cells in mixed, 3D culture with fibroblasts were more resistant to 10 µM doxorubicin at low ratios of 
tumor to stromal cells (4:1) but equally affected by the drug at higher ratios (1:4)245. Shen at al., 
found similar results using a micro-patterned interface of tumor to stromal cells wherein MCF7 cell 
proliferation was inhibited by reversine at the interface but not in the bulk250. Expanding these data 
sets to evaluate a range of drug doses would provide insight into how dose response varies 
between the tumor bulk and regions of more diffuse invasion.  
One challenge with co-cultures is the determination of drug response metrics for the 
discrete populations of cells. It is easiest to use cells expressing a reporter transgene or labeled 
with nontoxic dyes. Measurement of total fluorescence or bioluminescence then provides an 
estimate of the labeled cell number over the course of drug treatment251, 252. However, dead cells 
may remain within 3D models, so the use of total fluorescence readings in these systems may be 
inaccurate. More appropriate in 3D is to stain cells using a viability marker like propidium iodide or 
JC-1 and quantify cell viability and/or number using either confocal/multiphoton microscopy or flow 
cytometry245, 246, 249. These methods can be used to track the drug response of one cell type while 
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ignoring other cell types or examine it for multiple cell types via multiplexing of different 
fluorophores. Coculture systems do require deciding which sample is more appropriate for 
calculating yctrl: a cancer cell only sample or a sample with all the cell types. Arguably, the 
respective untreated sample should be used for each treated sample to compensate for any effects 
of the stromal cells on cancer cell viability or growth rate. Additionally, the multiple centrifugation 
steps involved in harvesting and labeling cells for flow cytometry carry a risk of decreasing cell 
yield, such that it would be best to seed separate samples at the start of the study for determining 
an accurate y0.  
Physically separating stromal and tumor cells using either conditioned media or culture inserts 
can isolate effects, but several studies have shown that direct cell-cell contact may be a crucial 
component of stromal-derived effects on cancer cells51, 250, 253. In mixed cultures, the most common 
methods to assess cell viability, such as MTT Assay, AlamarBlue, and CellTiter-Glo, measure the 
entire population of cells such that isolating the effects on only the cancer cells is not feasible. For 
example, by using CellTiter-Glo Ngo and Harley reported an increase in the overall growth rate of 
glioblastoma-endothelial cell cocultures with increasing Temozolomide concentration, but it is 
unknown if both cell types contributed equally.  
It is possible the cancer cells responded the same as in monoculture (growth rate inhibition) 
while endothelial cells increased their growth rate, or that only endothelial cells were affected and 
therefore protected the cancer cells. Separating the responses of different cell types may not 
always be a significant drawback, but the presence of stromal cells has potential to confound the 
results if overall survival apparently increases with drug treatment, as was reported by Yang et al., 
such that IC50 or EC50 would be impossible to calculate. Thus, it may be more appropriate in these 
multicellular cultures to calculate GR50 or GI50 to determine overall drug responses across 
conditions. 
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Figure 6.3: Decision tree for determining what drug response metrics can be calculated from 
drug response data. It is easiest to first look at a typical dose-response curve and calculate data 
from it. Then, depending on cell growth over the course of the assay, additional metrics may be 
calculated. In the first step, the criterion is whether the normalized cell growth decreased below 
0.5, which is required for IC50 calculation. Criterion for second step is whether exponential growth 
was achieved during the experiment. 
 
 
6.3 Materials and Methods 
 
6.3.1 Cell Culture 
All cell culture supplies were purchased from Thermo Fisher Scientific (Waltham, MA). The SKOV-
3 cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA) and the 
cells were grown in Roswell Park Memorial Institute (RPMI) medium, supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep). 
 
6.3.2 Primary Ovarian Cancer Ascites Culture 
Ascites samples were received from patients undergoing paracentesis at UMass Medical School 
(Worcester, MA), transported to UMass Amherst (Amherst, MA), and used immediately upon 
receipt. Samples were deidentified and were IRB exempt. Either single cells or ovarian ascites 
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carcinoma spheroids (OCAS) were recovered from patient samples and treated as described 
previously. Single cells were seeded on tissue culture polystyrene (TCPS) and OCAS were 
encapsulated directly into 3D poly (ethylene glycol)-maleimide (PEG-MAL) hydrogels. 
 
6.3.3 SKOV-3 multicellular tumor spheroids (MCTS) 
Square pyramidal microwells (400 μm side-wall dimension) were fabricated as described 
previously. Briefly, master molds containing square-pyramidal pits were generated by anisotropic 
etching of 100 crystalline silicon in potassium hydroxide (KOH). Microwells were generated from 
poly(dimethylsiloxane) (PDMS) using a two-stage replica molding process of the master mold as 
described previously. Microwells were arranged in a square array with no space between adjacent 
wells and placed in 12-well plates. For cell seeding, microwell surfaces were UV sterilized for 30 
minutes, pretreated with 5% Pluronic F-127 (Sigma-Aldrich, St. Louis, MO) for 30 minutes (2,465 x 
g, Eppendorf 5810R v3.3 centrifuge with A-4-62 rotor, Eppendorf, Hamburg, Germany), and then 
washed twice with sterile water. Cells were seeded at 1.00 × 104 cells/cm2. After 24 hours, 
multicellular tumor spheroids (MCTS) were collected by shaking the plate gently to dislodge most 
of them, and gently aspirating medium and MCTS. MCTS solution was spun down at 400 rpm for 
5 minutes. Medium was removed, and the MCTS were encapsulated in 3D PEG-MAL hydrogels. 
MCTS were handled using cut pipet tips to minimize shear stress.  
 
6.3.4 3D PEG-MAL Hydrogel Platform  
Patient OCAS were encapsulated into non-degradable 3D PEG-MAL hydrogels as described 
previously with minor modifications. The SKOV-3 MCTS were encapsulated into degradable 3D 
PEG-MAL hydrogels. The 3D RGD non-degradable hydrogel was prepared with a 20 kDa 4-arm 
PEG-MAL (Jenkem Technology, Plano, TX) at 10 wt % solution with 2 mM of cell adhesion peptide 
RGD (Genscript, Piscataway, NJ) and cross-linked at a 1:1 molar combination of the 1 kDa linear 
PEG-dithiol (Sigma-Aldrich). The 3D RGD degradable hydrogels were prepared in the same 
manner as the non-degradable hydrogel, plus cell-degradable cross-linker, Pan-matrix 
metalloproteinase (Pan-MMP, GCRDGPQGIWGQDRCG, Genscript). The final crosslinking 
concentration was 90 mM consisting of PDT (88 molar %) + Pan-MMP (12 molar %). The hydrogels 
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were synthesized by pipetting 1 μL of PDT or PDT/Pan-MMP solution onto the well surface, 
followed by pipetting 9 μL of the cell- containing PEG−MAL solution. MCTS and OCAS were 
transferred with cut pipet tips to minimize shear stress.  
 
6.3.5 Drug Screening Assay 
SKOV-3 cells were seeded in RPMI with 5% FBS and 1% pen/strep at 6,250 cell/cm2 on TCPS. 
Primary ovarian single cancer cells were seeded in RPMI with 10% FBS at the same density, also 
on TCPS. OCAS were collected and encapsulated in 3D RGD hydrogel upon receipt. Drugs were 
added after 24 hours in the same type of medium that the cells were seeded in and the cells were 
incubated with drugs for 48 hours. Paclitaxel (MP Biomedicals, Santa Ana, CA), Cisplatin (Tocris 
Bioscience, United Kingdom), and Mafosfamide (Niomech, Germany), were added in 10-fold serial 
dilutions at concentrations of 1x10−5 to 1x102 μM, and dimethyl sulfoxide (DMSO, Sigma-Aldrich) 
was used as a vehicle control for all drugs. Cell viability was assayed at 24 hours post-cell seeding 
in a control plate and after 48 hours of drug incubation using the CellTiter-Glo luminescent viability 
assay (Promega, Madison, WI). Luminescence values were measured in a BioTek Synergy H1 
plate reader (Winooski, VT). 
 
6.3.6 GR50 Metrics and Calculations 
The data in figure 5.2 was analyzed using the online GR calculator, 
http://www.grcalculator.org/grcalculator/. We used the initial cell counts calculation method and 
Case A (multiple cell counts per row) for the input file format. “Replicate” was removed from the 
grouping variables list before the data was analyzed. In Table C.2, the material that the cells were 
tested in or on is listed under the “perturbation” heading. The IC50 value for figure 5.2b was obtained 
using GraphPad prism v7.0c.  
 
6.3.7 Inhibition Metrics Calculations from Published Data 
Data from drug response curves were extracted with WebPlotDigitizer v4.1 from the published work 
cited in Tables C1-3. Re-plotted curves were used to calculate inhibition parameters IC50, Emax, 
EC50 and AUC with GraphPad prism v7.0d. Viability values were constrained to 0.00001 as a 
minimum for log calculations. Drug concentrations were expressed as log10 of concentrations in 
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µM. Viability data was then normalized, with the control set to 100%, and minimum set to 0%. 
Nonlinear regression with variable slope was used, with least squares fitting method. The IC50 was 
calculated from Prism dose-response inhibition analysis with variable slope of four parameters and 
following equation shown in figure 5.1. AUC was obtained from XY analysis in Prism. Additional 
parameters Emax and EC50 values were calculated following their respective equations shown in 
figure 5.1. 
 
6.3.8 Curve Response Class (CRC) Classifier Analysis 
Using guidelines described by Inglese et al.229 we classified the drug response curves from our 
own data and the data that we analyzed from the literature. In some cases, the r2 values that we 
observed for the non-linear fits to the equations were not greater than 0.9, which was criteria 
described by previously. However, the efficacy in these cases was greater than 80% and we 
observed dose response curves with two asymptotes. Since we observed dose responses 
(compounds were not inactive), we characterized the data presented here to the closest CRC that 
we could.  
 
6.4 Conclusions 
 
Drug screening in biomaterials could be particularly useful in making better predictions in the 
early stages of preclinical drug development. However, it can be challenging to compare drug 
responses across different platforms and conditions in the current literature. This is, in part, a result 
of inconsistent applications of drug response metrics, and differences in cell growth rates for cells 
cultured in different biomaterials. For this reason, we suggest the use of GI50 and GR50 to account 
for initial populations (y0), and number of cell divisions during an assay, since cell growth highly 
impacts dose response. However, in instances when steady cell growth is not achieved, multiple 
drug response metrics could be applied (e.g. IC50, EC50, Emax, and AUC) to account for possible 
experimental variation.  To aid researchers in determining what drug response metrics can be 
calculated from their data, we suggest the use of a decision tree (figure 6.3) based on the traditional 
drug response curve and cell growth rate data that are obtained for a drug response experiment. 
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First, visual inspection of a drug response curve will determine if an IC50 can be calculated if less 
than 50% of the control cell population is remaining at the highest drug concentration that was 
tested. If 100% cell death has been achieved, then the EC50 and IC50 will be equal. Furthermore, if 
the cells grew exponentially over the course of the drug screening assay, then the GI50 and GR50 
metrics can be applied. We also encourage other research groups to incorporate raw data and drug 
response curves in their reports that will allow other researchers to gather additional data for their 
analyses. In the long term, this will lead to more accurate predictions early in the drug development 
pipeline of how likely a drug will be successful in a clinical setting.  
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CHAPTER 7 
 
7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Overall Conclusions 
 
This dissertation presented the first hydrogel to culture human brain astrocytes that remained 
quiescent in vitro while demonstrating tight control on activation. Because of a wide variation in the 
brain modulus reported in the current literature, localized brain mechanics were explored via 
needle-induced cavitation rheology and volume-controlled cavity expansion in the brain for the first 
time.  These techniques can be adopted for further exploration of the local mechanical properties 
of other materials. In order to expand on the brain specific ECM composition, proteomics was 
performed in four human cortex samples for healthy donors. This information was compiled in a 
throughout list of integrin-binding and MMP-degradable proteins. It was demonstrated that 
combining the brain properties found via mechanics and proteomics into a synthetic hydrogel as 
biochemical components with matched mechanical properties resulted in a hydrogel that can 
control astrocyte activation for the first time in vitro. The degree of activation was further explored 
based on hydrogel composition or induced via cytokine dosing. Finally, to aid with the 
implementation of biomaterials as in vitro platforms to predict in vivo physiology, the correlation 
between current 2D, 3D and in vivo studies of glioblastoma motility was explored, and how an effect 
size can help standardize comparison across labs and culture dimensions. An additional study 
highlighted the importance of adopting growth rate in drug metric responses and how these can be 
implemented in current biomaterial platforms. Overall, this work can help integrate biomaterials as 
models to predict in vivo physiology. This case study with a brain hydrogel system can be used as 
a platform to understand mechanistic studies of astrocytes activation. 
7.2 Limitations and considerations for brain models 
 
Tissues are very complex structures that possess a 3-dimensional geometry227, an array of 
biochemical components156 and in certain instances adopt different mechanical properties 
dependent on the state of disease41. Biomaterials have the capability to replicate these properties 
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in vitro254. As the field moves towards the integration of more complex designs there are other 
parameters to consider87. However, one of the current challenges is the design of materials that 
remain simple and cost-effective while mimicking the complexity of the microenvironment of 
interest. 
7.2.1 Viscoelastic and strain-stiffening deformation in synthetic hydrogels 
 
Characterization of brain during deformation has shed light on its strain rate dependent 
deformation255, and viscoelastic nature100. Others, including this work, have shown the strain 
stiffening nature of brain100. Similarly, others have also shown the anisotropy present in white matter 
which is not existent in gray matter99. Here we characterized brain properties and tuned the 
modulus of a synthetic hydrogel to successfully match the measured Young’s modulus of brain (fig. 
4.1). However, one of the limitations of fully synthetic systems is that their response to deformation 
is different from certain strain hardening tissues33. Other groups have aimed to replicate 
viscoelastic features of tissues using combinations of proteins256 and synthetic polymers33, 257, 258. 
An interesting approach to modulate the chemical properties of hydrogels with MMP degradable 
sequences, recently introduced in work by Badeau et al.,259, has used logic-gated biomaterials that 
undergo precise MMP degradation that subsequently trigger drug delivery responses. Given that 
degradable crosslinkers in the hydrogel presented in this work can be degraded by MMPs, it would 
be of interest to adopt a similar approach and explore additional groups at each end of the GCRD 
motif groups that upon degradation would allow for re-crosslinking of exposed groups. Further 
crosslinking by the new exposed groups could result in changes in the network and mechanical 
properties of the hydrogel. This would be of interest for future work addressing dynamic transitions 
into diseases where tissues increase in modulus over time due to the deposition of proteins by 
other cells while still retaining the MMP and integrin-binding functionality introduced in the brain 
hydrogel design (section 4.1)31. 
7.2.2 Integrating tissue vasculature in hydrogel to increase complexity 
 
The brain consists of many compartments such as the frontal, parietal, temporal, occipital 
lobes and central gray matter structures1. Anatomically this organ can be further stratified into the 
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cerebral cortex representing the outermost gray matter overlying white matter1. Various studies 
have characterized the brain extracellular space where the blood brain barrier (BBB), interstitial 
matrix and perineuronal nets compose the microarchitecture5, 7, 8, 23. Similarly, the vasculature of 
the brain plays an integral part in the flow of oxygen throughout, keeping toxins and serum at bay 
and promoting cell extravasation and invasion during disease and has been shown to be altered 
during neurodegenerative diseases. Yet, major challenges and limitations in replicating the brain 
ECM compartments and vasculature has been attributed to increase in cost, and major complexity 
of the system66, 87.  
While other work as focused on recreating the unique physiology of the BBB in vitro it has 
been excluded from this system66, 87. One of the reasons being current challenges in the design of 
microchannels in the elastic homogeneous hydrogel not remaining intact throughout. However, 
future optimization of the system should aim to incorporate a vasculature component. Additionally, 
because the brain is stratified into many compartments that make it a unique organ, 
characterization of proteins in other locations like the cerebellum, or the spinal fluid could be 
conducted with proteomics. Although, aiming to recreate a full brain organ in vitro is the ultimate 
challenge, others could aim to recreate key features of other brain regions as introduced here, and 
incorporate hydrogels side-by-side while changing the formulation to represent other compartments 
within the brain. 
7.2.3 Expansion of other brain cell types in the brain hydrogel  
 
The cerebral cortex incorporates neurons, astrocytes, microglia, oligodendrocytes and other 
vasculature related cell types making it a very complex organ with a large and diverse cell 
population2, 260. Aims to characterize the distinct population of cells in the brain have been mostly 
focused on neurons, and until recently have emerged on glial cells2, 54. The first modern description 
of reactive astrocyte occurred in 1970s after the discovery of the glial fibrillary acidic protein 
(GFAP)261 and recent work, within the last 2-3 years, has aimed to expand on markers that are 
specific to astrocytes since work has shed light on the many different shades of astrocytes, 
microglia and neurons that compose the brain network2, 54, 262. Yet this work was focused on 
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astrocyte culture due to their key role in inflammation and the imminent need for better models of 
their culture263. Although this work demonstrates tight control of astrocyte activation in the 
formulation of the brain hydrogel (section 4.1), other cell types in the brain should be explored by 
future work. Given that astrocytes were able to remain viable after 2 weeks in culture, it is expected 
other brain cell types will also be viable in the brain hydrogel. 
7.2.4 Increasing knowledge of peptide sequences to be incorporated in the hydrogel 
 
There is a wide array of proteins present in brain tissue156. Here we characterized the 
proteins in human brain and filtered them based on literature knowledge of sequences that are 
known to be interactive with cells. This can limit the scope of peptides that are incorporated into 
the hydrogel and hence the formulation. Because other work has shown other receptors like CD44 
can have effects on astrocyte intracellular mechanisms264, and similarly, other enzymes outside of 
matrix metalloproteinases can remodel the microenvironment, like for example cathepsins265, 
additional parameters can be incorporated into the hydrogel if these are to be studied. Yet, a major 
challenge in the field is designing sufficiently complex yet simple in vitro models 266. As additional 
moieties and biofunctionalities are incorporated into the hydrogel this can increase the cost of the 
system and make it more labor intensive which is a challenge to take into account in future tissue 
specific hydrogel designs. 
7.3 Future directions 
 
7.3.1 Brain hydrogel to study cell-ECM traumatic brain injury astrocyte activation 
 
Reactive astrocytes play a key role in brain trauma and inflammation46. Radical changes 
in the central nervous system (CNS) have been shown to transform naïve astrocytes into reactive 
astrocytes that induce damage and can promote disease45. For example, work by Hara et al., 50 
recently illustrated that interaction of astrocytes with collagen type I induces astrocyte scar 
formation via the integrin-N-cadherin pathway. Similarly, others have shown activated astrocytes 
in traumatic brain injury (TBI), induced by impact or cavitation267, emerge soon after injury and 
accumulate at the site of injury as identified by staining with the intermediate filament marker 
 117 
GFAP157. However, how impact or cavitation-induced injury elicit mechanistic responses of 
astrocytes or other CNS cells remains unexplored. 
I propose the brain hydrogel presented in this work could be used as a platform to 
understand how cavitation-induced injury elicits astrocyte activation. The needle-induced cavitation 
rheology technique (section 2.1) used in this work for mechanical characterization of brain tissue 
allows for controlled local deformation in situ. Given that traumatic brain injury is expected to occur 
at very high strains39, I propose this technique could be used to induce local injury in the brain 
hydrogel. Merging a precise controlled mechanical technique with a hydrogel that provides tight 
control of astrocyte activation could help bridge the gap of what intracellular signaling pathways are 
activated upon traumatic brain injury in vitro.  
7.3.2 Brain hydrogel to understand astrocyte reactivity in cell-cell interactions during 
inflammation and brain trauma in vitro 
 
Both microglia and astrocytes become reactive in concert during brain trauma and both 
play a role in neuroinflammation.45, 63  Because of this, it has been a challenge to distinguish the 
role of both these cells in vivo45. Additionally, given that many key proteins are present in both cells, 
in vivo systems limit understanding cell-cell interactions and how external and internal cues elicit 
activation. For in vitro models, outside the challenge of no current model being able to replicate 
astrocyte reactivity, which has been addressed by this work, one major limitation in the field is that 
in vitro models that work for astrocytes usually do not work for microglia45. Hence, it has been very 
challenging to study microglia in vitro and how they might interact with astrocytes in a physiological 
and reactive setting. I propose the brain hydrogel presented in this work could be the first step to 
understand how reactive astrocytes influence microglia or if it is microglia that induces activation. 
Similarly, recent work by Liddelow et al.,55 shows that microglia induce reactive astrocytes 
produce a neurotoxin that affects neurons and oligodendrocytes that remains to be identified. 
Proteomics has proven to be a readily helpful tool in identifying proteins and molecules present in 
the extracellular compartment of tissue and in vitro10. I propose the brain hydrogel could be used 
as a platform to identify proteins and cytokines produced by reactive astrocytes. This would help 
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shed light to what astrocyte-mediated signals induce injury to other CNS cells like neurons and 
oligodendrocytes. 
 
 
Figure 7.1: Proteomics to identify ECM changes in disease. a) ECM proteins identified via 
proteomics workflow of breast cancer cells recovered after 2 days or 28 days of culture in serum 
free medium or 7 days of culture with 10% of serum containing media. Samples analyzed were 
prepared by Dr. Alyssa Schwartz and Dr. Christopher Hall. Heat map depicts ECM proteins present 
in all cell culture recovered conditions as collagens (orange), glycoproteins (green) and 
proteoglycans (blue). b) Distribution of core ECM proteins (collagens, glycoproteins and 
proteoglycans) and Matrisome associated proteins (Regulators (turquoise), ECM-affiliated (purple) 
and Secreted factors (dark purple) for samples of cell cultured recovered after 2 days, 28 days 
serum-free medium and 7 days with serum containing medium. Data shown is for two biological 
replicates per condition as mean and s.e.m. for number of proteins identified. c) Presence of cell-
derived fibronectin for each of the cell culture conditions. The protein was only detected after 28 
days of culture in serum free medium and one biological replicate of serum containing culture. 
 
7.3.3 Implementation of Proteomics for characterization of ECM changes in development 
and in dormancy  
 
Similarly, recent work has highlighted the ECM role in dormancy 30, 268. Most of the relapses 
seen in metastatic cancers like breast and lung are due to underlying dormant cells that remain in 
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the system even after the primary tumor has been eradicated269. Dormancy is hypothesized to be 
a result of early disseminated tumor cells (DTCs) to other secondary sites, which can undergo long-
term latency and survival and finally result in overt metastasis268, 270. Recent work by Carlson et 
al.,271 identified that DTCs are protected by the perivascular niche of the bone marrow 
microenvironment. Similarly, previous work in our lab78 identified that cell secreted fibronectin, an 
ECM protein secreted by cells, mediates cell survival in an integrin mediated signaling. Proteomic 
tools that allow for the throughout characterization of the ECM components are indispensable in 
identifying the composition of these perivascular niches that allow for microenvironment mediated 
resistance. Implementation of proteomics as a workflow to characterize different time points during 
dormancy seems like a good avenue to test ECM driven hypotheses. Figure 7.1 shows preliminary 
data I gathered in collaboration with Dr. Alyssa Schwartz and Dr. Lauren Barney of the presence 
of fibronectin after long-term culture of serum deprived cells in vitro with the notion that they 
assemble fibronectin in order to survive. Proteomics identified the signature profile of ECM proteins 
and how these changes between serum dosed and serum deprived cultures. Assessing for the 
presence of fibronectin confirmed this protein was present after 28 days of serum deprived culture 
while not initially. This highlights how proteomics can be a useful tool to identify ECM changes 
during disease.  
7.3.4 Expanding on tissue specific hydrogel design 
 
Proteomic work by others has also illustrated the ECM diversity in tissues10, 154. 
Comparisons between lung and colon tissues ECM highlighted there are a subset of proteins 
unique to tissues and could give rise to the macroscopic differences that are observed in different 
organs.  
We have extended our tissue specific hydrogel design to other tissues with information 
gathered by proteomics and designed hydrogels representing the thymus and omentum (fig. 7.2). 
We foresee the design of additional tissue specific hydrogels that can help pinpoint how tissues 
different set of ECM proteins regulate cell behavior in development and disease in vitro. Future 
work can expand of validation of these systems with the incorporation of tissue-specific cells. 
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7.3.5 Industrial applications of the brain hydrogel to identify neurodegenerative 
diseases and brain cancer targets 
 
The fast, controllable and reproducible formulation of this brain hydrogel platform makes it 
an attractive system for high throughput applications (fig. 7.3). Currently, one of the major 
challenges in finding suitable targets for neurodegenerative diseases and other brain cancers is  
 
 
Figure 7.2: Expansion of tissue-specific ECM hydrogel designs. Workflow of the identification 
of integrin-binding proteins and MMP-degradable proteins from mass spectrometry data screened 
for ECM proteins for a) fetal thymus b) pediatric thymus and c) omentum tissue. Omentum mass 
spec data was gathered from the Naba et al., “Characterization of the Extracellular Matrix of Normal 
and Diseased Tissues Using Proteomics”. Heat map depicting molar composition of integrin-
binding peptides for d) fetal- e) pediatric-thymus and f) omentum-specific hydrogels. Heatmap of 
MMP-degradable peptides for g) fetal and h) pediatric thymus hydrogels. 
 
that there are no good models of the brain in vitro66, 87, 272 and in vivo models show species 
differences44, 62, 64. For example, work has shed light on how some of the targets identified in the 
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murine brain do not play a role in human brain disease progression and vice-versa62, 64. This can 
be one of the reasons why pre-clinical work has struggled at clinical stages. 
Recent work has shown that extracellular targets in the brain, as well as blocking certain cytokines 
of protein expression can help suppress disease25, 51, 55, 273. I propose this hydrogel model with 
unique human brain features could help bridge the gap between pre-clinical and clinical work 
 
 
 
Figure 7.3: High throughput implementation of tissue-specific hydrogels. a) Breast cancer 
metastasizes to the brain, bone, lung and liver. b) Within the breast cancer sub-types each exhibits 
different degree of incidence of brain metastasis. c) Implementation of tissue specific high 
throughput screening could help understand preference to a specific ECM environment and test 
druggable targets. d) The use of an effect size could help compare results across different 
microenvironments based on a small (0.2<E<0.5), medium (0.5<E<0.8) or large (0.8>E) effect size 
response. e) example of effect size responses of astrocytes in the brain hydrogel after cytokine 
dosing and their effect on total distance migrated and migration speed as compared to control 3D 
brain hydrogel. f) example of effect size applied to data gathered from the Barney et al., “A cell-
ECM screening method to predict breast cancer metastasis” for the breast cancer cell line MDA-
MB-231 and g) SkBr3 after cell culture in 2D surfaces functionalized with bone-, brain- and lung-
inspired ECM proteins and their effect size on migration speed after dosed with different stimulation 
(EGF, integrin beta1, alpha2 and alpha 6 inhibitors). 
 
in industry to find targets that are druggable. For example, astrocyte reactivity is dependent 
on the type of injury where to date there have been two phenotypes identified A1 and A254, 55. A1 
neuroinflammatory astrocytes upregulate many genes destructive to synapses and are suggested 
to be harmful54-56. Alternatively, ischemia-induced A2 astrocytes upregulate many neurotrophic 
factors that promote survival, growth of neurons, and have been suggested to be helpful.57-59, 274 
However, there are still questions whether there are more states of activation in human astrocytes 
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similarly to how macrophages (another immune cell type) can be activated in different states. I 
propose the brain hydrogel as a platform to explore how inflammation triggered responses affect 
astrocytes mechanistically and screen their phenotype based on recent work by Liddelow et al., 
that showed the C3 marker could help identify between different states55. Additionally, I propose 
this hydrogel would allow for further understanding of the key intracellular signaling pathways that 
allow for polarization into an A1 or A2 phenotype.  
Work by others has suggested that A1 astrocytes become reactive via the nuclear factor-𝛋B (NF-𝛋B) pathway since many inflammatory agents, such as cytokines, bacteria or viruses can 
activate it.275, 276 Others have shown activation of this pathway in astrocytes during Alzheimer’s 
disease and Hunting-ton’s disease which provide evidence that NF-𝛋B-activated-astrocytes might 
be harmful56, 277, 278. Similarly, others have suggested that A2 astrocytes become reactive via JAK-
STAT3 pathway. This pathway in astrocytes is important during early brain development, since it 
helps to control astrogliogenesis and maturation279, 280. Studies have shown JAK-STAT3 in scar-
forming astrocyte activation after injury49, 60, 281. Drugs that control Stat3 and NF-𝛋B could have 
potential in modulating the activation state of reactive astrocytes into helpful or damaging cells to 
the CNS. I propose these mechanistic activations and potential drug targets can now be probed in 
vitro. 
7.4 Materials and Methods 
 
7.4.1 Proteomics sample preparation 
 
Sample were ECM-enriched. The ECM-rich pellet was solubilized and reduced in 8M Urea, 
100 mM of ammonium bicarbonate, and 10 mM dithiothreitol (DTT) (Fisher Scientific) for 30 
minutes at pH 8 and 37C. Samples were alkylated with 25 mM iodoacetamide (Sigma) in the dark 
at room temperature for 30 minutes before the solution was quenched with 5mM DTT. Prior to 
cleavage the solution was diluted to 2M Urea with 100 mM ammonium bicarbonate at pH 8. Proteins 
were cleaved via trypsin (Thermo Scientific) and lys-C endoproteinase (Promega), at a ratio 1: 50 
enzyme to protein overnight (12-16 hours) at 37C. Samples were cleaned and concentrated using 
a C18 column (Thermo Scientific). A reverse phase LC gradient was used to separate peptides 
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prior to mass analysis. Mass Fusion Tribrid (Thermo Scientific). Peptides were aligned against the 
Matrisome using the Thermo Proteome Discoverer 1.41.1410. Parameters used trypsin as a 
protease, with 4 missed cleavage per peptide, a precursor mass tolerance of 10 ppm, and fragment 
tolerance of 0.6 Da. 
 
7.4.2 Identifying integrin-binding and MMP-degradable proteins in Pediatric and Fetal 
Thymus 
 
Manual data mining was used to identify 14 integrin-binding and 20 MMP-degradable 
proteins in pediatric thymus. For the fetal thymus 21 proteins were integrin-binding and 27 were 
MMP-degradable. This list was used to identify which proteins would be represented by integrin-
binding or degradable peptide sequences. The proteins were relatively quantified with the peptide-
spectrum match (PSM) from the mass spectrometry data and normalized to the molecular weight 
of the protein. The ratio was annotated for each protein and a relative percent abundance was 
obtained from the ratio of each protein over a sum of the total ratio identified per sample. This value 
was averaged across all the patient scores and was used to determine the percentage of each 
integrin-binding peptide and MMP-degradable crosslinker to use for proteins in the thymus ECM 
cocktail represented in supplementary tables 1 and 2, respectively. 
 
7.4.3 Thymus mechanical characterization 
 
The effective Young’s modulus was measured using micro-indentation testing on a bulk 
thymus sample. A custom-built instrument was used as previously described282. Briefly, a flat 
cylindrical punch probe was indented into the samples at a fixed displacement rate of 10 um/s, for 
a maximum load of 1mN. The first 10% of the linear region of the force-indentation curves were 
analyzed using a Hertzian model modified by Shull et al. to account for dimensional confinement 
characterized by the ratio between the contact radius (a) and the sample height (h) to be between 
0.5<a/h<2 283. 
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APPENDIX A 
APPENDICES 
A. Extracellular Matrix of the human brain cortex integrin-binding and components 
 
Appendix A EXTRACELLULAR MATRIX OF THE HUMAN BRAIN CORTEX INTEGRIN-
BINDING AND MMP-DEGRADABLE COMPONENTS 
 
A.1: Proteomics of human brain cortex. 
 
Human Protein PSMs Category Division 
Donor 1 tenascin R precursor 25 ECM 
glycoprotein 
Core Matrisome 
laminin subunit beta 2 42 ECM 
glycoprotein 
Core Matrisome 
laminin subunit gamma 1 40 ECM 
glycoprotein 
Core Matrisome 
fibrinogen beta chain isoform 1 10 ECM 
glycoprotein 
Core Matrisome 
fibrinogen gamma chain 5 ECM 
glycoprotein 
Core Matrisome 
oligodendrocyte myelin glycoprotein 8 ECM 
glycoprotein 
Core Matrisome 
collagen alpha 1 (I) chain 48 Collagens Core Matrisome 
collagen alpha 2 (IV) chain 29 Collagens Core Matrisome 
collagen alpha 6 (VI) chain 62 Collagens Core Matrisome 
collagen alpha 2(I) 18 Collagens Core Matrisome 
versican 46 Proteoglycan Core Matrisome 
neurocan core 29 Proteoglycan Core Matrisome 
basement membrane specific 
heparan sulfate proteoglycan core 
61 Proteoglycan Core Matrisome 
neural cell adhesion molecule 1 
isoform 2 
32 ECM-affiliated 
Proteins 
Matrisome-
associated 
neurofascin isoform 4 precursor 37 ECM-affiliated 
Proteins 
Matrisome-
associated 
neural cell adhesion molecule L1 
isoform 3 
16 ECM-affiliated 
Proteins 
Matrisome-
associated 
annexin A2 isoform 1 15 ECM-affiliated 
Proteins 
Matrisome-
associated 
cathepsin D 11 ECM 
Regulators 
Matrisome-
associated 
Contactin-1 isoform 2 precursor 52 Other Other 
contactin associated protein 1 24 Other Other 
voltage dependent calcium channel 
subunit alpha 2 delta 1 
27 Other Other 
tetraspanin 7 3 Other Other 
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tubulointerstitial nephritis antigen like 10 Other Other 
Donor 2 Protein PSMs Category Division 
laminin subunit beta 2 155 ECM 
glycoprotein 
Core Matrisome 
laminin subunit gamma 1 164 ECM 
glycoprotein 
Core Matrisome 
laminin subunit alpha 5 precursor 115 ECM 
glycoprotein 
Core Matrisome 
fibrinogen beta chain isoform 1 
preproprotein 
38 ECM 
glycoprotein 
Core Matrisome 
fibrinogen gamma chain isoform 
gamma A 
19 ECM 
glycoprotein 
Core Matrisome 
EMILIN 1 60 ECM 
glycoprotein 
Core Matrisome 
tenascin R 48 ECM 
glycoprotein 
Core Matrisome 
nidogen 1 49 ECM 
glycoprotein 
Core Matrisome 
fibrinogen alpha chain isoform alpha 
E preproprotein 
49 ECM 
glycoprotein 
Core Matrisome 
fibrillin 1 82 ECM 
glycoprotein 
Core Matrisome 
nidogen 2 60 ECM 
glycoprotein 
Core Matrisome 
latent transforming growth factor beta 
binding protein 4 
65 ECM 
glycoprotein 
Core Matrisome 
laminin subunit beta 1 131 ECM 
glycoprotein 
Core Matrisome 
fibronectin isoform 4 preproprotein 89 ECM 
glycoprotein 
Core Matrisome 
elastin isoform d precursor 8 ECM 
glycoprotein 
Core Matrisome 
thrombospondin type 1 domain 
containing protein 1 isoform 2 
81 ECM 
glycoprotein 
Core Matrisome 
sushi, nidogen and EGF like domain 
containing protein 1 precursor 
86 ECM 
glycoprotein 
Core Matrisome 
collagen alpha 1(I) chain 140 Collagens Core Matrisome 
collagen alpha 2 (I) chain 64 Collagens Core Matrisome 
collagen alpha 3 (VI) chain 199 Collagens Core Matrisome 
collagen alpha 2 (IV) chain 110 Collagens Core Matrisome 
collagen alpha 2 (VI) chain isoform 
2C2 
104 Collagens Core Matrisome 
collagen alpha 1 (VI) chain precursor 48 Collagens Core Matrisome 
collagen alpha 1 (XVIII) chain isoform 
2 
102 Collagens Core Matrisome 
basement membrane specific 
heparan sulfate proteoglycan core 
protein 
128 Proteoglycans Core Matrisome 
biglycan preproprotein 27 Proteoglycans Core Matrisome 
prolargin precursor 36 Proteoglycans Core Matrisome 
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annexin A2 isoform 2 69 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neural cell adhesion molecule 1 
isoform 2 
49 ECM-affiliated 
Proteins 
Matrisome-
Associated 
annexin A1 44 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neural cell adhesion molecule L1 
isoform 3 precursor 
57 ECM-affiliated 
Proteins 
Matrisome-
Associated 
A disintegrin and metalloproteinase 
with thrombospondin motifs 13 
73 ECM 
Regulators 
Matrisome-
Associated 
protein glutamine gamma 
glutamyltransferase 2 
28 ECM 
Regulators 
Matrisome-
Associated 
cathepsin D preproprotein 28 ECM 
Regulators 
Matrisome-
Associated 
tubulointerstitial nephritis antigen like 39 Other Other 
phytanoyl CoA hydroxylase 
interacting protein 
34 Other Other 
contactin 1 isoform 1 135 Other Other 
titin isoform N2-A 2644 Other Other 
NSFL1 cofactor p47 isoform a 55 Other Other 
CUB and sushi domain containing 
protein 2 
103 Other Other 
X ray repair cross complementing 
protein 6 
50 Other Other 
contactin associated protein 1 8 Other Other 
integrin alpha D precursor 60 Other Other 
SLIT and NTRK like protein 5 
precursor 
33 Other Other 
phytanoyl CoA hydroxylase 
interacting protein like isoform 1 
64 Other Other 
complement component C1q 
receptor precursor 
22 Other Other 
myosin binding protein C cardiac type 101 Other Other 
neurexin 1 beta isoform alpha 2 
precursor 
81 Other Other 
Donor 3 Protein PSMs Category Division 
tenascin R 22 ECM 
glycoproteins 
Core Matrisome 
oligodendrocyte myelin glycoprotein 
precursor 
9 ECM 
glycoproteins 
Core Matrisome 
collagen alpha 1(I) chain 62 Collagens Core Matrisome 
collagen alpha 3 (VI) chain isoform 1 40 Collagens Core Matrisome 
versican core protein isoform 1 55 Proteoglycans Core Matrisome 
neurofascin isoform 4 28 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neural cell adhesion molecule 1 
isoform 2 
29 ECM-affiliated 
Proteins 
Matrisome-
Associated 
fibroblast growth factor 11 28 Secreted 
Factors 
Matrisome-
Associated 
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calcium activated chloride channel 
regulator 1 
14 Other Other 
kinesin like protein KIF21B 36 Other Other 
tubulointerstitial nephritis antigen like 12 Other Other 
SLIT and NTRK like protein 2 52 Other Other 
mucin-2 25 Other Other 
contactin associated protein 1 21 Other Other 
contactin 1 isoform 2 44 Other Other 
Donor 4 Protein PSMs Category Division 
laminin subunit beta 2 166 ECM 
glycoproteins 
Core Matrisome 
laminin subunit alpha 5 150 ECM 
glycoproteins 
Core Matrisome 
laminin subunit gamma 1 149 ECM 
glycoproteins 
Core Matrisome 
tenascin R 93 ECM 
glycoproteins 
Core Matrisome 
nidogen 1 73 ECM 
glycoproteins 
Core Matrisome 
EMILIN 1 51 ECM 
glycoproteins 
Core Matrisome 
elastin isoform d 8 ECM 
glycoproteins 
Core Matrisome 
fibrillin 1 95 ECM 
glycoproteins 
Core Matrisome 
nidogen 2 46 ECM 
glycoproteins 
Core Matrisome 
fibronectin isoform 4 preproprotein 73 ECM 
glycoproteins 
Core Matrisome 
laminin subunit alpha 4 isoform 2 
precursor 
147 ECM 
glycoproteins 
Core Matrisome 
fibrinogen gamma chain isoform 
gamma A 
16 ECM 
glycoproteins 
Core Matrisome 
oligodendrocyte myelin glycoprotein 
precursor 
39 ECM 
glycoproteins 
Core Matrisome 
laminin subunit alpha 3 isoform 3 189 ECM 
glycoproteins 
Core Matrisome 
tenascin X isoform 1 190 ECM 
glycoproteins 
Core Matrisome 
laminin subunit alpha 2 isoform b 265 ECM 
glycoproteins 
Core Matrisome 
von Willebrand factor A domain 
containing protein 1 isoform 1 
18 ECM 
glycoproteins 
Core Matrisome 
fibrinogen beta chain isoform 1 
preproprotein 
37 ECM 
glycoproteins 
Core Matrisome 
agrin precursor 71 ECM 
glycoproteins 
Core Matrisome 
fibrinogen alpha chain isoform alpha 
E preproprotein 
58 ECM 
glycoproteins 
Core Matrisome 
vitronectin precursor 21 ECM 
glycoproteins 
Core Matrisome 
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von Willebrand factor preproprotein 134 ECM 
glycoproteins 
Core Matrisome 
laminin subunit beta 3 136 ECM 
glycoproteins 
Core Matrisome 
thrombospondin 1-precursor 43 ECM 
glycoproteins 
Core Matrisome 
collagen alpha 3 (VI) chain isoform 1 503 Collagens Core Matrisome 
collagen alpha 2 (I) chain 167 Collagens Core Matrisome 
colalgen alpha 2 (VI) chain isoform 
2C2  
183 Collagens Core Matrisome 
collagen alpha 1 (I) chain 194 Collagens Core Matrisome 
collagen alpha 1 (VI) chain 132 Collagens Core Matrisome 
collagen alpha 1 (XIV) chain 140 Collagens Core Matrisome 
collagen alpha 1 (XII) chain long 
isoform 
266 Collagens Core Matrisome 
collagen alpha 2 (IV) chain 
preproprotein 
171 Collagens Core Matrisome 
collagen alpha 1 (XVIII) chain isoform 
3 
66 Collagens Core Matrisome 
collagen alpha 1 (XXI) chain 
precursor 
89 Collagens Core Matrisome 
collagen alpha 1 (XV) chain 
precursor 
32 Collagens Core Matrisome 
collagen alpha 1(III) chain 
preproprotein 
116 Collagens Core Matrisome 
collagen alpha 5 (IV) chain isoform 1 92 Collagens Core Matrisome 
basement membrane specific 
heparan sulfate proteoglycan core 
218 Proteoglycans Core Matrisome 
biglycan preproprotein 87 Proteoglycans Core Matrisome 
versican core protein isoform 1 160 Proteoglycans Core Matrisome 
fibromodulin precursor 31 Proteoglycans Core Matrisome 
mimecan preproprotein 38 Proteoglycans Core Matrisome 
prolargin precursor 53 Proteoglycans Core Matrisome 
lumican precursor 14 Proteoglycans Core Matrisome 
neurocan core protein precursor 74 Proteoglycans Core Matrisome 
decorin isoform a preproprotein 12 Proteoglycans Core Matrisome 
brevican core protein isoform 1 40 Proteoglycans Core Matrisome 
annexin A6 isoform 1 86 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neural cell adhesion molecule 1 
isoform 2 
89 ECM-affiliated 
Proteins 
Matrisome-
Associated 
galectin 1 21 ECM-affiliated 
Proteins 
Matrisome-
Associated 
annexin A2 isoform 1 64 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neurofascin isoform 1 60 ECM-affiliated 
Proteins 
Matrisome-
Associated 
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neural cell adhesion molecule L1 
isoform 3 precursor 
34 ECM-affiliated 
Proteins 
Matrisome-
Associated 
alpha tectorin precursor 87 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neuronal cell adhesion molecule 
isoform A precursor 
50 ECM-affiliated 
Proteins 
Matrisome-
Associated 
annexin A1 65 ECM-affiliated 
Proteins 
Matrisome-
Associated 
neural cell adhesion molecule 2 49 ECM-affiliated 
Proteins 
Matrisome-
Associated 
annexin A5 16 ECM-affiliated 
Proteins 
Matrisome-
Associated 
annexin A8-like protein 2 38 ECM-affiliated 
Proteins 
Matrisome-
Associated 
epithelial cell adhesion molecule 
precursor 
56 ECM-affiliated 
Proteins 
Matrisome-
Associated 
cathepsin D 46 ECM 
Regulators 
Matrisome-
Associated 
protein glutamine gamma 
glutamyltransferase 2 
39 ECM 
Regulators 
Matrisome-
Associated 
disintegrin and metalloproteinase 
domain containing protein 23 
74 ECM 
Regulators 
Matrisome-
Associated 
coagulation factor XIII A chain 
precursor 
28 ECM 
Regulators 
Matrisome-
Associated 
inter-alpha-trypsin inhibitor heavy 
chain H5 isoform 3 
78 ECM 
Regulators 
Matrisome-
Associated 
prothrombin preprotein 26 ECM 
Regulators 
Matrisome-
Associated 
alpha 2 macroglobulin like protein 1  78 ECM 
Regulators 
Matrisome-
Associated 
protein S100-A13 13 Secreted 
Factors 
Matrisome-
Associated 
transforming growth factor beta 
induced protein ig-H3 precursor 
56 Secreted 
Factors 
Matrisome-
Associated 
protein S100 A1 5 Secreted 
Factors 
Matrisome-
Associated 
secreted frizzled related protein 5 11 Secreted 
Factors 
Matrisome-
Associated 
fibroblast growth factor 11 45 Secreted 
Factors 
Matrisome-
Associated 
protogenin precursor 79 Other Other 
fibronectin type III domain containing 
protein 1 
145 Other Other 
midline 1 60 Other Other 
probable G-protein coupled receptor 
110 isoform 1 
69 Other Other 
X-ray repair cross-complementing 
protein 5 
80 Other Other 
protocadherin Fat 1 178 Other Other 
target of Nesh SH3 precursor 58 Other Other 
brother of CDO precursor 33 Other Other 
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tubulointerstitial nephritis antigen like 52 Other Other 
myomesin 2 231 Other Other 
leucine rich repeat containing protein 
8D 
82 Other Other 
fibronectin type III and SPRY domain 
containing protein 1 
53 Other Other 
killer cell lectin like receptor subfamily 
B member 1 
10 Other Other 
integrin beta 1 isoform 1A precursor 43 Other Other 
cation-independent mannose 6 
phosphate receptor precursor 
149 Other Other 
contactin associated protein like 2 
precursor 
51 Other Other 
X-ray repair cross-complementing 
protein 6 
43 Other Other 
copine 5 33 Other Other 
phytanoyl CoA hydroxylase 
interacting protein 
16 Other Other 
complement component C1q 
receptor precursor 
36 Other Other 
26S proteasome nonATPase 
regulatory subunit 4 
17 Other Other 
filamin C isoform b 251 Other Other 
filaggrin 199 Other Other 
neurexin 1 beta isoform alpha 2 
precursor 
66 Other Other 
leucine rich repeat transmembrane 
protein FLRT2 precursor 
22 Other Other 
leucine rich repeat LGI family 
member 2 
43 Other Other 
alpha 2 HS glycoprotein 15 Other Other 
general transcription factor IIH, 
polypeptide 2B 
33 Other Other 
mucin 16 376 Other Other 
contactin 6 precursor 93 Other Other 
interleukin 27 receptor subunit alpha  24 Other Other 
leucine rich repeat and fibronectin 
type III domain containing protein 3 
27 Other Other 
pappalysin 1 preproprotein 58 Other Other 
roundabout homolog 3 precursor 111 Other Other 
receptor type tyrosine protein 
phosphatase beta isoform a 
182 Other Other 
signal peptide, CUB and EGF like 
domain containing protein 2 isoform 1 
115 Other Other 
leucine rich repeat serine/threonine 
protein kinase 2 
160 Other Other 
contactin 1 isoform 1 152 Other Other 
titin isofrom N2-A 3400 Other Other 
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voltage dependent calcium channel 
subunit alpha 2 delta 1 
95 Other Other 
WD repeat containing protein 33 
isoform 1 
238 Other Other 
contactin associated protein 1 47 Other Other 
leucine rich repeat containing protein 
8B 
48 Other Other 
 
 
 
A.2: Human Cortex protein scores from the Protein Atlas 
(E)-endothelial cells, (G)-Glia, (N)-neurons, (NP)-Neuropil 
 
Protein (E) (G) (N) (NP) Average  RNA (RPKM) Category 
LAMC2 0 3 1 1 1.25 0.10 glycoprotein 
POSTN 0 3 3 0 1.5 0.30 glycoprotein 
FGB 3 0 2 1 1.5 0.10 glycoprotein 
SPARC 2 0 0 3 1.25 57.80 glycoprotein 
LAMA2 3 0 0 0 0.75 1.70 glycoprotein 
LAMB2 3 0 1 2 1.5 8.40 glycoprotein 
NID2 3 0 1 1 1.25 0.50 glycoprotein 
VWF 3 0 0 0 0.75 7.80 glycoprotein 
PSAP 1 2 3 0 1.5 358.30 glycoprotein 
TNXB 0 2 3 2 1.75 1.80 glycoprotein 
AGRN 2 1 3 0 1.5 21.60 glycoprotein 
VWA2 2 2 3 1 2 0.30 glycoprotein 
GPC3 1 2 3 1 1.75 0.20 glycoprotein 
GPC4 0 1 3 2 1.5 2.20 glycoprotein 
NFASC 1 0 1 3 1.25 13.40 glycoprotein 
TNN 0 0 2 3 1.25 0.00 glycoprotein 
NRP2 3 2 0 0 1.25 1.40 glycoprotein 
THBS3 2 1 3 1 1.75 6.30 glycoprotein 
LAMA1 2 0 1 2 1.25 0.70 glycoprotein 
LAMB3 0 0 1 2 0.75 2.00 glycoprotein 
THBS2 0 1 2 2 1.25 3.00 glycoprotein 
THBS1 2 0 0 0 0.5 0.90 glycoprotein 
FN1 2 0 0 0 0.5 9.80 glycoprotein 
VTN 2 1 2 0 1.25 1.90 glycoprotein 
TNR 0 0 0 2 0.5 13.90 glycoprotein 
FBLN1 2 0 1 2 1.25 3.30 glycoprotein 
ANGPT1 1 1 2 1 1.25 0.40 glycoprotein 
CD59 2 0 0 1 0.75 88.10 glycoprotein 
ENG 2 0 0 0 0.5 10.70 glycoprotein 
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STC1 0 0 0 2 0.5 1.30 glycoprotein 
CD55 0 0 0 2 0.5 3.20 glycoprotein 
FBLN7 0 2 2 2 1.5 2.10 glycoprotein 
VWA7 0 2 0 0 0.5 4.10 glycoprotein 
LAMB4 1 0 0 1 0.5 0.00 glycoprotein 
TNC 0 0 0 2 0.5 0.70 glycoprotein 
DAG1 1 0 0 0 0.25 10.40 glycoprotein 
AFM 0 0 1 0 0.25 0.00 glycoprotein 
VWA1 1 1 1 0 0.75 8.10 glycoprotein 
VWC2 1 0 1 0 0.5 1.30 glycoprotein 
LAMA4 1 0 0 0 0.25 2.00 glycoprotein 
FBN3 1 0 0 0 0.25 0.20 glycoprotein 
HSPG2 1 0 1 1 0.75 0.70 glycoprotein 
LAMC1 2 0 0 0 0.5 2.70 glycoprotein 
COL4A2 3 0 0 0 0.75 3.70 collagen 
COL21A1 2 2 3 2 2.25 0.70 collagen 
COL23A1 0 2 3 0 1.25 2.90 collagen 
COL4A1 2 0 1 0 0.75 2.20 collagen 
COL1A1 0 2 2 0 1 0.80 collagen 
COL15A1 2 0 0 0 0.5 0.30 collagen 
COL8A1 2 0 0 0 0.5 0.10 collagen 
COL6A2 1 2 2 2 1.75 4.70 collagen 
COL12A1 0 0 2 1 0.75 1.70 collagen 
COL15A1 2 0 0 0 0.5 0.30 collagen 
COL1A2 2 2 2 1 1.75 2.50 collagen 
COL8A2 2 0 0 0 0.5 0.20 collagen 
COL6A6 1 0 0 2 0.75 0.00 collagen 
COL9A3 0 1 2 1 1 10.00 collagen 
COL25A1 2 0 0 1 0.75 0.10 collagen 
COL22A1 0 1 2 0 0.75 0.40 collagen 
COL18A1 1 1 0 1 0.75 5.00 collagen 
COL5A1 1 0 1 0 0.5 1.20 collagen 
COL5A3 0 0 0 1 0.25 22.70 collagen 
COL19a1 0 0 1 1 0.5 0.10 collagen 
COL4A3 0 0 0 0 0 0.50 collagen 
COL6A2 3 0 0 0 0.75 4.70 collagen 
COL12A1 0 0 2 1 0.75 1.70 collagen 
CSPG4 1 0 3 2 1.5 4.00 proteoglycan 
BCAN 1 1 2 3 1.75 53.10 proteoglycan 
SDC3 1 2 1 1 1.25 38.30 proteoglycan 
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SDC2 2 2 2 2 2 11.00 proteoglycan 
LUM 0 0 0 2 0.5 0.50 proteoglycan 
VCAN 2 0 1 2 1.25 2.80 proteoglycan 
HAPLN2 0 0 0 2 0.5 25.20 proteoglycan 
GPC6 2 1 2 1 1.5 0.40 proteoglycan 
SDC2 2 2 2 2 2 11.00 proteoglycan 
PRG4 0 0 0 2 0.5 0.00 proteoglycan 
SDC3 1 2 1 1 1.25 38.30 proteoglycan 
SDC4 1 1 1 0 0.75 30.00 proteoglycan 
OGN 0 0 0 1 0.25 1.20 proteoglycan 
NCAN 0 0 0 2 0.5 31.80 proteoglycan 
ACAN 2 0 0 0 0.5 0.20 proteoglycan 
DCN 1 0 0 0 0.25 5.60 proteoglycan 
FBLN2 0 0 1 0 0.25 1.80 proteoglycan 
HPSE 0 2 3 0 1.25 0.30 ECM regulator 
PPT1 1 3 3 2 2.25 41.00 ECM regulator 
CNP 0 2 0 3 1.25 51.10 ECM regulator 
ADAMTS4 0 1 3 2 1.5 2.10 ECM regulator 
ADAM9 1 0 3 2 1.5 5.50 ECM regulator 
TIMP3 0 1 3 1 1.25 25.90 ECM regulator 
ADAMTS18 1 1 3 2 1.75 0.20 ECM regulator 
ADAMTSL4 0 2 3 2 1.75 0.80 ECM regulator 
ADAMTSL5 2 2 3 3 2.5 0.60 ECM regulator 
ADAMTS10 1 1 3 1 1.5 8.40 ECM regulator 
SOD1 1 2 1 1 1.25 151.20 ECM regulator 
SERPINA3 2 0 0 0 0.5  ECM regulator 
SERPINH1 2 0 0 0 0.5 7.10 ECM regulator 
NCSTN 0 1 2 0 0.75 11.20 ECM regulator 
PLAT 2 0 0 0 0.5 5.00 ECM regulator 
PRDX4 2 1 2 0 1.25 5.20 ECM regulator 
ADAM17 2 1 2 2 1.75 2.80 ECM regulator 
ARSA 1 2 2 0 1.25 11.50 ECM regulator 
ADAMTS3 2 2 2 2 2 0.70 ECM regulator 
ADAMTS20 0 1 1 2 1 0.00 ECM regulator 
ADAMTS2 2 1 2 2 1.75 0.60 ECM regulator 
PLAU 0 0 0 2 0.5 0.40 ECM regulator 
ADAM15 1 1 2 1 1.25 12.40 ECM regulator 
ADAMTS8 2 0 0 0 0.5 4.70 ECM regulator 
ADAM8 0 0 2 0 0.5 1.50 ECM regulator 
ADAMTS12 0 0 2 1 0.75 0.00 ECM regulator 
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ADAM23 2 1 2 0 1.25 17.00 ECM regulator 
ADAMTSL3 2 0 1 0 0.75 0.30 ECM regulator 
SERPINC1 0 0 0 1 0.25 0.10 ECM regulator 
ADAMTS13 0 1 1 1 0.75 4.20 ECM regulator 
TGFBR3 0 1 1 0 0.5 1.70 ECM regulator 
EDN1 0 1 1 0 0.5 5.60 ECM regulator 
ENTPD5 0 1 1 0 0.5 0.60 ECM regulator 
TIMP2 0 0 1 0 0.25 39.70 ECM regulator 
ADAMTS5 0 0 1 0 0.25 0.10 ECM regulator 
ADAMTS14 0 1 0 0 0.25 1.30 ECM regulator 
ADAM10 1 0 0 0 0.25 6.10 ECM regulator 
ADAMTS13 0 1 1 1 0.75 4.20 ECM regulator 
ADAMTS9 0 0 0 1 0.25 1.60 ECM regulator 
PLAUR 0 0 0 1 0.25 1.20 ECM regulator 
MMP2 3 0 0 0 0.75 0.70 ECM regulator 
MMP3 0 3 3 1 1.75 0.00 ECM regulator 
MMP7 0 0 1 0 0.25 0.00 ECM regulator 
MMP9 1 0 0 0 0.25 0.30 ECM regulator 
MMP10 1 1 1 1 1 0.00 ECM regulator 
MMP14 2 0 1 0 0.75 1.90 ECM regulator 
MMP15 1 1 2 2 1.5 3.10 ECM regulator 
MMP16 1 2 1 0 1 1.80 ECM regulator 
MMP25 0 1 1 2 1 0.60 ECM regulator 
MATN2 1 2 1 3 1.75 2.80 ECM-affiliated protein 
LGALS8 0 2 1 2 1.25 3.40 ECM-affiliated protein 
LGALS1 2 1 1 1 1.25 119.50 ECM-affiliated protein 
ICAM1 2 0 0 0 0.5 3.30 ECM-affiliated 
LGALS3BP 1 0 0 0 0.25 13.80 ECM-affiliated 
FRAS1 1 0 0 1 0.5 1.10 ECM-affiliated 
TGFA 2 3 2 0 1.75 1.80 Secreted factors 
VEGFA 1 0 2 1 1 13.00 Secreted factors 
FGF1 2 0 0 0 0.5 33.90 Secreted factors 
FGFR3 2 2 2 2 2 49.70 Secreted factors 
MIF 1 0 2 1 1 0.00 Secreted factors 
CX3CL1 1 1 2 1 1.25 22.90 Secreted factors 
WISP2 0 0 1 1 0.5 0.20 Secreted factors 
F8 1 0 1 1 0.75 2.50 Secreted factors 
CXCL8 0 0 0 1 0.25 1.50 Secreted factors 
NTN1 0 0 0 2 0.5 1.40 Secreted factors 
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A.3: Integrin-binding proteins of the human brain cortex via proteomics. 
 
Protein Peptide Sequence Peptide 
Reference 
Integrin integrin 
references 
NID1/ 
entactin 
RGD 284 a5b1 285 
VWF 286 avb3, 
aIIbB2 
286 
VTN 
 
avb3 
 
FBN1 287 avb3 287 
COL6A1 288 a1b1, 
a10b1 
288 
COL6A3 
COL6A2 
FGA 289 a5b1 289 
FGB 
 
NFASC 290 b1 290 
FN PHSRN-RGDS 291 a5b1 291 
COL1A1 GFOGERGVQ, DGEA 292 a1b1  293 
COL1A2 
 
COL4A1 GLOGEN 292 a1b1 292 
COL4A2 
 
COL4A1 FYFDLR 294 a2b1 294 
COL4A2 294 
COL1A2 DGEA 295 a2b1 295 
LAMB2 YIGSR 296 a6b1 
 
LAMC1 LRE 297 a3b1 298 
LAMA5 IKVAV 299 
  
FGG GWTVFQKRLDGS 300 avb3 300 
Perlecan  TWSKVGGHLRPGIVQSG 301 b1 302 
COL18A1 IVRRADRAAVP 303 b1 (a3b1) 303 
ELN GRKRK 304 avb3  304 
FGA GPR 305 axb2 305 
COL18A1 
  
a1b1 306 
NID1/entactin 
  
a3b1 307 
Perlecan 
  
avb3 308 
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A.4: MMP-degradable proteins via Proteomics. 
 
Protein MMP cleavage # Samples Cleavage Reference 
dMAG MMP2 3 309 
COL1A1 MMP-2 (GPQG*IAGQRGVVGL) 4 310 
COL1A2 MMP2 (GPQG*LLGAhypGFLGL) 3 
COL4A1 MMP2 4 311 
COL4A2 MMP2 4 
COL6A1 MMP2 2 312 
COL6A2 MMP2 2 
COL6A3 MMP2 3 
COL18A1 MMP2 3 313 
LAMC MMP2 4 314 
LAMC2 MMP2 (TAAA-LTSC) 4 315 
NFASC MMP2    3 
NCAN MMP2 2 
ELN MMP2 2 311 
VTN MMP2 2 316 
fibrillin-1 MMP2 2 317 
LGALS1 MMP2 2 318 
dMAG MMP7 3 309 
FN MMP7 2 319 
TNR MMP7 4 320 
AGRN MMP7 (IST*FRA) 3 321 
PCAN MMP7   3 322 
VCAN MMP7 4 319 
NID1 MMP7 (GLU34-LEU35) (GLY275-LEU276) 
(ALA637-LEU638) (CYS747-ILE746) 
2 
ELN MMP7 2 311 
VTN MMP7 2 316 
dMAG MMP9 3 309 
COL6A1 MMP9 2 312 
COL6A2 MMP9 2 
COL6A3 MMP9 3 
COL18A1 MMP9 (YVH-LRP) (SLA-HTH) 3 313 
vWf MMP9 3 323 
NTN-1 MMP9 2 324 
NID1 MMP9 2 325 
ELN MMP9 2 311 
VTN MMP9 2 316 
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Fibrillin  MMP9 2 317 
COL1A1 MMP1  (GL*AGQRGIVGL*) 4 326 
COL1A2 MMP1  (GL*AGQRGIVGL*) 3 
TNR MMP1 4 320 
AGRN MMP1 (EQH*IRS) 3 321 
COL1A1 MMP-8 (GPQG-IAQG) 4 311 
TNR MMP8 4 320 
vWf MMP8 3 323 
COL1A1 MMP13 (GPQG-IAQG) 4 311 
COL18A1 MMP13 (YVH-LRP) (SLA-HTH) 3 313 
FN MMP13 2 327 
TNR MMP13 4 320 
FGA MMP-13 (HKYKAXEH) (VKDHXSKH) 
(LVAXRGAH) 
2 328 
FGB MMP-13 (HKYKAXEH) (VKDHXSKH) 
(LVAXRGAH) 
3 
FGG MMP-13 (HKYKAXEH) (VKDHXSKH) 
(LVAXRGAH) 
3 
Fibrillin MMP13 2 317 
COL18A1 MMP3 (YVH-LRP) (SLA-HTH) 3 313 
FN MMP3 2 325 
TNR MMP3 4 320 
AGRN MMP3 (PHT* MLN) 3 321 
PCAN MMP3   3 325 
NID1 MMP3 2 
VTN MMP3 2 316 
COL18A1 MMP12 (YVH-LRP) (SLA-HTH) 3 313 
FGA MMP-12 (HKYKAEEHT) (YKAEEHTV) 
(LTRNGPL) (LVALRGAH) (LRGAHPY)  
2 328 
ELN MMP12 2 311 
Fibrillin MMP12 2 317 
COL18A1 MMP20 (YVH-LRP) (SLA-HTH) 3 313 
COL18A1 MMP14 3 
LAMA5 MMP14 2 329 
LAMB MMP14 3 
LAMC MMP14 4 
FN MMP14 2 327 
TNR MMP14 4 320 
PCAN MMP14 3 325 
FGA MMP-14 (LTRNGPL) (LVALRGA) 2 328 
FGG MMP-14 (LTRNGPL) (LVALRGA) 3 
NID1 MMP14 2 325 
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LGALS1 MMP14 2 330 
TNR MT2-MMP 4 320 
TNR MMP19 4 
NID1 MMP19 2 331 
 
A.5: Integrin-binding proteins found via Protein Atlas. 
 
Protein Gene Peptide Integrin Expression Reference 
COL I COL1A1 DGEA α1β1 1 295 
COL1A2 1.75 
 
COL IV COL4A1 FYDLR α2β1 0.75 294 
COL4A2 0.75 
 
LAMA LAMA2 IKVAK α4β1 0.75 299 
LAMA5 0.125 
 
LAMB LAMB2 YIGSR α6β1 1.5 296 
LAMB4 0.5 
 
LAMC LAMC1 LRE α3β1 0.5 297 
LAMC2 1.25 
 
POSTN POSTN ALMKYHILNTLQCS
E 
αXβ2 1.5 332 
THSB THSB3 VTCG CD36,  1.75 333 
COL 
XVIII 
COL18A
1 
IVRRADRAAVP α3β1 0.5 303 
TN TNC AEGDIEL α9β1 0.5 334 
THSB THBS2 RGD α5β1 1.25 335 
NFASC NFASC α5β1 1.25 290 
FBN FBN1 αVβ3 0.25 287 
VTN VTN αVβ3 0.75 336 
VWF VWF αVβ3 0.75 286 
TNX TNXB α5β1 1.75 337 
COL VI COL6A2 α1β1,α7β1, 
α10β1 
0.75 338 
COL6A6 0.75 
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A.6: MMP-degradable proteins found via Protein Atlas. 
 
Protein Expression Cleaved Reference 
THSB1 0.5 MMP2 339 
POSTN 1.5 MMP2 340 
BCAN 1.75 MMP-2(HPSA-FSEA) 320 
Laminin 1.25 MMP2 
VCAN 1.25 MMP-2 (PPEA-LRGI) 315 
ACAN 0.5 MMP2 (IPEN-FFGV) 
COL1A1 1 MMP2 (GPQG-IAGQ) 
COL1A2 1 MMP2 (GPQG-LLGA) 
decorin 0.25 MMP2 (DAAS-LLGL) 
LGALS3 0.25 MMP2 (PPGA-YHGA) 
LAMC2 1.25 MMP2 (TAAA-LTSC) 
SPARC  0.75 MMP2 (HPVG-LLAR) 
NCAN 0.5 MMP2 
COL18A1 0.75 MMP2 313 
ELN 0.75 MMP2 311 
COL4A1 0.75 MMP2 325 
COL4A2 0.75 MMP2 (PPG-FLG) 
COL6A2 1.75 MMP2 312 
COL6A6 0.75 MMP2 
NFASC 1.25 MMP2    
VTN 1.25 MMP2 316 
LGALS1 1.25 MMP2 (ACGLVA) 318 
fibrillin-1 0 MMP2 317 
AVERAGE 0.91304348 
  
POSTN 1.5 MMP3 325 
BCAN 1.75 MMP3 320 
Laminin 1.25 MMP3 
ACAN 0.5 MMP3 325 
COL1A1 1 MMP3 
COL1A2 1 MMP3 
NCAN 0.5  MMP-3 (IVAM-LRAP) 315 
COL18A1 0.75 MMP3 (YVH-LRP) (SLA-HTH) 313 
PERLECAN 0.75 MMP3   325 
COL4A1 0.75 MMP3 
COL4A2 0.75 MMP3 
VTN 1.25 MMP3 321 
TNXB 1.75 MMP3 325 
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FN1 0.5 MMP3 
TNC 0.5 MMP3 
AGRN 1.5 MMP3 (PHT* MLN) 321 
AVERAGE 1 
  
POSTN 1.5 MMP9 325 
Laminin 1.25 MMP9 320 
ACAN 0.5 MMP9 325 
LGALS3 0.25 MMP9 341 
COL18A1 0.75 MMP9 (YVH-LRP) (SLA-HTH) 313 
ELN 0.75 MMP9 311 
COL6A2 1.75 MMP9 312 
VWF 0.75 MMP9 323 
VTN 1.25 MMP9 316 
TNXB 1.75 MMP9 325 
TNC 0.5 MMP9 
COL3A1 0 MMP9 (PGQLQG) 
fibrillin-1 0 MMP9 317 
netrin-1 0.5 MMP9 
 
AVERAGE 0.82142857 
  
POSTN 1.5 MMP14 325 
ACAN 0.5 MMP14 
COL18A1 0.75 MMP14 313 
PERLECAN 0.75 MMP14 325 
TNXB 1.75 MMP14 
FN1 0.5 MMP14 327 
LGALS1 1.25 MMP14 330 
TNC 0.5 MMP14 325 
AVERAGE 0.9375 
  
BCAN 1.75 MMP7 (ALA360-PHE361) 320 
Laminin 1.25 MMP7 
ACAN 0.5 MMP7 (ASN341-PHE342) 319 
Decorin 0.25 MMP7 (ASP1-GLU2) 
SPARC 0.75 MMP7 (GLU20-VAL21) (GLN37-PHE38)  
COL18A1 0.75 MMP7 (VVQLHD) 325 
COL18A1 0.75 MMP7 (GLN1276-LEU1277) 319 
PERLECAN 0.75 MMP7   322 
ELN 0.75 MMP7 311 
COL4A2 0.75 MMP7 319 
VTN 1.25 MMP7 316 
VCAN 1.25 MMP7  319 
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TNC 0.5 MMP7 (LEU155-ASP156) 
AGRN 1.5 MMP7 (IST*FRA) 321 
FBLN1 1.25 MMP7 342 
FBLN2 0.25 MMP7 (ARG378-PHE379) (SER553-LEU554) 
syndecan-1 0 MMP7   319 
 
A.7: Design of Synthetic Brain ECM. 
 
Peptide Sequence Atlas MS Average 
% in Brain 
hydrogel 
POSTN ALMKYHILNTLQCSE 10% 0% 4.8% 5% 
COL18 IVRRADRAAVP 2% 7% 4.1% 4% 
LAMA IKVAV 5% 0% 2.4% 2% 
LAMB YIGSR 14% 10% 12.4% 12% 
COLI DGEA 14% 37% 25.6% 26% 
COLIV FYFDLR 2% 13% 7.5% 8% 
FGB 
RGD 43% 
33% 
37.7% 38% 
NFASC 
NID2 
COL6A6 
TNXB  
FBLN  
THSB2  
THSB3 VTCG 8% 0% 4.0% 4% 
TNC AEIDGIEL 3% 0% 1.6% 2% 
 Total 100% 100% 100.0% 100.0% 
MMP2 IPVS-LRSG 20% 20% 20.1% 20% 
MMP3 RPFS-MIMG 22% 20% 21.1% 21% 
MMP7 VPLS-LTMG 19% 20% 19.3% 19% 
MMP9 VPLS-LYSG 18% 21% 19.6% 20% 
MMP14 IPES-LRAG 21% 19% 19.9% 20% 
 Total   100.0% 100.0% 
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APPENDIX B 
 
B. VARIATION IN MOTILITY ASSAY PARAMETERS IN THE CURRENT LITERATURE 
 
B.1: Common metrics used in the literature to determine tumor cell motility. 
 
 
Metric Measurement Description Units Frequency 
of use 
% Migrating Cell count Number of cells moving, 
usually assessed by a baseline 
distance 
% 
 
% Invasion Cell count Number of cells that have 
crossed a boundary  
%, fold 
change 
9 
Persistence Fitted 
parameter 
Time at which a cell is moving 
in one direction before 
switching 
time 4 
MSD X, Y, time  Measure of deviation of cell 
w.r.t. its initial position 
µm2 1 
Chemotactic 
Index 
X and Y 
coordinates  
Net distance / total distance  0-1 
 
Net Distance X and Y 
coordinates 
Shortest distance between the 
initial and final position of the 
cell 
µm 
 
Total Distance X and Y 
coordinates 
Total distance traveled by the 
cell 
µm 
 
Speed X, Y, time  Distance traveled by cell per 
unit of time 
µm/min 12 
Velocity X, Y, time  Displacement of cell per unit of 
time (vector) 
µm/min 
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B.2: Concentration of basement membrane extract (i.e. Matrigel) used in tissue culture insert 
invasion assay experiments. 
 
Cell line BME Concentration Reference 
MDA-MB-231 not specified 343 
MDA-MB-231 344 
MDA-MB-231 
 
MCF7 50 µg/ml 345 
SKBR3 not specified 346 
SUM149 343 
HMECs 
 
PC3 50 µg/ml 347 
DU-145 
 
MDA-MB-231 0.2umol 348 
T-47D 
 
Hs578T not specified 349 
MCF10A 
 
BT549 344 
  
B.3: Tissue culture inserts used in assays with tumor cells. 
Cell line Pore size 
(µm) 
Material of membrane Reference 
MDA-MB-231 8 polycarbonate 343 
MDA-MB-231 8 344 
MDA-MB-231 8 
 
MCF7 0.8 polyethylene terephthalate 350 
SKBR3 ND ND 346 
SUM149 8 polycarbonate 343 
HMECs 8 
 
PC3 8 347 
DU-145 8 
 
MDA-MB-231 8 polyethylene terephthalate 348 
T-47D 8 
 
Hs578T 8 polycarbonate 349 
MCF10A 8 
 
BT549 8 344 
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B.4: Cell seeding and invasion metric data for tissue culture insert tumor cell invasion 
assays from the literature. 
 
Cell line Initial cells 
seeded 
Invasion Data Format Reported Invasion 
Value 
Ref 
MDA-MB-231 125,000 cells  Cell Per Field 147.8 cell per field 
343 
MDA-MB-231 250,000 cells  Invasion Value 89 invasion value 
351 
MDA-MB-231 50,000 cells/well Number of invaded cells 1381.49 invaded cells 
344 
MDA-MB-231 50,000 cells/well 434.78  invaded cells 
344 
MDA-MB-231 200,000/ml cells Fold Change 2.45 fold 
350 
MCF7 100,000 cells  Percentage Invasive Cells 4.70% 
345 
SKBR3 150,000 cells  Number of invaded cells 30.28  of invasive cells 
346 
MDA-MB-435 200,000/ml cells Fold Change 1.95 fold 
350 
SUM149 125,000 cells Cell Per Field 20 cell per field 
343 
HMECs 125,000 cells 52.44 cell per field 
343 
PC3 50000 cells 96.3 cell per field 
347 
DU-145 50000 cells 81.91 cell per field 
347 
MCF7 100000 cells image only cannot quantify   
352 
MDA-MB-435 100000 cells image only cannot quantify   
352 
MDA-MB-231 40,000 cells cell per field 85.1 transmembrane cells 
348 
T-47D 40,000 cells cell per field 8.97 transmembrane cells 
348 
Hs578T 
50,000 cells 
cell number 16744 cell number 
349 
MCF10A 50,000 cells 
cell number 
2590 cell number 
349 
BT549 50,000 cells/well average cell per field 1249 average cell # per 
field 
344 
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B.5: Assay readout for tissue culture insert invasion assays. 
 
Cell line Endpoint (hours) Reference 
MDA-MB-231 24 343 
MDA-MB-231 24 344 
MDA-MB-231 24 344 
MCF7 12 345 
SKBR3 48 346 
SUM149 24 343 
HMECs 24 343 
PC3 18 347 
DU-145 18 347 
MDA-MB-231 48 348 
T-47D 48 348 
Hs578T 48 349 
MCF10A 48 349 
BT549 24 344 
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B.6: Tissue culture insert migration assay readout. 
 
Cell line Experiment time Analysis method for readout Ref. 
MCF7 18 h staining with 0.5% crystal violet avg. migrated cells 
bound per field 
352 
MCF7 0h, 12h, 36h stained and counted 
345 
MDA-MB-231 24 h stained with Diff-Quick staining set and counted 
343 
MDA-MB-231 48 hours fixed 4% PFA, stained hematoxylin and eosin, counted 
348 
MDA-MB-231 24-48hrs fixed 10% formalin, stained 0.05% crystal violet. 
Distance migration from spheroid center 
344  
MDA-MB-231 
24 hours 
fixed methanol, stained crytal violet.  
350 
MDA-MB-435 18 h staining with 0.5% crystal violet avg. migrated cells 
bound per field 
352 
MDA-MB-435 24 hours fixed methanol, stained crytal violet.  
350 
MDA-MB-453   stained and counted 
345 
SKBR3 24 hours fixed methanol, stained 4 g/L crystal violet 
346 
BT549 24-48hrs fixed 10% formalin, stained 0.05% crystal violet. 
Distance migration from spheroid center 
344 
SUM149 24 h stained with Diff-Quick staining set and counted 
343 
HMECs 24 h stained with Diff-Quick staining set and counted 
343 
T-47D 48 hours fixed 4% PFA, stained hematoxylin and eosin, counted 
348 
Hs578T 48 hours trypzinization and cell number counted 
349 
MCF10A 
48 hours 
trypzinization and cell number counted 
349 
PC-3 0h, 6h, 24h, 48h %cell migration = [1-(scratch area at Tx (Hrs)/scratch 
area at T0] 
347 
DU-145 0h, 24h, 48h, 72h %cell migration = [1-(scratch area at Tx (Hrs)/scratch 
area at T0] 
347 
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B.7: Type of medium used in tissue culture insert invasion assays in lower chamber. 
 
Cell line Medium used with supplements in bottom chamber Ref. 
MCF7 fibroblast conditioned medium, 50ug/ml ascorbic acid serum free 
DMEM (lower chamber) 
352 
MCF7 lower chamber 500uL 10% FCS-DMEM 
345 
MDA-MB-231 bottom chambers 750 ul serum free medium 
348 
MDA-MB-231 RPMI 10% FBS 
351 
MDA-MB-231 FBS and fibronectin in lower chamber 
344 
MDA-MB-231 RPMI1640 20% FBS 
350 
MDA-MB-435 fibroblast conditioned medium, 50ug/ml ascorbic acid serum free DME 
352 
MDA-MB-435 RPMI1640 20% FBS 
350 
MDA-MB-453 lower chamber 500uL 10% FCS-DMEM 
345 
SKBR3 
500 uL RPMI 1640, 10% serum bottom 346 
BT549 
FBS and fibronectin in lower chamber 
344 
Hs578T complete medium with 10% FBS (750 µl) 
349 
MCF10A complete medium with 10% FBS (750 µl) 
349 
T-47D 
bottom chambers 750 µl serum free medium 
348 
PC-3 0.8ml serum free medium with 25ug/ml fibronectin 
347 
DU-145 0.8ml serum free medium with 25ug/ml fibronectin 
347 
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APPENDIX C 
 
C. VARIATION IN DRUG RESPONSE METRICS REPORTED IN THE LITERATURE FOR 
SAME CELL LINES 
 
 
C.1: Range IC50 per drug and cell line combination. 
Drug Cell line Format 
Reported 
IC50 
Calculated Gro
up  
 IC50 
Emax (growth 
inhibition) AUC EC50 R2 Curve 
Paclita
xel 
MCF7 
2D 0.003 uM 0.003 uM 78% @ 11 uM 224.70 0.004 uM 0.97 Partial 353 
2D 
3.2-8.3 
uM 0.009 uM 71% @ 0.2 uM 156.40 0.006 uM 0.95 Incomplete 354  
2D - 10.9 nM 55% @ 500nM 385.2 18nM 0.96 Partial 355 
3D GFR 
Matrigel 0.006 uM 0.005 uM 34% @ 191 uM 452.20 0.008 uM 0.97 Partial 353 
3D 
PEG-
Heparin  - 2.81nM 37% @ 500nM 381.9 2.33nM 0.91 Complete 355 
MDA-
MB-
231 
2D 0.004 uM 0.002 uM 97% @ 50 uM 139.60 0.004 uM 0.98 Partial 353 
2D - 17.97 nM 45% @ 500nM 418.8 13.59nM 0.86 Partial 355 
2D 7.5 uM 4.6 uM 97% @ 25uM 2.375 5.26 uM 0.89 Incomplete 356 
3D GFR 
Matrigel 0.03 uM 0.03 uM 74% @ 199 uM 335.70 0.04 uM 1.00 Complete 353 
3D 
PEG-
Heparin  - 4.41nM 37% @ 500nM 411.9 7.31nM 0.94 Complete 355 
3D 
fibroin 
Silk 50uM 50.3uM 58% @ 60uM 3.326 25uM 0.98 Incomplete 356 
Doxoru
bicin MCF7 
2D 0.23 uM 0.3 uM 
100% @ 112 
uM 340.60 0.3 uM 0.98 Complete 239 
2D 0.84uM 0.88uM 99% @ 117uM 249.6 0.66uM 1.00 Incomplete 357 
3D GFR 
matrigel 
Could not 
be 
calculated 14.2 uM 
100% @ 239 
uM 457.60 8.8 uM 1.00 Partial 239 
3D 
Matrigel 
EC50=12
uM 
not 
reached 41% @ 4uM 237.3 1.76uM 1.00 Incomplete 358 
3D 
agarose 70uM 
32.79 
ug/mL 
(60uM) 79% @ 115uM  294.8 19uM 1.00 Partial 357 
Tamoxi
fen MCF7 
2D 7.74 uM 7.11 uM 80% @ 100uM 81.47 4.9uM 1.00 Partial 359 
2D 14.0uM 7.443uM 99% @ 807uM 163.6 14.49uM 0.97 Complete 360 
3D 20.62 uM 21uM 58% @ 90uM 126.4 14.4uM 0.99 Complete 359 
3D pNG 
cryogel 45.6uM 45.09uM 95% @ 800uM 224.9 38.5uM 0.99 Complete 360 
 149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.2: Examples where IC50 was not reached (drug concentration did not kill half of the cells). 
 
 
 
 
 
3D 
polynipp
am 
spheroid
s 72.6uM 71.35uM 88% @ 80uM 235.9 39uM 0.99 Complete 
Epirubi
cin 
MDA-
MB-
231 
2D 0.05 uM 0.04 uM 
100% @ 1.1 
uM 204.30 0.03 uM 0.97 Partial 353 
2D 0.6uM 0.49uM 85% @ 10uM 287.7 0.41uM 1.00 Partial  361 
3D GFR 
Matrigel 0.58 uM 0.5 uM 100% @ 52 uM 282.20 0.3 uM 0.99 Complete 353 
3D 
spheroid 0.6uM 0.317uM 70% @ 10uM 285.3 0.28uM 1.00 Partial 
361 
Doceta
xel 
MDA-
MB-
231 
2D 0.2uM 0.065uM 73% @ 10uM 247.4 0.05uM 1.00 Partial 
2D 31.4uM 35uM 93% 123uM 297.9 25.12uM 0.96 Incomplete 362 
3D 10uM 
not 
reached 29% @ 0.1uM 312.4 
could not 
determine 0.88 Incomplete 361 
Drug Cell line 
For
mat Reported 
Calculated 
Ref 
 IC50 
Emax 
(growth 
inhibition) AUC EC50 
 
R2 
 
Curve 
Doxoru
bicin MCF7 3D EC50=12uM 
Drug 
did 
not 
kill 
half 
of the 
cells 
(IC50 
not 
reach
ed) 
41% @ 4uM 237.3 1.76uM 
 
 
 
0.99 
 
 
 
Incomplete  358 
Methotr
exate JIMT1 2D 
IC50 not 
reported 30% @ 20uM 
406.8
0 0.02 uM 
ND. Incomplete 
363 
Helenin
e JIMT1 2D 
IC50 not 
reported 11% @ 20 uM 
511.7
0 2.0 uM 
N.D. Incomplete 
API-2 JIMT1 2D 
IC50 not 
reported 17% @ 20 uM 
398.7
0 11.1 uM 
N.D. Incomplete 
Gemcit
abine BXPC3 3D 
showed 
resistance, No 
IC50 6% @ 500nM 255.2 230nM 
N.D. 
 
N.D. 
Incomplete 
 
Incomplete 
234 
Gemcit
abine 
Capan-
1 3D 
showed 
resistance, No 
IC50 
25% @ 500 
nM 231.4 63 nM 
 
 
1.00 
 
 
Partial 
Doceta
xel 
MDA-
MB-
231 3D IC50=10uM 29% @ 0.1uM 312.4 
could not 
determine 
 
0.88 
 
Incomplete 
361 
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C.3: IC50 reported in a publication differed from that calculated by our lab independently. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Cell line Format Reported 
Calculated 
  
Ref 
 IC50 Emax  AUC EC50 
 
R2 
 
Curve 
Paclitaxel 
SPCA-1 3D 
IC50=2.97
uM 7.9uM 
84% @ 
8.5uM 19.7 7.75uM 
 
0.99 
Incom
plete 364 
786-0 2D 
38.0-51.3 
uM 782 uM 
62% @ 0.1 
uM 212.20 0.04 uM 0.97 Partial 
354 
SW620 2D 2.6-3.6 uM 
0.006 
uM 
100% @ 0.2 
uM 128.70 
0.006 
uM 0.95 Partial 
HT29 2D 2.8-4.7 uM 
0.003 
uM 
100% @ 0.2 
uM 119.20 
0.003 
uM 0.96 Partial 
HeLa 2D 2.3-7.4 uM 
0.02 
uM 
98% @ 0.1 
uM 372.00 
0.008 
uM 0.99 Partial 
SY5Y 2D 1.7-2.0 uM 
0.006 
uM 
94% @ 0.1 
uM 377.10 
0.005 
uM 0.99 Partial 
PC3 2D 
12.9-13.0 
uM 
0.03 
uM 
100% @ 0.2 
uM 159.90 0.02 uM 0.99 Partial 
Doxorubi
cin 
HEPG2 (co-cultured with 
LX-2) 3D 50.4 uM 
24.5 
uM 
69% @ 1957 
uM 341.20 17.6 uM 0.99 Partial 
365 
Doxorubi
cin 
HEPG2 (co-cultured with 
LX-2) 2D 33.1 uM 
228.7 
uM 
99% @ 213 
uM 421.90 27.4 uM 0.89 Partial 
Doxorubi
cin + 0.1 
uM 
calcipotri
ol 
HEPG2 (co-cultured with 
LX-2) 3D 6.9 uM 
3.92 
uM 
76% @ 1660 
uM 317.10 5.89 uM 0.92 Partial 
Doxorubi
cin + 0.1 
uM 
calcipotri
ol 
HEPG2 (co-cultured with 
LX-2) 2D 43.7 uM 
624.8 
uM 
96% @ 225 
uM 388.40 42.7 uM 0.96 Partial 
Epirubicin MCF7 3D 0.5 uM 9.1 uM 
98% @ 196 
uM 406.30 3.8 uM 0.96 Partial 353 
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